## The specificities of protein kinase inhibitors: an update

Biochemical Journal 371, 199-204 DOI: 10.1042/bj20021535

Citation Report

#	Article	IF	CITATIONS
1	Monitoring synaptic vesicle recycling in frog motor nerve terminals with FM dyes. Journal of Neurocytology, 2003, 32, 539-549.	1.5	46
2	A reinvestigation of the multisite phosphorylation of the transcription factor c-Jun. EMBO Journal, 2003, 22, 3876-3886.	7.8	245
3	RNAi and 2DE, a promising combination for analysis of phospho-signalling and substrate identification. International Journal of Peptide Research and Therapeutics, 2003, 10, 437-445.	0.1	0
4	Sphingosine-1-phosphate-induced ERK activation protects human melanocytes from UVB-induced apoptosis. Archives of Pharmacal Research, 2003, 26, 739-746.	6.3	22
5	GSK-3-Selective Inhibitors Derived from Tyrian Purple Indirubins. Chemistry and Biology, 2003, 10, 1255-1266.	6.0	720
6	Caenorhabditis elegans early embryogenesis and vulval morphogenesis require chondroitin biosynthesis. Nature, 2003, 423, 439-443.	27.8	205
7	GSK-3α regulates production of Alzheimer's disease amyloid-β peptides. Nature, 2003, 423, 435-439.	27.8	1,113
8	Targeting JNK for therapeutic benefit: from junk to gold?. Nature Reviews Drug Discovery, 2003, 2, 554-565.	46.4	540
9	RNAi and 2DE, a promising combination for analysis of phospho-signalling and substrate identification. International Journal of Peptide Research and Therapeutics, 2003, 10, 437-445.	1.9	0
10	Protein kinase CÉ›-dependent activation of proline-rich tyrosine kinase 2Âin neonatal rat ventricular myocytes. Journal of Molecular and Cellular Cardiology, 2003, 35, 1121-1133.	1.9	31
11	Differential effects of quercetin and resveratrol on Band 3 tyrosine phosphorylation signalling of red blood cells. Biochemical and Biophysical Research Communications, 2003, 305, 541-547.	2.1	24
12	Cyclin-dependent kinase inhibitors. Current Opinion in Pharmacology, 2003, 3, 362-370.	3.5	99
13	Intersectin Activates Ras but Stimulates Transcription through an Independent Pathway Involving JNK. Journal of Biological Chemistry, 2003, 278, 47038-47045.	3.4	61
14	Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents. Annals of the Rheumatic Diseases, 2003, 62, 90ii-93.	0.9	9
15	Engulfment of Apoptotic Cells Is Negatively Regulated by Rho-mediated Signaling. Journal of Biological Chemistry, 2003, 278, 49911-49919.	3.4	138
16	An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 15434-15439.	7.1	329
17	Identification of Selective Inhibitors of NAD+-dependent Deacetylases Using Phenotypic Screens in Yeast. Journal of Biological Chemistry, 2003, 278, 52773-52782.	3.4	67
18	Reconstitution of Src-dependent Phospholipase CÎ <sup>3</sup> Phosphorylation and Transient Calcium Release by Using Membrane Rafts and Cell-free Extracts from Xenopus Eggs. Journal of Biological Chemistry, 2003, 278, 38413-38420.	3.4	57

#	Article	IF	CITATIONS
19	Phosphatidylinositol 3′-Kinase-dependent Activation of Renal Mesangial Cell Ki-Ras and ERK by Advanced Glycation End Products. Journal of Biological Chemistry, 2003, 278, 39349-39355.	3.4	50
20	Novel Small Molecule Cyclin-Dependent Kinases Modulators in Human Clinical Trials. Cancer Biology and Therapy, 2003, 2, 83-94.	3.4	103
21	Src Family Kinases: Potential Targets for the Treatment of Human Cancer and Leukemia. Current Pharmaceutical Design, 2003, 9, 2043-2059.	1.9	113
22	Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition. Biochemical Journal, 2003, 375, 255-262.	3.7	116
23	Regulation of myosin phosphorylation and myofilament Ca <sup>2+</sup> sensitivity in vascular smooth muscle. Journal of Smooth Muscle Research, 2004, 40, 219-236.	1.2	72
24	Targeting MAPK Signalling: Prometheus Fire or Pandoras Box?. Current Pharmaceutical Design, 2004, 10, 1885-1905.	1.9	54
25	Disruption of Rho signal transduction upon cell detachment. Journal of Cell Science, 2004, 117, 3511-3518.	2.0	46
26	Recent Evidence Regarding a Role for Cdk5 Dysregulation in Alzheimers Disease. Current Alzheimer Research, 2004, 1, 33-38.	1.4	51
27	Â2-Chimaerin, Cyclin-Dependent Kinase 5/p35, and Its Target Collapsin Response Mediator Protein-2 Are Essential Components in Semaphorin 3A-Induced Growth-Cone Collapse. Journal of Neuroscience, 2004, 24, 8994-9004.	3.6	195
28	The Stability of Tristetraprolin mRNA Is Regulated by Mitogen-activated Protein Kinase p38 and by Tristetraprolin Itself. Journal of Biological Chemistry, 2004, 279, 32393-32400.	3.4	136
29	A small-molecule approach to studying invasive mechanisms of Toxoplasma gondii. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 7433-7438.	7.1	128
30	Mechanisms for Lysophosphatidic Acid-induced Cytokine Production in Ovarian Cancer Cells. Journal of Biological Chemistry, 2004, 279, 9653-9661.	3.4	172
31	PKA phosphorylation of Src mediates Rap1 activation in NGF and cAMP signaling in PC12 cells. Journal of Cell Science, 2004, 117, 6085-6094.	2.0	116
32	Critical Role for Hematopoietic Cell Kinase (Hck)-mediated Phosphorylation of Gab1 and Gab2 Docking Proteins in Interleukin 6-induced Proliferation and Survival of Multiple Myeloma Cells. Journal of Biological Chemistry, 2004, 279, 21658-21665.	3.4	60
33	A c-Jun NH2-Terminal Kinase Inhibitor SP600125 (Anthra[1,9-cd]pyrazole-6 (2H)-one) Blocks Activation of Pancreatic Stellate Cells. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 520-527.	2.5	43
34	Roscovitine Inhibits Activation of Promoters in Herpes Simplex Virus Type 1 Genomes Independently of Promoter-Specific Factors. Journal of Virology, 2004, 78, 9352-9365.	3.4	45
35	Polycystin-1 Activates the Calcineurin/NFAT (Nuclear Factor of Activated T-cells) Signaling Pathway. Journal of Biological Chemistry, 2004, 279, 55455-55464.	3.4	93
36	HPC1/RNASEL Mediates Apoptosis of Prostate Cancer Cells Treated with 2′,5′-Oligoadenylates, Topoisomerase I Inhibitors, and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. Cancer Research, 2004, 64, 9144-9151.	0.9	64

#	Article	IF	CITATIONS
37	Cell Cycle-Dependent Phosphorylation of C/EBPβ Mediates Oncogenic Cooperativity between C/EBPβ and H-Ras V12. Molecular and Cellular Biology, 2004, 24, 7380-7391.	2.3	72
38	Reverse Two-hybrid Screening Identifies Residues of JNK Required for Interaction with the Kinase Interaction Motif of JNK-interacting Protein-1. Journal of Biological Chemistry, 2004, 279, 43178-43189.	3.4	25
39	Glucose Utilization Is Essential for Hypoxia-Inducible Factor 1α-Dependent Phosphorylation of c-Jun. Molecular and Cellular Biology, 2004, 24, 4128-4137.	2.3	24
40	Induction of MMP-10 and MMP-1 in a squamous cell carcinoma cell line by ultraviolet radiation. Biological Chemistry, 2004, 385, 75-86.	2.5	34
41	ACAP1, a Novel Binding Partner of Nitric Oxide-sensitive Guanylyl Cyclase. Journal of Biological Chemistry, 2004, 279, 49346-49354.	3.4	37
42	Chemical Proteomic Analysis Reveals Alternative Modes of Action for Pyrido[2,3-d]pyrimidine Kinase Inhibitors. Molecular and Cellular Proteomics, 2004, 3, 1181-1193.	3.8	74
43	Phosphorylation of Sp1 by Cyclin-dependent Kinase 2 Modulates the Role of Sp1 in CTP:Phosphocholine Cytidylyltransferase l± Regulation during the S Phase of the Cell Cycle. Journal of Biological Chemistry, 2004, 279, 40220-40226.	3.4	48
44	Extracellular matrix regulates human airway smooth muscle cell migration. European Respiratory Journal, 2004, 24, 545-551.	6.7	69
45	Organization of mammary epithelial cells into 3D acinar structures requires glucocorticoid and JNK signaling. Journal of Cell Biology, 2004, 166, 133-143.	5.2	59
46	Inhibitors of Protein Kinase Signaling Pathways. Circulation, 2004, 109, 1196-1205.	1.6	124
47	15-Deoxy-Δ12,14-Prostaglandin J2 Inhibits IFN-Inducible Protein 10/CXC Chemokine Ligand 10 Expression in Human Microglia: Mechanisms and Implications. Journal of Immunology, 2004, 173, 3504-3513.	0.8	20
48	Discovery and Development of GSK3 Inhibitors for the Treatment of Type 2 Diabetes. Current Pharmaceutical Design, 2004, 10, 1105-1137.	1.9	147
49	The Use of CDK Inhibitors in Oncology: A Pharmaceutical Perspective. Cell Cycle, 2004, 3, 740-744.	2.6	40
50	Proteomic Analysis of Kinase Inhibitor Selectivity and Function. Cell Cycle, 2004, 3, 391-393.	2.6	41
51	Kinase selectivity profiling by inhibitor affinity chromatography. Expert Review of Proteomics, 2004, 1, 303-315.	3.0	8
52	Follicle Stimulating Hormone-Induced DNA Synthesis in the Granulosa Cells of Hamster Preantral Follicles Involves Activation of Cyclin-Dependent Kinase-4 Rather Than Cyclin D2 Synthesis1. Biology of Reproduction, 2004, 70, 509-517.	2.7	19
53	The Development of a CDK2-Docking Site Peptide that Inhibits p53 and Sensitizes Cells to Death. Cell Cycle, 2004, 3, 79-88.	2.6	18
54	Muscarinic M2 Receptor Stimulation of Cav1.2b Requires Phosphatidylinositol 3-Kinase, Protein Kinase C, and c-Src. Circulation Research, 2004, 94, 626-633.	4.5	43

#	Article	IF	CITATIONS
55	Obligatory Role of Src Kinase in the Signaling Mechanism for TRPC3 Cation Channels. Journal of Biological Chemistry, 2004, 279, 40521-40528.	3.4	132
56	An Apoptotic Signaling Pathway in the Interferon Antiviral Response Mediated by RNase L and c-Jun NH2-terminal Kinase. Journal of Biological Chemistry, 2004, 279, 1123-1131.	3.4	127
57	NF-ÂB RelA opposes epidermal proliferation driven by TNFR1 and JNK. Genes and Development, 2004, 18, 17-22.	5.9	120
58	Thyroid-stimulating Hormone/cAMP and Glycogen Synthase Kinase 3β Elicit Opposing Effects on Rap1GAP Stability. Journal of Biological Chemistry, 2004, 279, 5501-5507.	3.4	39
59	The Function of Mitogen-activated Protein Kinase Phosphatase-1 in Peptidoglycan-stimulated Macrophages. Journal of Biological Chemistry, 2004, 279, 54023-54031.	3.4	101
60	Protocols for Regulation and Study of Diphosphoinositol Polyphosphates. Molecular Pharmacology, 2004, 66, 1585-1591.	2.3	13
61	Inhibition of Cell Proliferation and Cell Cycle Progression by Specific Inhibition of Basal JNK Activity. Journal of Biological Chemistry, 2004, 279, 11957-11966.	3.4	131
62	Cyclin/CDK Regulates the Nucleocytoplasmic Localization of the Human Papillomavirus E1 DNA Helicase. Journal of Virology, 2004, 78, 13954-13965.	3.4	70
63	The Critical Features and the Mechanism of Inhibition of a Kinase Interaction Motif-based Peptide Inhibitor of JNK. Journal of Biological Chemistry, 2004, 279, 36327-36338.	3.4	54
64	cAMP-induced degradation of cyclin D3 through association with GSK-3β. Journal of Cell Science, 2004, 117, 3769-3783.	2.0	49
65	CSK-3β inhibition/β-catenin stabilization in ventral midbrain precursors increases differentiation into dopamine neurons. Journal of Cell Science, 2004, 117, 5731-5737.	2.0	135
66	Evaluation of Kinase Inhibitor Selectivity by Chemical Proteomics. Assay and Drug Development Technologies, 2004, 2, 215-224.	1.2	45
67	Rapid Structure-Activity and Selectivity Analysis of Kinase Inhibitors by BioMAP Analysis in Complex Human Primary Cell-Based Models. Assay and Drug Development Technologies, 2004, 2, 431-442.	1.2	74
68	Mixed-Lineage Kinases: A Target for the Prevention of Neurodegeneration. Annual Review of Pharmacology and Toxicology, 2004, 44, 451-474.	9.4	138
69	Proapoptotic function of protein kinase CK2α" is mediated by a JNK signaling cascade. American Journal of Physiology - Renal Physiology, 2004, 287, G192-G201.	3.4	15
70	Expression of cyclin E in resting and activated B-chronic lymphocytic leukaemia cells: cyclin E/cdk2 as a potential therapeutic target. British Journal of Haematology, 2004, 125, 141-148.	2.5	13
71	PfPK7, an atypical MEK-related protein kinase, reflects the absence of classical three-component MAPK pathways in the human malaria parasite Plasmodium falciparum. Molecular Microbiology, 2004, 55, 184-186.	2.5	88
72	Counteraction of axonal growth inhibitory properties of Semaphorin 3A and myelin-associated proteins by a synthetic neurotrophic compound. Journal of Neurochemistry, 2004, 90, 1423-1431.	3.9	16

#	Article	IF	CITATIONS
73	Phosphorylation of the enteropathogenic E. coli receptor by the Src-family kinase c-Fyn triggers actin pedestal formation. Nature Cell Biology, 2004, 6, 618-625.	10.3	113
74	GSK3 inhibitors: development and therapeutic potential. Nature Reviews Drug Discovery, 2004, 3, 479-487.	46.4	696
75	Strategies to overcome resistance to targeted protein kinase inhibitors. Nature Reviews Drug Discovery, 2004, 3, 1001-1010.	46.4	305
76	Cell cycle molecules and vertebrate neuron death: E2F at the hub. Cell Death and Differentiation, 2004, 11, 49-60.	11.2	102
77	Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125. EMBO Journal, 2004, 23, 2185-2195.	7.8	250
78	A novel CDK5-dependent pathway for regulating GSK3 activity and kinesin-driven motility in neurons. EMBO Journal, 2004, 23, 2235-2245.	7.8	245
79	D4476, a cellâ€permeant inhibitor of CK1, suppresses the siteâ€specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Reports, 2004, 5, 60-65.	4.5	232
80	β1â€Integrins induce phosphorylation of Akt on serine 473 independently of focal adhesion kinase and Src family kinases. EMBO Reports, 2004, 5, 901-905.	4.5	99
81	Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia, 2004, 18, 747-755.	7.2	125
82	Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells. Oncogene, 2004, 23, 596-604.	5.9	145
83	ERK1/2 and p38 cooperate to induce a p21CIP1-dependent G1 cell cycle arrest. Oncogene, 2004, 23, 3284-3295.	5.9	84
84	Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins. Oncogene, 2004, 23, 4400-4412.	5.9	86
85	Self-renewal of teratocarcinoma and embryonic stem cells. Oncogene, 2004, 23, 7150-7160.	5.9	489
86	Molecular interdiction of Src-family kinase signaling in hematopoietic cells. Oncogene, 2004, 23, 8024-8032.	5.9	22
87	MAPK cascade signalling and synaptic plasticity. Nature Reviews Neuroscience, 2004, 5, 173-183.	10.2	1,264
88	Regulation of RANTES/CCL5 expression in human astrocytes by interleukin-1 and interferon-beta. Journal of Neurochemistry, 2004, 90, 297-308.	3.9	53
89	Interactions of LY333531 and Other Bisindolyl Maleimide Inhibitors with PDK1. Structure, 2004, 12, 215-226.	3.3	79
90	Roles of mitogen activated protein kinases and EGF receptor in arsenite-stimulated matrix metalloproteinase-9 production. Toxicology and Applied Pharmacology, 2004, 200, 177-185.	2.8	36

#	Article	IF	Citations
91	15-Deoxy-Δ (12,14)-PGJ2 inhibits astrocyte IL-1 signaling: inhibition of NF-κB and MAP kinase pathways and suppression of cytokine and chemokine expression. Journal of Neuroimmunology, 2004, 153, 132-142.	2.3	15
92	Can mouse models for brain tumors inform treatment in pediatric patients?. Seminars in Cancer Biology, 2004, 14, 71-77.	9.6	1
93	Targeting JNK3 for the treatment of neurodegenerative disorders. Drug Discovery Today, 2004, 9, 932-939.	6.4	113
94	ML-9, a myosin light chain kinase inhibitor, reduces intracellular Ca2+ concentration in guinea pig trachealis. European Journal of Pharmacology, 2004, 486, 325-333.	3.5	24
95	Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons. Biochemical Pharmacology, 2004, 67, 1947-1964.	4.4	31
96	Aggravation of necrotic death of glucose-deprived cells by the MEK1 inhibitors U0126 and PD184161 through depletion of ATP. Biochemical Pharmacology, 2004, 68, 351-360.	4.4	34
97	Targeting cell cycle and apoptosis for the treatment of human malignancies. Current Opinion in Cell Biology, 2004, 16, 670-678.	5.4	96
98	1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3β. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 413-416.	2.2	171
99	PDE2 inhibition by the PI3 kinase inhibitor LY294002 and analogues. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 2847-2851.	2.2	25
100	Novel actions of tyrphostin AG 879: inhibition of RAF-1 and HER-2 expression combined with strong antitumoral effects on breast cancer cells. Cellular and Molecular Life Sciences, 2004, 61, 2624-2631.	5.4	11
101	Glycogen synthase kinase-3 regulates IGFBP-1 gene transcription through the thymine-rich insulin response element. BMC Molecular Biology, 2004, 5, 15.	3.0	40
102	Inhibiting Src family tyrosine kinase activity blocks glutamate signalling to ERK1/2 and Akt/PKB but not JNK in cultured striatal neurones. Journal of Neurochemistry, 2004, 88, 1127-1139.	3.9	45
103	Auto-reverse nuclear migration in bipolar mammalian cells on micropatterned surfaces. Cytoskeleton, 2004, 59, 38-49.	4.4	18
104	Motility of a biflagellate sperm: Waveform analysis and cyclic nucleotide activation. Cytoskeleton, 2004, 59, 120-130.	4.4	7
105	Calcium transients regulate patterned actin assembly during myofibrillogenesis. Developmental Dynamics, 2004, 229, 231-242.	1.8	24
106	The role of the cytoskeleton in cellular adhesion molecule expression in tumor necrosis factor-stimulated endothelial cells. Journal of Cellular Biochemistry, 2004, 91, 926-937.	2.6	33
107	Differential regulation of platelet-derived growth factor stimulated migration and proliferation in osteoblastic cells. Journal of Cellular Biochemistry, 2004, 93, 741-752.	2.6	67
108	Synthesis and biological evaluation of novel macrocyclic bis-7-azaindolylmaleimides as potent and highly selective glycogen synthase kinase-31² (CSK-31²) inhibitors. Bioorganic and Medicinal Chemistry, 2004, 12, 1239-1255.	3.0	31

#	Article	IF	CITATIONS
109	Design, synthesis, and biological evaluation of novel 7-azaindolyl-heteroaryl-maleimides as potent and selective glycogen synthase kinase-3β (GSK-3β) inhibitors. Bioorganic and Medicinal Chemistry, 2004, 12, 3167-3185.	3.0	30
110	Synthesis and Target Identification of Hymenialdisine Analogs. Chemistry and Biology, 2004, 11, 247-259.	6.0	128
111	Dimethylaminopurine inhibits metabolic effects of insulin in primary adipocytes. Journal of Nutritional Biochemistry, 2004, 15, 303-312.	4.2	4
112	Characterization of a Conserved Structural Determinant Controlling Protein Kinase Sensitivity to Selective Inhibitors. Chemistry and Biology, 2004, 11, 691-701.	6.0	130
113	Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2004, 1697, 197-209.	2.3	60
114	Molecular dissection of egg fertilization signaling with the aid of tyrosine kinase-specific inhibitor and activator strategies. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2004, 1697, 103-121.	2.3	26
115	Contribution of UVB and UVA to UV-dependent stimulation of cyclooxygenase-2 expression in artificial epidermis. Photochemical and Photobiological Sciences, 2004, 3, 257-262.	2.9	53
116	Kinase Targets and Inhibitors for the Treatment of Airway Inflammatory Diseases. BioDrugs, 2004, 18, 167-180.	4.6	14
117	Potent inhibition of human platelets by cGMP analogs independent of cGMP-dependent protein kinase. Blood, 2004, 103, 2593-2600.	1.4	104
118	Design, Synthesis, and Biological Activity of Novel, Potent, and Selective (Benzoylaminomethyl)thiophene Sulfonamide Inhibitors of c-Jun-N-Terminal Kinase. Journal of Medicinal Chemistry, 2004, 47, 6921-6934.	6.4	61
119	Optimization of Protein Kinase CK2 Inhibitors Derived from 4,5,6,7-Tetrabromobenzimidazole. Journal of Medicinal Chemistry, 2004, 47, 6239-6247.	6.4	168
120	Protein Kinase G from Pathogenic Mycobacteria Promotes Survival Within Macrophages. Science, 2004, 304, 1800-1804.	12.6	494
121	Osmotic stress, a proinflammatory signal in Caco-2 cells. Biochimie, 2004, 86, 533-541.	2.6	44
122	Signalling pathways involved in multisite phosphorylation of the transcription factor ATF-2. FEBS Letters, 2004, 572, 177-183.	2.8	79
123	Indomethacin and ibuprofen induce Hsc70 nuclear localization and activation of the heat shock response in HeLa cells. Biochemical and Biophysical Research Communications, 2004, 313, 863-870.	2.1	19
124	Activation of tissue plasminogen activator gene transcription by Neovastat, a multifunctional antiangiogenic agent. Biochemical and Biophysical Research Communications, 2004, 320, 205-212.	2.1	20
125	2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. Biochemical and Biophysical Research Communications, 2004, 321, 1040-1044.	2.1	172
126	Quantitative measurement of estrogen-induced ERK 1 and 2 activation via multiple membrane-initiated signaling pathways. Steroids, 2004, 69, 181-192.	1.8	98

#	Article	IF	CITATIONS
127	Pharmacological inhibitors of glycogen synthase kinase 3. Trends in Pharmacological Sciences, 2004, 25, 471-480.	8.7	559
128	The Tubulin-Binding Agent Combretastatin A-4-Phosphate Arrests Endothelial Cells in Mitosis and Induces Mitotic Cell Death. American Journal of Pathology, 2004, 165, 1401-1411.	3.8	125
129	Distinct Stimulus-Specific Histone Modifications at Hsp70 Chromatin Targeted by the Transcription Factor Heat Shock Factor-1. Molecular Cell, 2004, 15, 585-594.	9.7	69
130	Indirubin-3′-oxime inhibits c-Jun NH2-terminal kinase: anti-apoptotic effect in cerebellar granule neurons. Neuroscience Letters, 2004, 367, 355-359.	2.1	37
131	PMA Induces the MUC5AC Respiratory Mucin in Human Bronchial Epithelial Cells, via PKC, EGF/TGF-α, Ras/Raf, MEK, ERK and Sp1-dependent Mechanisms. Journal of Molecular Biology, 2004, 344, 683-695.	4.2	162
132	Cdk5 Phosphorylation of Doublecortin Ser297 Regulates Its Effect on Neuronal Migration. Neuron, 2004, 41, 215-227.	8.1	220
133	Involvement of the cGMP signalling pathway in the regulation of viability in insulin-secreting BRIN-BD11 cells. FEBS Letters, 2004, 559, 118-124.	2.8	16
134	Inhibition of Protein Kinase CK2 by Condensed Polyphenolic Derivatives. An in Vitro and in Vivo Study. Biochemistry, 2004, 43, 12931-12936.	2.5	87
135	Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3. Biochemical Journal, 2004, 384, 477-488.	3.7	299
136	On the roles of cGMP and glycoprotein lb in platelet activation. Blood, 2004, 103, 4371-4372.	1.4	7
136 137	On the roles of cGMP and glycoprotein Ib in platelet activation. Blood, 2004, 103, 4371-4372. Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. Blood, 2004, 103, 4373-4374.	1.4 1.4	7
	Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients		
137	Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. Blood, 2004, 103, 4373-4374. GPIb-dependent platelet activation is dependent on Src kinases but not MAP kinase or cGMP-dependent	1.4	6
137 138	Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. Blood, 2004, 103, 4373-4374. CPIb-dependent platelet activation is dependent on Src kinases but not MAP kinase or cGMP-dependent kinase. Blood, 2004, 103, 2601-2609. Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian	1.4	6 81
137 138 139	Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. Blood, 2004, 103, 4373-4374.   CPIb-dependent platelet activation is dependent on Src kinases but not MAP kinase or cGMP-dependent kinase. Blood, 2004, 103, 2601-2609.   Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochemical Journal, 2004, 377, 249-255.   Identification of glycogen synthase as a new substrate for stress-activated protein kinase 2b/p38beta.	1.4 1.4 3.7	6 81 286
137 138 139 140	Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. Blood, 2004, 103, 4373-4374.   GPIb-dependent platelet activation is dependent on Src kinases but not MAP kinase or cGMP-dependent kinase. Blood, 2004, 103, 2601-2609.   Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochemical Journal, 2004, 377, 249-255.   Identification of glycogen synthase as a new substrate for stress-activated protein kinase 2b/p38beta. Biochemical Journal, 2004, 379, 133-139.   Identification of filamin C as a new physiological substrate of PKBα using KESTREL. Biochemical Journal,	1.4 1.4 3.7 3.7	6 81 286 49
137 138 139 140 141	Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. Blood, 2004, 103, 4373-4374.   GPIb-dependent platelet activation is dependent on Src kinases but not MAP kinase or cGMP-dependent kinase. Blood, 2004, 103, 2601-2609.   Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochemical Journal, 2004, 377, 249-255.   Identification of glycogen synthase as a new substrate for stress-activated protein kinase 2b/p38beta. Biochemical Journal, 2004, 379, 133-139.   Identification of filamin C as a new physiological substrate of PKBα using KESTREL. Biochemical Journal, 2004, 384, 489-494.	1.4 1.4 3.7 3.7	6 81 286 49 41

#	Article	IF	CITATIONS
145	Dimethyl-Celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-Inhibitory function, potently mimics the anti-tumor effects of celecoxib on burkitt's lymphoma in vitro and in vivo. Cancer Biology and Therapy, 2005, 4, 571-582.	3.4	78
146	Regulation of FAK Ser-722 phosphorylation and kinase activity by GSK3 and PP1 during cell spreading and migration. Biochemical Journal, 2005, 391, 359-370.	3.7	89
147	Identification of calcium-regulated heat-stable protein of 24ÂkDa (CRHSP24) as a physiological substrate for PKB and RSK using KESTREL. Biochemical Journal, 2005, 389, 775-783.	3.7	31
148	Nogo-B is a new physiological substrate for MAPKAP-K2. Biochemical Journal, 2005, 391, 433-440.	3.7	31
149	Endogenous and synthetic inhibitors of the Src-family protein tyrosine kinases. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1754, 210-220.	2.3	94
150	Crystallography for protein kinase drug design: PKA and SRC case studies. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1754, 38-49.	2.3	12
151	The Kinome Is Not Enough. Chemistry and Biology, 2005, 12, 1057-1058.	6.0	4
152	Small Molecules Driving Myotube Fission. Chemistry and Biology, 2005, 12, 1058-1060.	6.0	4
153	New 2-bromomethyl-8-substituted-benzo[c]chromen-6-ones. Synthesis and biological properties. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 135-138.	2.2	59
154	Features of Selective Kinase Inhibitors. Chemistry and Biology, 2005, 12, 621-637.	6.0	582
155	A Proteome-Wide CDK/CRK-Specific Kinase Inhibitor Promotes Tumor Cell Death in the Absence of Cell Cycle Progression. Chemistry and Biology, 2005, 12, 1103-1115.	6.0	44
156	Characterisation of kinase-selective inhibitors by chemical proteomics. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1754, 183-190.	2.3	34
157	Protein kinase signaling cascades in CNS trauma. IUBMB Life, 2005, 57, 711-718.	3.4	30
158	Identification of Novel Extracellular Signal-Regulated Kinase Docking Domain Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 4586-4595.	6.4	112
159	Indirubin, a Chinese anti-leukaemia drug, promotes neutrophilic differentiation of human myelocytic leukaemia HL-60 cells. British Journal of Haematology, 2005, 130, 681-690.	2.5	31
160	Ceramide alters endothelial cell permeability by a nonapoptotic mechanism. British Journal of Pharmacology, 2005, 145, 132-140.	5.4	28
161	A small molecule–kinase interaction map for clinical kinase inhibitors. Nature Biotechnology, 2005, 23, 329-336.	17.5	1,785
162	Response to Molecule–kinase interaction map. Nature Biotechnology, 2005, 23, 1346-1348.	17.5	3

ARTICLE IF CITATIONS Plant transgenic science knowledge. Nature Biotechnology, 2005, 23, 1348-1349. 17.5 10 163 Regulatory phosphorylation of Bim: sorting out the ERK from the JNK. Cell Death and Differentiation, 164 11.2 2005, 12, 1008-1014. Ablation of the spindle assembly checkpoint by a compound targeting Mps1. EMBO Reports, 2005, 6, 165 4.5 101 866-872. Neuroprotection against Focal Ischemic Brain Injury by Inhibition of c-Jun N-Terminal Kinase and Attenuation of the Mitochondrial Apoptosis-Signaling Pathway. Journal of Cerebral Blood Flow and 214 Metabolism, 2005, 25, 694-712. Characterization of vinblastine-induced Bcl-xL and Bcl-2 phosphorylation: evidence for a novel protein kinase and a coordinated phosphorylation/dephosphorylation cycle associated with apoptosis 167 5.9 74 induction. Oncogene, 2005, 24, 107-117. A transient increase in the activity of Src-family kinases induced by cell detachment delays anoikis of intestinal epithelial cells. Oncogene, 2005, 24, 1727-1737. Paclitaxel induces the phosphorylation of the eukaryotic translation initiation factor 4E-binding 169 5.9 31 protein 1 through a Cdk1-dependent mechanism. Oncogene, 2005, 24, 4851-4860. Regulation of aryl hydrocarbon receptor signal transduction by protein tyrosine kinases. Cellular 3.6 96 Signalling, 2005, 17, 39-48. Bombesin and angiotensin II rapidly stimulate Src phosphorylation at Tyr-418 in fibroblasts and 171 3.6 15 intestinal epithelial cells through a PP2-insensitive pathway. Cellular Signalling, 2005, 17, 93-102. The conditional kinase i "MEKK1:ER\* selectively activates the JNK pathway and protects against serum 3.6 withdrawal-induced cell death. Cellular Signalling, 2005, 17, 1412-1422. 6-(Methylsulfinyl)hexyl isothiocyanate suppresses inducible nitric oxide synthase expression through the inhibition of Janus kinase 2-mediated JNK pathway in lipopolysaccharide-activated murine 173 4.4 124 macrophages. Biochemical Pharmacology, 2005, 70, 1211-1221. Investigating serum factors promoting erythrocytic growth of Plasmodium falciparum. Experimental 174 1.2 Parasitology, 2005, 109, 7-15. Protein phosphatase  $1\hat{l}$  is tyrosine-phosphorylated and inactivated by peroxynitrite in erythrocytes 175 2.9 24 through the src family kinase fgr. Free Radical Biology and Medicine, 2005, 38, 1625-1636. HNE increases HO-1 through activation of the ERK pathway in pulmonary epithelial cells. Free Radical Biology and Medicine, 2005, 39, 355-364. Investigating Wnt signaling: a chemogenomic safari. Drug Discovery Today, 2005, 10, 1467-1474. 177 6.4 87 Characterization of two T. gondii CK1 isoforms. Molecular and Biochemical Parasitology, 2005, 141, 33 15-27. Combining RNA interference and kinase inhibitors against cell signalling components involved in 179 2.6 12 cancer. BMC Cancer, 2005, 5, 125. Investigating the neuroprotective mechanism of action of a CDK5 inhibitor by phosphoproteome analysis. Journal of Cellular Biochemistry, 2005, 95, 817-826.

#	Article	IF	CITATIONS
181	Cooperation between antioxidants and 1,25â€dihydroxyvitamin D <sub>3</sub> in induction of leukemia HL60 cell differentiation through the JNK/APâ€1/Egrâ€1 pathway. Journal of Cellular Physiology, 2005, 204, 964-974.	4.1	67
182	Synthesis of Novel Dipyrazolopyrimidine Fused Heterotricyclic Compounds. Chinese Journal of Chemistry, 2005, 23, 182-184.	4.9	9
183	Calcium transients regulate titin organization during myofibrillogenesis. Cytoskeleton, 2005, 60, 129-139.	4.4	14
184	Structure-Aided Optimization of Kinase Inhibitors Derived from Alsterpaullone. ChemBioChem, 2005, 6, 541-549.	2.6	38
185	The Target Discovery Process. ChemBioChem, 2005, 6, 468-479.	2.6	33
186	High-Throughput Screening for Kinase Inhibitors. ChemBioChem, 2005, 6, 481-490.	2.6	116
187	Chemical Inhibitors when Timing Is Critical: A Pharmacological Concept for the Maturation of T Cell Contacts. ChemBioChem, 2005, 6, 152-161.	2.6	8
188	Identification of tyrosine-phosphorylated proteins of the mitochondrial oxidative phosphorylation machinery. Cellular and Molecular Life Sciences, 2005, 62, 1478-1488.	5.4	62
189	Tracking functions of cGMP-dependent protein kinases (cGK). Frontiers in Bioscience - Landmark, 2005, 10, 1313.	3.0	61
190	Protein Kinase Inhibitors for the Treatment of Disease: The Promise and the Problems. , 2005, , 1-7.		0
191	Progress in the Discovery of Polo-like Kinase Inhibitors. Current Topics in Medicinal Chemistry, 2005, 5, 181-197.	2.1	114
192	Constitutive secretion of serum albumin requires reversible protein tyrosine phosphorylation events in trans-Golgi. American Journal of Physiology - Cell Physiology, 2005, 289, C748-C756.	4.6	16
193	Src family kinase involvement in rat preglomerular microvascular contractile and [Ca2+]iresponses to ANG II. American Journal of Physiology - Renal Physiology, 2005, 288, F658-F664.	2.7	13
194	Effects of the JNK inhibitor anthra[1,9-cd]pyrazol-6(2H)-one (SP-600125) on soluble guanylyl cyclase α1gene regulation and cGMP synthesis. American Journal of Physiology - Cell Physiology, 2005, 289, C778-C784.	4.6	7
195	Hypoxia alters biophysical properties of endothelial cells via p38 MAPK- and Rho kinase-dependent pathways. American Journal of Physiology - Cell Physiology, 2005, 289, C521-C530.	4.6	65
196	ls myosin light-chain phosphorylation a regulatory signal for the osmotic activation of the Na+-K+-2Clâ^ cotransporter?. American Journal of Physiology - Cell Physiology, 2005, 289, C68-C81.	4.6	45
197	Antagonistic regulation of swelling-activated Clâ^' current in rabbit ventricle by Src and EGFR protein tyrosine kinases. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H2628-H2636.	3.2	28
198	Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells. Molecular Cancer Therapeutics, 2005, 4, 1772-1785.	4.1	28

#	Article	IF	CITATIONS
199	Roscovitine Targets, Protein Kinases and Pyridoxal Kinase. Journal of Biological Chemistry, 2005, 280, 31208-31219.	3.4	312
200	The inositol trisphosphate pathway mediates platelet-activating-factor-induced pulmonary oedema. European Respiratory Journal, 2005, 25, 849-857.	6.7	30
201	Inhibition of Granulocyte-Macrophage Colony-Stimulating Factor Signaling and Microglial Proliferation by Anti-CD45RO: Role of Hck Tyrosine Kinase and Phosphatidylinositol 3-Kinase/Akt. Journal of Immunology, 2005, 174, 2712-2719.	0.8	83
202	Evidence that phosphorylation of the microtubule-associated protein Tau by SAPK4/p38δ at Thr50 promotes microtubule assembly. Journal of Cell Science, 2005, 118, 397-408.	2.0	120
203	Activation of p53-Dependent Apoptosis by Acute Ablation of Glycogen Synthase Kinase-3β in Colorectal Cancer Cells. Clinical Cancer Research, 2005, 11, 4580-4588.	7.0	84
204	Human Cytomegalovirus Infection Induces Specific Hyperphosphorylation of the Carboxyl-Terminal Domain of the Large Subunit of RNA Polymerase II That Is Associated with Changes in the Abundance, Activity, and Localization of cdk9 and cdk7. Journal of Virology, 2005, 79, 15477-15493.	3.4	61
205	Formation of the head organizer in hydra involves the canonical Wnt pathway. Development (Cambridge), 2005, 132, 2907-2916.	2.5	232
206	BIRB796 Inhibits All p38 MAPK Isoforms in Vitro and in Vivo. Journal of Biological Chemistry, 2005, 280, 19472-19479.	3.4	265
207	The Paullones: A Family of Pharmacological Inhibitors of Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3. , 2005, , 47-64.		6
208	Role of Mitogen-Activated Protein Kinases and NF-κB in the Regulation of Proinflammatory and Anti-Inflammatory Cytokines by Porphyromonas gingivalis Hemagglutinin B. Infection and Immunity, 2005, 73, 3990-3998.	2.2	60
209	Betaine Suppresses Proinflammatory Signaling During Aging: The Involvement of Nuclear Factor-ÂB via Nuclear Factor-Inducing Kinase/IÂB Kinase and Mitogen-Activated Protein Kinases. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2005, 60, 1252-1264.	3.6	83
210	Regulation of smooth muscle calcium sensitivity: KCl as a calcium-sensitizing stimulus. American Journal of Physiology - Cell Physiology, 2005, 288, C769-C783.	4.6	222
211	Inflammatory Pathway Analysis Using a High Content Screening Platform. Assay and Drug Development Technologies, 2005, 3, 261-271.	1.2	36
212	c-Jun N-terminal Kinase (JNK) Positively Regulates NFATc2 Transactivation through Phosphorylation within the N-terminal Regulatory Domain. Journal of Biological Chemistry, 2005, 280, 20867-20878.	3.4	59
213	Inhibiting Myosin Light Chain Kinase Induces Apoptosis In Vitro and In Vivo. Molecular and Cellular Biology, 2005, 25, 6259-6266.	2.3	68
214	Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert Opinion on Investigational Drugs, 2005, 14, 457-477.	4.1	112
215	Attenuation of Murine Collagen-Induced Arthritis by a Novel, Potent, Selective Small Molecule Inhibitor of IκB Kinase 2, TPCA-1 (2-[(Aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), Occurs via Reduction of Proinflammatory Cytokines and Antigen-Induced T Cell Proliferation. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 373-381.	2.5	260
216	Requirement of the MAP kinase signaling pathways for mouse preimplantation development. Development (Cambridge), 2005, 132, 1773-1783.	2.5	60

#	Article	IF	CITATIONS
217	Physiological Role for Casein Kinase 1 in Glutamatergic Synaptic Transmission. Journal of Neuroscience, 2005, 25, 6601-6609.	3.6	58
218	Hypotonic shock mediation by p38 MAPK, JNK, PKC, FAK, OSR1 and SPAK in osmosensing chloride secreting cells of killifish opercular epithelium. Journal of Experimental Biology, 2005, 208, 1063-1077.	1.7	106
219	Src Family Kinase Inhibitors Block Amphiregulin-Mediated Autocrine ErbB Signaling in Normal Human Keratinocytes. Molecular Pharmacology, 2005, 67, 1145-1157.	2.3	27
220	AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Molecular Cancer Therapeutics, 2005, 4, 1900-1911.	4.1	84
221	Thrombin-induced Tyrosine Phosphorylation of HS1 in Human Platelets Is Sequentially Catalyzed by Syk and Lyn Tyrosine Kinases and Associated with the Cellular Migration of the Protein. Journal of Biological Chemistry, 2005, 280, 21029-21035.	3.4	34
222	Essential Role for Mitogen-activated Protein (MAP) Kinase Phosphatase-1 in Stress-responsive MAP Kinase and Cell Survival Signaling. Journal of Biological Chemistry, 2005, 280, 16461-16466.	3.4	144
223	α1- and β1-Adrenoceptor Signaling Fully Compensates for β3-Adrenoceptor Deficiency in Brown Adipocyte Norepinephrine-Stimulated Glucose Uptake. Endocrinology, 2005, 146, 2271-2284.	2.8	64
224	Progesterone Inhibits the Estrogen-Induced Phosphoinositide 3-Kinase→AKT→GSK-3β→Cyclin D1→pRB Pathv to Block Uterine Epithelial Cell Proliferation. Molecular Endocrinology, 2005, 19, 1978-1990.	vay 8.7	100
225	Role of the p38 Mitogen-Activated Protein Kinase Pathway in Cytokine-Mediated Hematopoietic Suppression in Myelodysplastic Syndromes. Cancer Research, 2005, 65, 9029-9037.	0.9	60
226	Cancer Cells Become Susceptible to Natural Killer Cell Killing after Exposure to Histone Deacetylase Inhibitors Due to Glycogen Synthase Kinase-3–Dependent Expression of MHC Class I–Related Chain A and B. Cancer Research, 2005, 65, 11136-11145.	0.9	243
227	Bim Is a Direct Target of a Neuronal E2F-Dependent Apoptotic Pathway. Journal of Neuroscience, 2005, 25, 8349-8358.	3.6	92
228	Ribotoxic Stress Response to the Trichothecene Deoxynivalenol in the Macrophage Involves the Src Family Kinase Hck. Toxicological Sciences, 2005, 85, 916-926.	3.1	111
229	Hydrogen Peroxide Potentiates Volume-sensitive Excitatory Amino Acid Release via a Mechanism Involving Ca2+/Calmodulin-dependent Protein Kinase II*. Journal of Biological Chemistry, 2005, 280, 3548-3554.	3.4	44
230	Varicella-Zoster Virus IE63 Protein Phosphorylation by Roscovitine-sensitive Cyclin-dependent Kinases Modulates Its Cellular Localization and Activity. Journal of Biological Chemistry, 2005, 280, 29135-29143.	3.4	28
231	Inhibition of Tumor Growth, Angiogenesis, and Tumor Cell Proliferation by a Small Molecule Inhibitor of c-Jun N-terminal Kinase. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 325-332.	2.5	61
232	Unraveling Kinase Signaling Pathways with Chemical Genetic and Chemical Proteomic Approaches. Cell Cycle, 2005, 4, 434-437.	2.6	9
233	Synthesis and Identification of [1,3,5]Triazine-pyridine Biheteroaryl as a Novel Series of Potent Cyclin-Dependent Kinase Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 4535-4546.	6.4	85
234	Connexin43 synthesis, phosphorylation, and degradation in regulation of transient inhibition of gap junction intercellular communication by the phorbol ester TPA in rat liver epithelial cells. Experimental Cell Research, 2005, 302, 143-152.	2.6	62

-			_	
C 17		ON	REPOR	Τ.
	IAL		REPOR	

#	Article	IF	CITATIONS
235	Role of Rho, Rac, and Rho-kinase in phosphorylation of myosin light chain, development of polarity, and spontaneous migration of Walker 256 carcinosarcoma cells. Experimental Cell Research, 2005, 308, 422-438.	2.6	52
236	Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6. Journal of Medicinal Chemistry, 2005, 48, 2388-2406.	6.4	438
237	Recent advances in the discovery of Src kinase inhibitors. Expert Opinion on Therapeutic Patents, 2005, 15, 1183-1207.	5.0	23
238	Second-generation kinase inhibitors. Expert Opinion on Therapeutic Targets, 2005, 9, 975-993.	3.4	55
239	C-terminal Src kinase (CSK) and CSK-homologous kinase (CHK)—endogenous negative regulators of Src-family protein kinases. Growth Factors, 2005, 23, 233-244.	1.7	99
240	Design of a Novel Class of Peptide Inhibitors of Cyclin-dependent Kinase/Cyclin Activation. Journal of Biological Chemistry, 2005, 280, 13793-13800.	3.4	49
241	Modulation of Cell Adhesion Molecules in Various Epithelial Cell Lines after Treatment with PP2â€. Molecular Pharmaceutics, 2005, 2, 170-184.	4.6	8
242	Pyrimidine and Purine Analogues, Effects on Cell Cycle Regulation and the Role of Cell Cycle Inhibitors to Enhance Their Cytotoxicity. Nucleosides, Nucleotides and Nucleic Acids, 2005, 24, 1997-2022.	1.1	24
243	High Affinity Targets of Protein Kinase Inhibitors Have Similar Residues at the Positions Energetically Important for Binding. Journal of Molecular Biology, 2005, 352, 1134-1156.	4.2	42
244	Crystal Structures of Active Src Kinase Domain Complexes. Journal of Molecular Biology, 2005, 353, 222-231.	4.2	72
245	Therapeutic promise of JNK ATP-noncompetitive inhibitors. Trends in Molecular Medicine, 2005, 11, 232-239.	6.7	41
246	Activation-Loop Autophosphorylation Is Mediated by a Novel Transitional Intermediate Form of DYRKs. Cell, 2005, 121, 925-936.	28.9	278
247	Calmodulin-dependent protein kinase kinase-β is an alternative upstream kinase for AMP-activated protein kinase. Cell Metabolism, 2005, 2, 9-19.	16.2	1,397
248	Prostaglandin-dependent activation of ERK mediates cell proliferation induced by transforming growth factor Î <sup>2</sup> in mouse osteoblastic cells. Bone, 2005, 36, 93-100.	2.9	35
249	Identification of different specificity requirements between SGK1 and PKBα. FEBS Letters, 2005, 579, 991-994.	2.8	45
250	Modulation of Prosurvival Signaling in Fibroblasts by a Protein Kinase Inhibitor Protects against Fibrotic Tissue Injury. American Journal of Pathology, 2005, 166, 367-375.	3.8	115
251	Improved yields for baculovirus-mediated expression of human His6-PDK1 and His6-PKBβ/Akt2 and characterization of phospho-specific isoforms for design of inhibitors that stabilize inactive conformations. Protein Expression and Purification, 2005, 43, 44-56.	1.3	15
252	Regulation of Src kinase activity during Xenopus oocyte maturation. Developmental Biology, 2005, 278, 289-300.	2.0	24

#	Article	IF	CITATIONS
253	Context-specific inhibition of JNKs: overcoming the dilemma of protection and damage. Trends in Pharmacological Sciences, 2005, 26, 455-61.	8.7	140
254	Substituting c-Jun N-terminal kinase-3 (JNK3) ATP-binding site amino acid residues with their p38 counterparts affects binding of JNK- and p38-selective inhibitors. Archives of Biochemistry and Biophysics, 2005, 438, 195-205.	3.0	11
255	Design and Synthesis of the First Generation of Novel Potent, Selective, and in Vivo Active (Benzothiazol-2-yl)acetonitrile Inhibitors of the c-Jun N-Terminal Kinase. Journal of Medicinal Chemistry, 2005, 48, 4596-4607.	6.4	119
256	Phospho-specific flow cytometry in drug discovery. Drug Discovery Today: Technologies, 2005, 2, 295-302.	4.0	11
257	Rapid Computational Identification of the Targets of Protein Kinase Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 4138-4152.	6.4	50
260	Self-Reporting Fluorescent Substrates of Protein Tyrosine Kinases. Journal of the American Chemical Society, 2006, 128, 1808-1809.	13.7	75
262	Preconditioning Doses of NMDA Promote Neuroprotection by Enhancing Neuronal Excitability. Journal of Neuroscience, 2006, 26, 4509-4518.	3.6	213
263	Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy. Nature Clinical Practice Oncology, 2006, 3, 564-574.	4.3	86
264	Involvement of Golgi-associated Lyn tyrosine kinase in the translocation of annexin II to the endoplasmic reticulum under oxidative stress. Experimental Cell Research, 2006, 312, 1205-1217.	2.6	64
265	JNK phosphorylation of paxillin, acting through the Rac1 and Cdc42 signaling cascade, mediates neurite extension in N1E-115 cells. Experimental Cell Research, 2006, 312, 2954-2961.	2.6	40
266	Effects of tumour necrosis factor α (TNFα) on Mytilus haemocytes: role of stress-activated mitogen-activated protein kinases (MAPKs). Biology of the Cell, 2006, 98, 233-244.	2.0	46
267	c-Jun N-Terminal Kinase Plays a Major Role in Murine Acetaminophen Hepatotoxicity. Gastroenterology, 2006, 131, 165-178.	1.3	409
268	4-Arylazo-3,5-diamino-1H-pyrazole CDK Inhibitors:  SAR Study, Crystal Structure in Complex with CDK2, Selectivity, and Cellular Effects. Journal of Medicinal Chemistry, 2006, 49, 6500-6509.	6.4	166
269	Comparative Binding Energy Analysis Considering Multiple Receptors:  A Step toward 3D-QSAR Models for Multiple Targets. Journal of Medicinal Chemistry, 2006, 49, 6241-6253.	6.4	24
270	Blocking Stress Signaling Pathways with Cell Permeable Peptides. Advances in Experimental Medicine and Biology, 2006, 588, 133-143.	1.6	2
271	Novel Structural Features of CDK Inhibition Revealed by an ab Initio Computational Method Combined with Dynamic Simulations. Journal of Medicinal Chemistry, 2006, 49, 5141-5153.	6.4	37
272	Kinetic Properties of a MNB/DYRK1A Mutant Suitable for the Elucidation of Biochemical Pathwaysâ€. Biochemistry, 2006, 45, 12011-12019.	2.5	51
273	c-Jun N-Terminal Kinases Mediate Reactivation of Akt and Cardiomyocyte Survival After Hypoxic Injury In Vitro and In Vivo. Circulation Research, 2006, 98, 111-118.	4.5	127

#	Article	IF	CITATIONS
274	A Rapid, Reversible, and Tunable Method to Regulate Protein Function in Living Cells Using Synthetic Small Molecules. Cell, 2006, 126, 995-1004.	28.9	786
275	Differential roles of Rho-kinase and myosin light chain kinase in regulating shape, adhesion, and migration of HT1080 fibrosarcoma cells. Biochemical and Biophysical Research Communications, 2006, 343, 602-608.	2.1	36
276	Mitotic phosphorylation of tankyrase, a PARP that promotes spindle assembly, by CSK3. Biochemical and Biophysical Research Communications, 2006, 350, 574-579.	2.1	21
277	Inhibiting myosin light chain kinase retards the growth of mammary and prostate cancer cells. European Journal of Cancer, 2006, 42, 948-957.	2.8	33
278	PIASxα Differentially Regulates the Amplitudes of Transcriptional Responses Following Activation of the ERK and p38 MAPK Pathways. Molecular Cell, 2006, 22, 477-487.	9.7	40
279	Cell Apoptosis: Requirement of H2AX in DNA Ladder Formation, but Not for the Activation of Caspase-3. Molecular Cell, 2006, 23, 121-132.	9.7	317
280	Lipopolysaccharide-induced c-Src expression plays a role in nitric oxide and TNFα secretion in macrophages. Molecular Immunology, 2006, 43, 308-316.	2.2	59
281	Src family tyrosine kinases differentially modulate exocytosis from rat brain nerve terminals. Neurochemistry International, 2006, 49, 80-86.	3.8	15
282	Cellular stress increases RGS2 mRNA and decreases RGS4 mRNA levels in SH-SY5Y cells. Neuroscience Letters, 2006, 402, 205-209.	2.1	22
283	JNK inhibitor SP600125 reduces COX-2 expression by attenuating mRNA in activated murine J774 macrophages. International Immunopharmacology, 2006, 6, 987-996.	3.8	43
284	CRF signaling: molecular specificity for drug targeting in the CNS. Trends in Pharmacological Sciences, 2006, 27, 531-538.	8.7	89
285	Kinase-Dependent Differentiation of a Retinal Ganglion Cell Precursor. , 2006, 47, 427.		85
287	Rapid stimulation of tyrosine phosphorylation signals downstream of G-protein-coupled receptors for thromboxane A2 in human platelets. Biochemical Journal, 2006, 400, 127-134.	3.7	35
288	Src protein tyrosine kinase family and acute inflammatory responses. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2006, 291, L129-L141.	2.9	148
289	Signal Transduction Therapy with Rationally Designed Kinase Inhibitors. Current Signal Transduction Therapy, 2006, 1, 67-95.	0.5	43
290	Src tyrosine kinase as a chemotherapeutic target: is there a clinical case?. Anti-Cancer Drugs, 2006, 17, 123-131.	1.4	33
291	Inhibition of Mitogen-Activated Protein Kinases (MAPKs) as a Strategy to Prevent Intimal Hyperplasia Following Cardiovascular Interventions. Vascular Disease Prevention, 2006, 3, 173-183.	0.2	0
292	Protein Kinase Assays for Drug Discovery. , 0, , 189-201.		0

#	Article	IF	CITATIONS
293	Different roles for non-receptor tyrosine kinases in arachidonate release induced by zymosan and Staphylococcus aureus in macrophages. , 2006, 3, 8.		10
294	Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: Deciphering the molecular basis of the kinase inhibitors selectivity. Proteins: Structure, Function and Bioinformatics, 2006, 66, 912-929.	2.6	18
295	Human intrahepatic biliary epithelial cells function in innate immunity by producing ILâ€6 and ILâ€8 via the TLR4â€NFâ€₽̂B and â€MAPK signaling pathways. Liver International, 2006, 26, 467-476.	3.9	120
296	The Many Faces of H89: A Review. Cardiovascular Drug Reviews, 2006, 24, 261-274.	4.1	275
297	New targets and challenges in the molecular therapeutics of cancer. British Journal of Clinical Pharmacology, 2006, 62, 5-14.	2.4	33
298	Identifying off-target effects and hidden phenotypes of drugs in human cells. Nature Chemical Biology, 2006, 2, 329-337.	8.0	286
299	New approaches to molecular cancer therapeutics. Nature Chemical Biology, 2006, 2, 689-700.	8.0	361
300	Assay of protein kinases using radiolabeled ATP: a protocol. Nature Protocols, 2006, 1, 968-971.	12.0	220
301	Mechanisms of drug inhibition of signalling molecules. Nature, 2006, 441, 457-462.	27.8	281
302	Upregulation of TRAIL-R2 is not involved in HDACi mediated sensitization to TRAIL-induced apoptosis. Cell Death and Differentiation, 2006, 13, 2160-2162.	11.2	19
303	Regulation of Nur77 nuclear export by c-Jun N-terminal kinase and Akt. Oncogene, 2006, 25, 2974-2986.	5.9	135
304	Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways. Oncogene, 2006, 25, 4857-4866.	5.9	69
305	Tyrosine kinase and phosphatase regulation of slow delayed-rectifier K+current in guinea-pig ventricular myocytes. Journal of Physiology, 2006, 573, 469-482.	2.9	25
306	Synthesis and SAR of 1,9-dihydro-9-hydroxypyrazolo[3,4-b]quinolin-4-ones as novel, selective c-Jun N-terminal kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2590-2594.	2.2	25
307	Putative therapeutic agents for the learning and memory deficits of people with Down syndrome. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3772-3776.	2.2	36
308	Conditional Control of Protein Function. Chemistry and Biology, 2006, 13, 11-21.	6.0	87
309	The purines: Potent and versatile small molecule inhibitors and modulators of key biological targets. Bioorganic and Medicinal Chemistry, 2006, 14, 3987-4006.	3.0	290
310	A Crosstalk Between Myeloma Cells and Marrow Stromal Cells Stimulates Production of DKK1 and Interleukin-6: A Potential Role in the Development of Lytic Bone Disease and Tumor Progression in Multiple Myeloma. Stem Cells, 2006, 24, 986-991.	3.2	226

#	Article	IF	CITATIONS
311	Inhibition of UVA-induced c-Jun N-terminal Kinase Activity Results in Caspase-dependent Apoptosis in Human Keratinocytes. Photochemistry and Photobiology, 2006, 82, 423.	2.5	9
312	Differing mechanisms of cAMP- versus seawater-induced oocyte maturation in marine nemertean worms II. The roles of tyrosine kinases and phosphatases. Molecular Reproduction and Development, 2006, 73, 1564-1577.	2.0	18
313	Differing mechanisms of cAMP- versus seawater-induced oocyte maturation in marine nemertean worms I. The roles of serine/threonine kinases and phosphatases. Molecular Reproduction and Development, 2006, 73, 1578-1590.	2.0	18
314	Regulation of K–Cl cotransport by protein phosphatase 1α in mouse erythrocytes. Pflugers Archiv European Journal of Physiology, 2006, 451, 760-768.	2.8	16
315	Myosin-based contraction is not necessary for cardiac c-looping in the chick embryo. Anatomy and Embryology, 2006, 211, 443-454.	1.5	24
316	Using a mammalian cell cycle simulation to interpret differential kinase inhibition in anti-tumour pharmaceutical development. BioSystems, 2006, 83, 91-97.	2.0	37
317	Focal adhesion and actin organization by a cross-talk of TM4SF5 with integrin α2 are regulated by serum treatment. Experimental Cell Research, 2006, 312, 2983-2999.	2.6	31
318	Serine phosphorylation differentially affects RhoA binding to effectors: Implications to NGF-induced neurite outgrowth. Cellular Signalling, 2006, 18, 704-714.	3.6	52
320	Inhibition of TNFα-induced activation of nuclear factor κB by kava (Piper methysticum) derivatives. Biochemical Pharmacology, 2006, 71, 1206-1218.	4.4	83
321	Oxidative stress-driven mechanisms of nordihydroguaiaretic acid-induced apoptosis in FL5.12 cells. Toxicology and Applied Pharmacology, 2006, 214, 230-236.	2.8	16
322	Organometallic Compounds with Biological Activity: A Very Selective and Highly Potent Cellular Inhibitor for Glycogen Synthase Kinase 3. ChemBioChem, 2006, 7, 1443-1450.	2.6	110
323	Collagen type I selectively activates ectodomain shedding of the discoidin domain receptor 1: Involvement of Src tyrosine kinase. Journal of Cellular Biochemistry, 2006, 98, 672-684.	2.6	39
324	Can MM-PBSA calculations predict the specificities of protein kinase inhibitors?. Journal of Computational Chemistry, 2006, 27, 1990-2007.	3.3	55
325	Temporal change in local forces and total force all over the surface of the sea urchin egg during cytokinesis. Cytoskeleton, 2006, 63, 208-221.	4.4	21
326	Role of extracellular-regulated kinase and c-jun NH2-terminal kinase in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurofilament phosphorylation. Journal of Neuroscience Research, 2006, 83, 680-693.	2.9	16
327	Apoptosis induced by chemotherapeutic agents involves c-Jun N-terminal kinase activation in sarcoma cell lines. Journal of Orthopaedic Research, 2006, 24, 1153-1162.	2.3	16
328	Replication-Dependent DNA Damage Response Triggered by Roscovitine Induces an Uncoupling of DNA Replication Proteins. Cell Cycle, 2006, 5, 2153-2159.	2.6	12
329	C-Jun N-Terminal Kinase Mediates Tumor Necrosis Factor-α Suppression of Differentiation in Myoblasts. Endocrinology, 2006, 147, 4363-4373.	2.8	39

#	Article	IF	CITATIONS
330	Activation of the Apoptotic JNK Pathway Through the Rac1â€Binding Scaffold Protein POSH. Methods in Enzymology, 2006, 406, 479-489.	1.0	13
331	Identification of a Novel Pathway Essential for the Immediate-Early, Interferon-Independent Antiviral Response to Enveloped Virions. Journal of Virology, 2006, 80, 226-235.	3.4	61
332	Aggregated IgG inhibits the differentiation of human fibrocytes. Journal of Leukocyte Biology, 2006, 79, 1242-1251.	3.3	91
333	Potential Use of Pharmacological Cyclin-Dependent Kinase Inhibitors as Anti-HIV Therapeutics. Current Pharmaceutical Design, 2006, 12, 1949-1961.	1.9	47
334	Herpes Simplex Viruses in Antiviral Drug Discovery. Current Pharmaceutical Design, 2006, 12, 1357-1370.	1.9	23
335	Computational Approaches to Model Ligand Selectivity in Drug Design. Current Topics in Medicinal Chemistry, 2006, 6, 41-55.	2.1	37
336	Natural Product-Derived Small Molecule Activators of Hypoxia-Inducible Factor-1 (HIF-1). Current Pharmaceutical Design, 2006, 12, 2673-2688.	1.9	62
337	B cell proliferation following CD40 stimulation results in the expression and activation of Src protein tyrosine kinase. International Immunology, 2006, 18, 375-387.	4.0	25
338	Role of a tyrosine kinase in the CO2-induced stimulation of HCO3â^' reabsorption by rabbit S2 proximal tubules. American Journal of Physiology - Renal Physiology, 2006, 291, F358-F367.	2.7	26
339	Effects of SAPK/JNK inhibitors on preimplantation mouse embryo development are influenced greatly by the amount of stress induced by the media. Molecular Human Reproduction, 2006, 12, 217-224.	2.8	44
340	c-Jun N-terminal kinase-dependent mechanisms in respiratory disease. European Respiratory Journal, 2006, 28, 651-661.	6.7	45
341	câ€jun Nâ€terminal kinase hyperphosphorylates R406W tau at the PHFâ€1 site during mitosis. FASEB Journal, 2006, 20, 762-764.	0.5	33
342	Mitogen activated protein kinase inhibitors: where are we now and where are we going?. Annals of the Rheumatic Diseases, 2006, 65, iii83-iii88.	0.9	68
343	Transforming Growth Factor B1 Stimulated DNA Synthesis in the Granulosa Cells of Preantral Follicles: Negative Interaction with Epidermal Growth Factor1. Biology of Reproduction, 2006, 75, 140-148.	2.7	11
344	Dynamic Positive Feedback Phosphorylation of Mixed Lineage Kinase 3 by JNK Reversibly Regulates Its Distribution to Triton-soluble Domains. Journal of Biological Chemistry, 2006, 281, 19134-19144.	3.4	32
345	Antagonists of Myosin Light Chain Kinase and of Myosin II Inhibit Specific Events of Egg Activation in Fertilized Mouse Eggs1. Biology of Reproduction, 2006, 74, 169-176.	2.7	60
346	Distinct Priming Kinases Contribute to Differential Regulation of Collapsin Response Mediator Proteins by Glycogen Synthase Kinase-3 in Vivo. Journal of Biological Chemistry, 2006, 281, 16591-16598.	3.4	198
347	In vitro and In vivo Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells. Cancer Research, 2006, 66, 11314-11322.	0.9	352

#	Article	IF	CITATIONS
348	Five Years of Progress on Cyclin-Dependent Kinases and other Cellular Proteins as Potential Targets for Antiviral Drugs. Antiviral Chemistry and Chemotherapy, 2006, 17, 293-320.	0.6	70
349	Selective Repression of Low-Density Lipoprotein Receptor Expression by SP600125: Coupling of Histone H3-Ser10 Phosphorylation and Sp1 Occupancy. Molecular and Cellular Biology, 2006, 26, 1307-1317.	2.3	14
350	Distinct Mechanisms of Clathrin-independent Endocytosis Have Unique Sphingolipid Requirements. Molecular Biology of the Cell, 2006, 17, 3197-3210.	2.1	137
351	An Essential Role for the Integrin-Linked Kinase-Glycogen Synthase Kinase-3Â Pathway during Dendrite Initiation and Growth. Journal of Neuroscience, 2006, 26, 13344-13356.	3.6	64
352	Role of Src homology 2 domain-mediated PTK signaling in mouse zygotic development. Reproduction, 2006, 132, 413-421.	2.6	28
353	Inhibition of RET tyrosine kinase by SU5416. Journal of Molecular Endocrinology, 2006, 37, 199-212.	2.5	68
354	Dependence of Cisplatin-Induced Cell Death In Vitro and In Vivo on Cyclin-Dependent Kinase 2. Journal of the American Society of Nephrology: JASN, 2006, 17, 2434-2442.	6.1	90
355	Improved Tumor Control through Circadian Clock Induction by Seliciclib, a Cyclin-Dependent Kinase Inhibitor. Cancer Research, 2006, 66, 10720-10728.	0.9	109
356	Physiological Concentrations of Insulin Induce Endothelin-Dependent Vasoconstriction of Skeletal Muscle Resistance Arteries in the Presence of Tumor Necrosis Factor-α Dependence on c-Jun N-Terminal Kinase. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 274-280.	2.4	73
357	Phosphorylation of Amphiphysin I by Minibrain Kinase/Dual-specificity Tyrosine Phosphorylation-regulated Kinase, a Kinase Implicated in Down Syndrome. Journal of Biological Chemistry, 2006, 281, 23712-23724.	3.4	61
358	Perlecan Proteolysis Induces an α2β1 Integrin- and Src Family Kinase-dependent Anti-apoptotic Pathway in Fibroblasts in the Absence of Focal Adhesion Kinase Activation. Journal of Biological Chemistry, 2006, 281, 30383-30392.	3.4	62
359	Imprint of evolutionary conservation and protein structure variation on the binding function of protein tyrosine kinases. Bioinformatics, 2006, 22, 1846-1854.	4.1	14
360	c-Jun N-terminal Kinase-mediated Stabilization of Microsomal Prostaglandin E2 Synthase-1 mRNA Regulates Delayed Microsomal Prostaglandin E2 Synthase-1 Expression and Prostaglandin E2 Biosynthesis by Cardiomyocytes. Journal of Biological Chemistry, 2006, 281, 16443-16452.	3.4	27
361	IL-1β and TNF-α Regulation of the Adenosine Receptor (A2A) Expression: Differential Requirement for NF-κB Binding to the Proximal Promoter. Journal of Immunology, 2006, 177, 7173-7183.	0.8	72
362	Matrix Metalloproteinase-2 Expression by Vascular Smooth Muscle Cells Is Mediated by Both Stimulatory and Inhibitory Signals in Response to Growth Factors. Journal of Biological Chemistry, 2006, 281, 25915-25925.	3.4	63
363	Disruption of JNK2 Decreases the Cytokine Response to <i>Plasmodium falciparum</i> Glycosylphosphatidylinositol In Vitro and Confers Protection in a Cerebral Malaria Model. Journal of Immunology, 2006, 177, 6344-6352.	0.8	50
364	Effects of Glycogen Synthase Kinase 3β and Cyclin-Dependent Kinase 5 Inhibitors on Morphine-Induced Analgesia and Tolerance in Rats. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 832-839.	2.5	44
365	Identification of SRC as a key PKA-stimulated tyrosine kinase involved in the capacitation-associated hyperactivation of murine spermatozoa. Journal of Cell Science, 2006, 119, 3182-3192.	2.0	170

#	Article	IF	CITATIONS
366	Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2274-2279.	7.1	516
367	Overcoming the Hurdle of Fluorescent Compounds in Kinase Screening: A Case Study. Assay and Drug Development Technologies, 2006, 4, 185-196.	1.2	13
368	Activation of p53 in Cervical Cancer Cells by Human Papillomavirus E6 RNA Interference Is Transient, but Can Be Sustained by Inhibiting Endogenous Nuclear Export–Dependent p53 Antagonists. Cancer Research, 2006, 66, 11817-11824.	0.9	36
369	The Proline-Histidine-Rich CDK2/CDK4 Interaction Region of C/EBPα Is Dispensable for C/EBPα-Mediated Growth Regulation In Vivo. Molecular and Cellular Biology, 2006, 26, 1028-1037.	2.3	21
370	AML1/RUNX1 Phosphorylation by Cyclin-Dependent Kinases Regulates the Degradation of AML1/RUNX1 by the Anaphase-Promoting Complex. Molecular and Cellular Biology, 2006, 26, 7420-7429.	2.3	69
371	Stimulation of the Epithelial Sodium Channel (ENaC) by cAMP Involves Putative ERK Phosphorylation Sites in the C Termini of the Channel's β- and γ-Subunit. Journal of Biological Chemistry, 2006, 281, 9859-9868.	3.4	60
372	Src Activation Is Not Necessary for Transforming Growth Factor (TGF)-Î <sup>2</sup> -mediated Epithelial to Mesenchymal Transitions (EMT) in Mammary Epithelial Cells. Journal of Biological Chemistry, 2006, 281, 59-68.	3.4	42
373	Plumbagin (5-Hydroxy-2-methyl-1,4-naphthoquinone) Induces Apoptosis and Cell Cycle Arrest in A549 Cells through p53 Accumulation via c-Jun NH2-Terminal Kinase-Mediated Phosphorylation at Serine 15 in Vitro and in Vivo. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 484-494.	2.5	199
374	The selectivity of protein kinase inhibitors: a further update. Biochemical Journal, 2007, 408, 297-315.	3.7	2,287
375	Differential Function of PTPα and PTPα Y789F in T Cells and Regulation of PTPα Phosphorylation at Tyr-789 by CD45. Journal of Biological Chemistry, 2007, 282, 20925-20932.	3.4	17
376	Phosphatidylinositol Ether Lipid Analogues That Inhibit AKT Also Independently Activate the Stress Kinase, p381±, through MKK3/6-independent and -dependent Mechanisms. Journal of Biological Chemistry, 2007, 282, 27020-27029.	3.4	49
377	Small-molecule-mediated rescue of protein function by an inducible proteolytic shunt. Proceedings of the United States of America, 2007, 104, 11209-11214.	7.1	88
378	Methods for Studying Signalâ€Dependent Regulation of Translation Factor Activity. Methods in Enzymology, 2007, 431, 113-142.	1.0	33
379	Supervillin slows cell spreading by facilitating myosin II activation at the cell periphery. Journal of Cell Science, 2007, 120, 3792-3803.	2.0	54
380	Inhibitory role of Src family tyrosine kinases on Ca2+-dependent insulin release. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E845-E852.	3.5	25
381	Fluorescence Resonance Energy Transfer in Quantum Dot-Protein Kinase Assemblies. Journal of Biomedicine and Biotechnology, 2007, 2007, 1-5.	3.0	7
382	Structure-Based Approaches in the Design of GSK-3 Selective Inhibitors. Current Protein and Peptide Science, 2007, 8, 352-364.	1.4	26
383	Protein Kinases as Small Molecule Inhibitor Targets in Inflammation. Current Medicinal Chemistry, 2007, 14, 2214-2234.	2.4	85

#	Article	IF	CITATIONS
384	Ca2+ signaling in hypoxic pulmonary vasoconstriction: effects of myosin light chain and Rho kinase antagonists. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 293, L674-L685.	2.9	57
385	Exploring sequence-structure relationships in the tyrosine kinome space: functional classification of the binding specificity mechanisms for cancer therapeutics. Bioinformatics, 2007, 23, 1919-1926.	4.1	19
386	Molecular basis for specificity in the druggable kinome: sequence-based analysis. Bioinformatics, 2007, 23, 563-572.	4.1	52
387	Characterization of a Protein Kinase B Inhibitor In Vitro and in Insulin-Treated Liver Cells. Diabetes, 2007, 56, 2218-2227.	0.6	87
388	Inflammatory Signaling in Cartilage: MAPK and NF-κ B Pathways in Chondrocytes and the Use of Inhibitors for Research into Pathogenesis and Therapy of Osteoarthritis. Current Drug Targets, 2007, 8, 305-313.	2.1	141
389	IL-1β–Induced Transcriptional Up-Regulation of Bradykinin B1and B2Receptors in Murine Airways. American Journal of Respiratory Cell and Molecular Biology, 2007, 36, 697-705.	2.9	36
390	Ethanol Induces Long-Term Facilitation of NR2B-NMDA Receptor Activity in the Dorsal Striatum: Implications for Alcohol Drinking Behavior. Journal of Neuroscience, 2007, 27, 3593-3602.	3.6	169
391	PKN Activation via Transforming Growth Factor-β1 (TGF-β1) Receptor Signaling Delays G2/M Phase Transition in Vascular Smooth Muscle Cells. Cell Cycle, 2007, 6, 739-749.	2.6	18
392	Transforming Growth Factor $\hat{l}^2$ Is a Critical Regulator of Adult Human Islet Plasticity. Molecular Endocrinology, 2007, 21, 1467-1477.	3.7	23
393	Chemical genetics: Reshaping biology through chemistry. HFSP Journal, 2007, 1, 104-114.	2.5	7
394	5-Hydroxytryptamine4 Receptor Activation of the Extracellular Signal-regulated Kinase Pathway Depends on Src Activation but Not on G Protein or β-Arrestin Signaling. Molecular Biology of the Cell, 2007, 18, 1979-1991.	2.1	68
395	Attenuation of Ozone-Induced Airway Inflammation and Hyper-Responsiveness by c-Jun NH2 Terminal Kinase Inhibitor SP600125. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 351-359.	2.5	56
396	Hematopoiesis and Thymic Apoptosis Are Not Affected by the Loss of Cdk2. Molecular and Cellular Biology, 2007, 27, 5079-5089.	2.3	26
397	PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with <i>EGFR</i> and <i>ERBB2</i> Mutations that Are Resistant to Gefitinib. Cancer Research, 2007, 67, 11924-11932.	0.9	674
398	Estradiol-17β regulates mouse uterine epithelial cell proliferation through insulin-like growth factor 1 signaling. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 15847-15851.	7.1	118
399	Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth. Molecular Cancer Therapeutics, 2007, 6, 2220-2229.	4.1	30
400	Aberrant Splicing of Cyclin-Dependent Kinase–Associated Protein Phosphatase KAP Increases Proliferation and Migration in Glioblastoma. Cancer Research, 2007, 67, 130-138.	0.9	60
401	Inhibition of Src family kinases enhances retinoic acid induced gene expression and myeloid differentiation. Molecular Cancer Therapeutics, 2007, 6, 3081-3090.	4.1	28

#	Article	IF	CITATIONS
402	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20523-20528.	7.1	342
403	Intracellular signaling during myocardial ischemia. , 0, , 90-100.		0
404	IL-1β stimulates rat cardiac fibroblast migration via MAP kinase pathways. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H1139-H1147.	3.2	104
405	A sharper instrument for dissecting signalling events: a specific AGC kinase inhibitor. Biochemical Journal, 2007, 401, e1-3.	3.7	5
406	Regulation of p73-mediated apoptosis by c-Jun N-terminal kinase. Biochemical Journal, 2007, 405, 617-623.	3.7	72
407	Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis. Blood, 2007, 109, 560-565.	1.4	96
408	Src family tyrosine kinases mediate contraction of rat isolated tail arteries in response to a hyposmotic stimulus. Journal of Hypertension, 2007, 25, 1871-1878.	0.5	14
409	MAPKs and Their Inhibitors in Neuronal Differentiation. Current Enzyme Inhibition, 2007, 3, 298-308.	0.4	3
410	Subject Index To Volume 5. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2007, 6, 3-6.	1.1	0
411	Blocking Apoptotic Intracellular Signaling Cascades with Cell-Permeable Peptides. Current Signal Transduction Therapy, 2007, 2, 175-179.	0.5	0
412	c-Jun N-terminal kinase mediates constitutive human eosinophil apoptosis. Pulmonary Pharmacology and Therapeutics, 2007, 20, 580-587.	2.6	12
413	Localized activation of Src-family protein kinases in the mouse egg. Developmental Biology, 2007, 306, 241-254.	2.0	56
414	LTP Inhibits LTD in the Hippocampus via Regulation of GSK3β. Neuron, 2007, 53, 703-717.	8.1	632
415	c-Jun N-terminal kinase inhibitor SP600125 modulates the period of mammalian circadian rhythms. Neuroscience, 2007, 145, 812-823.	2.3	36
416	c-Jun N-terminal kinase signaling regulates events associated with both health and degeneration in motoneurons. Neuroscience, 2007, 147, 680-692.	2.3	21
417	Triterpenoid saponin, oleanolic acid 3-O-Î <sup>2</sup> -d-glucopyranosyl(1â†'3)-α-l-rhamnopyranosyl(1â†'2)-α-l-arabinopyranoside (OA) from Aralia elata inhibits LPS-induced nitric oxide production by down-regulated NF-ήB in raw 264.7 cells. Archives of Biochemistry and Biophysics, 2007, 467, 227-233.	3.0	50
418	Cell cycle molecules define a pathway required for neuron death in development and disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2007, 1772, 392-401.	3.8	108
419	Human B lymphocytes and non-Hodgkin's lymphoma cells become polyploid in response to the protein kinase inhibitor SU6656. Blood Cells, Molecules, and Diseases, 2007, 39, 130-134.	1.4	9

		Report	
# 420	ARTICLE Systematic Discovery of In Vivo Phosphorylation Networks. Cell, 2007, 129, 1415-1426.	IF 28.9	Citations
421	Functional Redundancy of GSK-3α and GSK-3β in Wnt/β-Catenin Signaling Shown by Using an Allelic Series of Embryonic Stem Cell Lines. Developmental Cell, 2007, 12, 957-971.	7.0	428
422	Synthesis, Biological Testing, and Binding Mode Prediction of 6,9-Diarylpurin-8-ones as p38 MAP Kinase Inhibitors. Journal of Medicinal Chemistry, 2007, 50, 2060-2066.	6.4	23
423	GTP Binding Is Essential to the Protein Kinase Activity of LRRK2, a Causative Gene Product for Familial Parkinson's Diseaseâ€. Biochemistry, 2007, 46, 1380-1388.	2.5	246
424	GSK-3-Mediated Phosphorylation Enhances Maf-Transforming Activity. Molecular Cell, 2007, 28, 584-597.	9.7	102
425	Src-Family Kinases Are Activated in Non-Small Cell Lung Cancer and Promote the Survival of Epidermal Growth Factor Receptor-Dependent Cell Lines. American Journal of Pathology, 2007, 170, 366-376.	3.8	141
426	Using Chemical Genetics and ATP Analogues To Dissect Protein Kinase Function. ACS Chemical Biology, 2007, 2, 299-314.	3.4	59
427	Diversity of the intracellular mechanisms underlying the anti-tumor properties of indirubins. International Congress Series, 2007, 1304, 60-74.	0.2	14
428	Use of Hyperosmolar Stress to Measure Stress-Activated Protein Kinase Activation and Function in Human HTR Cells and Mouse Trophoblast Stem Cells. Reproductive Sciences, 2007, 14, 534-547.	2.5	34
429	Automated, Quantitative Screening Assay for Antiangiogenic Compounds Using Transgenic Zebrafish. Cancer Research, 2007, 67, 11386-11392.	0.9	215
430	Novel Inositol Phospholipid Headgroup Surrogate Crystallized in the Pleckstrin Homology Domain of Protein Kinase Bα. ACS Chemical Biology, 2007, 2, 242-246.	3.4	20
431	Reconstitution of Modular PDK1 Functions on Trans-Splicing of the Regulatory PH and Catalytic Kinase Domains. Bioconjugate Chemistry, 2007, 18, 1294-1302.	3.6	10
432	A Model for the Recognition of Protein Kinases Based on the Entropy of 3D van der Waals Interactions. Journal of Proteome Research, 2007, 6, 904-908.	3.7	78
433	Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors. Journal of Medicinal Chemistry, 2007, 50, 409-424.	6.4	474
434	Targeting Strategies to Modulate the NF-κB and JNK Signal Transduction Network. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2007, 6, 71-84.	1.1	3
435	Chemical Biology. , 2007, , 129-149.		3
436	Protein Kinase Inhibitors for the Treatment of Inflammation - An Overview. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2007, 6, 3-4.	1.1	1
437	Tetrabromocinnamic Acid (TBCA) and Related Compounds Represent a New Class of Specific Protein Kinase CK2 Inhibitors. ChemBioChem, 2007, 8, 129-139.	2.6	109

#	Article	IF	CITATIONS
438	Europium Tetracycline as a Luminescent Probe for Nucleoside Phosphates and Its Application to the Determination of Kinase Activity. Chemistry - A European Journal, 2007, 13, 4342-4349.	3.3	119
439	In silico profiling of tyrosine kinases binding specificity and drug resistance using Monte Carlo simulations with the ensembles of protein kinase crystal structures. Biopolymers, 2007, 85, 333-348.	2.4	25
440	Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: Potential proinflammatory mechanisms. Arthritis and Rheumatism, 2007, 56, 3347-3357.	6.7	88
441	Computational chemistry approach to protein kinase recognition using 3D stochastic van der Waals spectral moments. Journal of Computational Chemistry, 2007, 28, 1042-1048.	3.3	56
442	Exogenous heat shock protein 27 uniquely blocks differentiation of monocytes to dendritic cells. European Journal of Immunology, 2007, 37, 2812-2824.	2.9	43
443	Synthesis and Evaluation of 3-Phenylpyrazolo[3,4-d]pyrimidine-Peptide Conjugates as Src Kinase Inhibitors. ChemMedChem, 2007, 2, 1346-1360.	3.2	25
444	Synthesis of aminopyrimidylindoles structurally related to meridianins. Tetrahedron, 2007, 63, 10169-10176.	1.9	29
445	Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 668-672.	2.2	47
446	Inverse In Silico Screening for Identification of Kinase Inhibitor Targets. Chemistry and Biology, 2007, 14, 1207-1214.	6.0	80
447	Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene, 2007, 26, 3291-3310.	5.9	2,421
448	Cooperation between JNK1 and JNK2 in activation of p53 apoptotic pathway. Oncogene, 2007, 26, 7222-7230.	5.9	122
449	Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nature Reviews Drug Discovery, 2007, 6, 391-403.	46.4	429
450	Myosin light chain kinaseâ€independent inhibition by MLâ€9 of murine TRPC6 channels expressed in HEK293 cells. British Journal of Pharmacology, 2007, 152, 122-131.	5.4	29
451	The binding and phosphorylation of Thr231 is critical for Tau's hyperphosphorylation and functional regulation by glycogen synthase kinase 3β. Journal of Neurochemistry, 2007, 103, 802-813.	3.9	76
452	Natural Products Active in Aberrant c-Kit Signaling. Chemical Biology and Drug Design, 2007, 69, 321-330.	3.2	14
453	Rewired ERK-JNK Signaling Pathways in Melanoma. Cancer Cell, 2007, 11, 447-460.	16.8	260
454	Early myeloid cells expressing c-KIT isoforms differ in signal transduction, survival and chemotactic responses to Stem Cell Factor. Cellular Signalling, 2007, 19, 2572-2581.	3.6	21
455	Cytotoxicity of NF-Î⁰B inhibitors Bay 11-7085 and caffeic acid phenethyl ester to Ramos and other human B-lymphoma cell lines. Experimental Hematology, 2007, 35, 1495-1509.	0.4	30

#	Article	IF	CITATIONS
456	A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discovery Today, 2007, 12, 622-633.	6.4	170
457	Inhibition of Src family tyrosine kinases prevents lipopolysaccharide-induced hyporeactivity in isolated rat tail arteries. Vascular Pharmacology, 2007, 46, 195-200.	2.1	7
458	Gadd45a, the gene induced by the mood stabilizer valproic acid, regulates neurite outgrowth through JNK and the substrate paxillin in N1E-115 neuroblastoma cells. Experimental Cell Research, 2007, 313, 1886-1896.	2.6	54
459	Photobleaching reveals complex effects of inhibitors on transcribing RNA polymerase II in living cells. Experimental Cell Research, 2007, 313, 3026-3033.	2.6	8
460	The role of intracellular signaling in insulin-mediated regulation of drug metabolizing enzyme gene and protein expression. , 2007, 113, 88-120.		140
461	Glutathione regulation of redox-sensitive signals in tumor necrosis factor-α-induced vascular endothelial dysfunction. Toxicology and Applied Pharmacology, 2007, 221, 168-178.	2.8	6
462	Concise Review: Regulation of Embryonic Stem Cell Lineage Commitment by Mitogen-Activated Protein Kinases. Stem Cells, 2007, 25, 1090-1095.	3.2	90
463	Glycogen synthase kinase-3 regulation of chromatin segregation and cytokinesis in mouse preimplantation embryos. Molecular Reproduction and Development, 2007, 74, 178-188.	2.0	32
464	Distinct responses of human granulosa lutein cells after hCG or LH stimulation in a spheroidal cell culture system. Molecular Reproduction and Development, 2007, 74, 1312-1316.	2.0	11
465	Crystal structures of the Nâ€ŧerminal kinase domain of human RSK1 bound to three different ligands: Implications for the design of RSK1 specific inhibitors. Protein Science, 2007, 16, 2626-2635.	7.6	38
466	Abrupt Reoxygenation of Microvascular Endothelial Cells After Hypoxia Activates ERK1/2 and JNK1, Leading to NADPH Oxidase-Dependent Oxidant Production. Microcirculation, 2007, 14, 125-136.	1.8	19
467	Inhibition of ERK and JNK Decreases Both Osmosensitive Taurine Release and Cell Proliferation in Glioma Cells. Neurochemical Research, 2007, 32, 1940-1949.	3.3	12
468	Molecular connexions between dementia and diabetes. Neuroscience and Biobehavioral Reviews, 2007, 31, 1046-1063.	6.1	148
469	Myosin Light Chain Kinase Inhibition: Correction of Increased Intestinal Epithelial Permeability In Vitro. Pharmaceutical Research, 2008, 25, 1377-1386.	3.5	63
470	Promotion of Neuronal Plasticity by (â^')-Epigallocatechin-3-Gallate. Neurochemical Research, 2008, 33, 776-783.	3.3	48
471	Analysis of the transcriptional activity of endogenous NFAT5 in primary cells using transgenic NFAT-luciferase reporter mice. BMC Molecular Biology, 2008, 9, 13.	3.0	35
472	Odin (ANKS1A) is a Src family kinase target in colorectal cancer cells. Cell Communication and Signaling, 2008, 6, 7.	6.5	29
473	Two specific drugs, BMS-345541 and purvalanol A induce apoptosis of HTLV-1 infected cells through inhibition of the NF-kappaB and cell cycle pathways. AIDS Research and Therapy, 2008, 5, 12.	1.7	16

#	Article	IF	CITATIONS
474	Signal transduction pathways involved in interaction of galactosylceramide/sulfatideâ€containing liposomes with cultured oligodendrocytes and requirement for myelin basic protein and glycosphingolipids. Journal of Neuroscience Research, 2008, 86, 1448-1458.	2.9	31
475	Preclinical efficacy on GSKâ€3 inhibitors: Towards a future generation of powerful drugs. Medicinal Research Reviews, 2008, 28, 773-796.	10.5	93
476	Stimulus Dependence of the Action of Smallâ€Molecule Inhibitors in the CD3/CD28 Signalling Network. ChemMedChem, 2008, 3, 1404-1411.	3.2	1
477	Apoptosis of estrogenâ€receptor negative breast cancer and colon cancer cell lines by PTPα and src RNAi. International Journal of Cancer, 2008, 122, 1999-2007.	5.1	53
478	3,4,5â€trihydroxybenzaldehyde from <i>Geum japonicum</i> has dual inhibitory effect on matrix metalloproteinase 9; inhibition of gelatinoytic activity as well as MMPâ€9 expression in TNFâ€Î± induced HASMC. Journal of Cellular Biochemistry, 2008, 105, 524-533.	2.6	11
479	Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology, 2008, 47, 1557-1566.	7.3	227
480	Inhibitors of c-Jun N-terminal kinases—JuNK no more?. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2008, 1784, 76-93.	2.3	114
481	Implications for selectivity of 3,4-diarylquinolinones as p38αMAP kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1431-1435.	2.2	48
482	Identification of Chemical Inhibitors to Human Tissue Transglutaminase by Screening Existing Drug Libraries. Chemistry and Biology, 2008, 15, 969-978.	6.0	59
483	The Nrf2–Keap1 defence pathway: Role in protection against drug-induced toxicity. Toxicology, 2008, 246, 24-33.	4.2	304
484	Roscovitine-Derived, Dual-Specificity Inhibitors of Cyclin-Dependent Kinases and Casein Kinases 1. Journal of Medicinal Chemistry, 2008, 51, 5229-5242.	6.4	124
485	Assessment of Chemical Coverage of Kinome Space and Its Implications for Kinase Drug Discovery. Journal of Medicinal Chemistry, 2008, 51, 7898-7914.	6.4	158
486	DYRK1A-Dosage Imbalance Perturbs NRSF/REST Levels, Deregulating Pluripotency and Embryonic Stem Cell Fate in Down Syndrome. American Journal of Human Genetics, 2008, 83, 388-400.	6.2	139
487	DYRK1A phosphorylates caspase <b>9</b> at an inhibitory site and is potently inhibited in human cells by harmine. FEBS Journal, 2008, 275, 6268-6280.	4.7	104
488	Roscovitine Reduces Neuronal Loss, Glial Activation, and Neurologic Deficits after Brain Trauma. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 1845-1859.	4.3	108
489	Ligand release-independent transactivation of epidermal growth factor receptor by transforming growth factor-β involves multiple signaling pathways. Oncogene, 2008, 27, 614-628.	5.9	55
490	Targeting c-Jun and JunB proteins as potential anticancer cell therapy. Oncogene, 2008, 27, 641-652.	5.9	36
491	CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene, 2008, 27, 5797-5807.	5.9	165

		CITATION R	EPORT	
#	Article		IF	CITATIONS
492	A quantitative analysis of kinase inhibitor selectivity. Nature Biotechnology, 2008, 26,	127-132.	17.5	2,186
493	A traffic-activated Golgi-based signalling circuit coordinates the secretory pathway. Na Biology, 2008, 10, 912-922.	ture Cell	10.3	175
494	Src-family kinases play an essential role in differentiation signaling downstream of mac colony-stimulating factor receptors mediating persistent phosphorylation of phospholi MAP kinases ERK1 and ERK2. Leukemia, 2008, 22, 161-169.	rrophage ipase C-l³2 and	7.2	19
495	Two conventional protein kinase C isoforms, α and βI, are involved in the ATPâ€induce volumeâ€regulated anion channel and glutamate release in cultured astrocytes. Journa Neurochemistry, 2008, 105, 2260-2270.		3.9	37
496	Mitogenâ€activated protein kinases in hemostasis and thrombosis. Journal of Thrombo Haemostasis, 2008, 6, 2007-2016.	osis and	3.8	141
497	SRC-dependent signalling regulates actin ruffle formation induced by glycerophosphoi 4-phosphate. Biochimica Et Biophysica Acta - Molecular Cell Research, 2008, 1783, 23	nositol 11-2322.	4.1	14
498	Glycogen synthase kinases $3\hat{l}_{\pm}$ and $3\hat{l}^2$ in cardiac myocytes: Regulation and consequer inhibition. Cellular Signalling, 2008, 20, 206-218.	ices of their	3.6	50
499	8-Prenylkaempferol suppresses inducible nitric oxide synthase expression through inte JNK-mediated AP-1 pathway in murine macrophages. European Journal of Pharmacolog 430-436.	rfering with y, 2008, 590,	3.5	34
500	Structures of P. falciparum Protein Kinase 7 Identify an Activation Motif and Leads for Design. Structure, 2008, 16, 228-238.	Inhibitor	3.3	62
501	<i>In Silico</i> Drug Profiling of the Human Kinome Based on a Molecular Marker for C Reactivity. Molecular Pharmaceutics, 2008, 5, 728-738.	Cross	4.6	7
502	Design, synthesis and characterization of "clickable―4-anilinoquinazoline kinase i Molecular BioSystems, 2008, 4, 542.	nhibitors.	2.9	10
505	Slow motility in hair cells of the frog amphibian papilla: Myosin light chain-mediated sh Hearing Research, 2008, 241, 7-17.	ape change.	2.0	4
506	Activation of p38 and JNK MAPK pathways abrogates requirement for new protein synt phorbol ester mediated induction of select MMP and TIMP genes. Matrix Biology, 2008		3.6	28
507	Chemical inhibition of Src family kinases affects major LPS-activated pathways in prima macrophages. Molecular Immunology, 2008, 45, 990-1000.	ary human	2.2	65
508	Role of apoptosis signal-regulating kinase 1 in complement-mediated glomerular epith Molecular Immunology, 2008, 45, 2236-2246.	elial cell injury.	2.2	36
509	Discovery and biochemical characterization of selective ATP competitive inhibitors of t mitotic kinesin KSP. Archives of Biochemistry and Biophysics, 2008, 469, 220-231.	he human	3.0	49
510	Role for mitogen-activated protein kinase p38α in lung epithelial branching morphoge Developmental Biology, 2008, 314, 224-235.	nesis.	2.0	44
511	c-Jun N-terminal kinase pathways in diabetes. International Journal of Biochemistry and 2008, 40, 2702-2706.	Cell Biology,	2.8	54

#	Article	IF	CITATIONS
512	Indirubin-3′-monoxime, a derivative of a Chinese anti-leukemia medicine, inhibits Notch1 signaling. Cancer Letters, 2008, 265, 215-225.	7.2	26
513	Myosin light-chain kinase contributes to the proliferation and migration of breast cancer cells through cross-talk with activated ERK1/2. Cancer Letters, 2008, 270, 312-327.	7.2	68
514	TCR signaling and environment affect vasoactive intestinal peptide receptor-1 (VPAC-1) expression in primary mouse CD4 T cells. Brain, Behavior, and Immunity, 2008, 22, 1032-1040.	4.1	14
515	Chlamydia trachomatis tarp is phosphorylated by src family tyrosine kinases. Biochemical and Biophysical Research Communications, 2008, 371, 339-344.	2.1	66
516	Protective role of c-Jun N-terminal kinase 2 in acetaminophen-induced liver injury. Biochemical and Biophysical Research Communications, 2008, 374, 6-10.	2.1	42
517	Downregulation of Diacylglycerol Kinase Delta Contributes to Hyperglycemia-Induced Insulin Resistance. Cell, 2008, 132, 375-386.	28.9	194
518	Design, Synthesis, and Biological Evaluation of Novel 3-Aryl-4-(1 <i>H</i> -indole-3yl)-1,5-dihydro-2 <i>H</i> -pyrrole-2-ones as Vascular Endothelial Growth Factor Receptor (VEGF-R) Inhibitors. Journal of Medicinal Chemistry, 2008, 51, 3814-3824.	6.4	82
519	A Novel Mechanism of Mechanical Stress-Induced Hypertrophy. Novartis Foundation Symposium, 2008, , 20-40.	1.1	3
520	Virtual Screening to Successfully Identify Novel Janus Kinase 3 Inhibitors: A Sequential Focused Screening Approach. Journal of Medicinal Chemistry, 2008, 51, 7015-7019.	6.4	17
521	Endogenous methyl palmitate modulates nicotinic receptor-mediated transmission in the superior cervical ganglion. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 19526-19531.	7.1	39
522	Suppression of v-Src Transformation by Andrographolide via Degradation of the v-Src Protein and Attenuation of the Erk Signaling Pathway. Journal of Biological Chemistry, 2008, 283, 5023-5033.	3.4	44
523	Relative Resistance of Cdk5-phosphorylated CRMP2 to Dephosphorylation. Journal of Biological Chemistry, 2008, 283, 18227-18237.	3.4	42
524	Serotonin (5-HT) Transport in Human Platelets is Modulated by Src-Catalysed Tyr-Phosphorylation of the Plasma Membrane Transporter SERT. Cellular Physiology and Biochemistry, 2008, 21, 087-094.	1.6	21
525	The Effect of the JNK Inhibitor, JIP Peptide, on Human T Lymphocyte Proliferation and Cytokine Production. Journal of Immunology, 2008, 181, 7300-7306.	0.8	23
526	Inhibitors of Cyclin Dependent Kinases: Useful Targets for Cancer Treatment. Current Cancer Drug Targets, 2008, 8, 53-75.	1.6	77
527	Prostanoid F receptors elicit an inotropic effect in rat left ventricle by enhancing myosin light chain phosphorylation. Cardiovascular Research, 2008, 80, 407-415.	3.8	12
528	Mechanical factors activate <i>ß</i> â€cateninâ€dependent oncogene expression in APC <sup>1638N/+</sup> mouse colon. HFSP Journal, 2008, 2, 286-294.	2.5	74
529	Different Mitogen-Activated Protein Kinase-Dependent Cytokine Responses in Cells of the Monocyte Lineage. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 306-312.	2.5	63

#	ARTICLE	IF	CITATIONS
530	Combined Inhibition of c-Src and Epidermal Growth Factor Receptor Abrogates Growth and Invasion of Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2008, 14, 4284-4291.	7.0	95
531	N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine. Molecular Cancer Therapeutics, 2008, 7, 2713-2724.	4.1	51
532	Tissue-specific PKA inhibition using a chemical genetic approach and its application to studies on sperm capacitation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20740-20745.	7.1	54
533	Constitutive Activity of JNK2α2 Is Dependent on a Unique Mechanism of MAPK Activation. Journal of Biological Chemistry, 2008, 283, 34935-34945.	3.4	24
534	T Cell Ig and Mucin Domain-1-Mediated T Cell Activation Requires Recruitment and Activation of Phosphoinositide 3-Kinase. Journal of Immunology, 2008, 180, 6518-6526.	0.8	56
535	Transforming Growth Factor-β1 (TGFβ1) Stimulates Connective Tissue Growth Factor (CCN2/CTGF) Expression in Human Gingival Fibroblasts through a RhoA-independent, Rac1/Cdc42-dependent Mechanism. Journal of Biological Chemistry, 2008, 283, 10835-10847.	3.4	49
536	JNK MAP kinase activation is required for MTOC and granule polarization in NKG2D-mediated NK cell cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3017-3022.	7.1	98
537	Illuminating signaling network functional biology through quantitative phosphoproteomic mass spectrometry. Briefings in Functional Genomics & Proteomics, 2008, 7, 383-394.	3.8	4
538	Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB Journal, 2008, 22, 3224-3233.	0.5	210
539	A chemical biology approach reveals period shortening of the mammalian circadian clock by specific inhibition of CSK-31². Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20746-20751.	7.1	273
540	Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2358-2362.	7.1	46
541	Localization of PTP-1B, SHP-2, and Src Exclusively in Rat Brain Mitochondria and Functional Consequences. Journal of Biological Chemistry, 2008, 283, 24406-24411.	3.4	62
542	Immunomodulation of human B cells following treatment with intravenous immunoglobulins involves increased phosphorylation of extracellular signal-regulated kinases 1 and 2. International Immunology, 2008, 20, 1369-1379.	4.0	21
543	The Role of Akt-GSK-3β Signaling and Synaptic Strength in Phencyclidine-Induced Neurodegeneration. Neuropsychopharmacology, 2008, 33, 1343-1353.	5.4	58
544	Selective Induction of Expression of a Ligand for the NKG2D Receptor by Proteasome Inhibitors. Cancer Research, 2008, 68, 1546-1554.	0.9	90
545	Src tyrosine kinase alters gating of hyperpolarization-activated HCN4 pacemaker channel through Tyr <sup>531</sup> . American Journal of Physiology - Cell Physiology, 2008, 294, C355-C362.	4.6	43
546	The small GTPase Rac-1 is a regulator of mesangial cell morphology and thrombospondin-1 expression. American Journal of Physiology - Renal Physiology, 2008, 294, F407-F413.	2.7	17
547	Unique Biology of Mcl-1: Therapeutic Opportunities in Cancer. Current Molecular Medicine, 2008, 8, 138-147.	1.3	166

#	Article	IF	CITATIONS
548	Pharmacological characterization of a small molecule inhibitor of c-Jun kinase. American Journal of Physiology - Endocrinology and Metabolism, 2008, 295, E1142-E1151.	3.5	23
549	Platelets undergo phosphorylation of Syk at Y525/526 and Y352 in response to pathophysiological shear stress. American Journal of Physiology - Cell Physiology, 2008, 295, C1045-C1054.	4.6	27
550	Regulation of contractility by Hsp27 and Hic-5 in rat mesenteric small arteries. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H961-H969.	3.2	32
551	Reactive oxygen species mediate RhoA/Rho kinase-induced Ca <sup>2+</sup> sensitization in pulmonary vascular smooth muscle following chronic hypoxia. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2008, 295, L515-L529.	2.9	132
552	JAK2, But Not Src Family Kinases, Is Required for STAT, ERK, and Akt Signaling in Response to Growth Hormone in Preadipocytes and Hepatoma Cells. Molecular Endocrinology, 2008, 22, 1825-1841.	3.7	47
553	Endoplasmic Reticulum Stress Increases the Expression of Methylenetetrahydrofolate Reductase through the IRE1 Transducer. Journal of Biological Chemistry, 2008, 283, 3151-3160.	3.4	20
554	Inhibition of the Cyclin-Dependent Kinases at the Beginning of Human Cytomegalovirus Infection Specifically Alters the Levels and Localization of the RNA Polymerase II Carboxyl-Terminal Domain Kinases cdk9 and cdk7 at the Viral Transcriptosome. Journal of Virology, 2008, 82, 394-407.	3.4	62
555	Thrombin Induces Fibroblast CCL2/JE Production and Release via Coupling of PAR <sub>1</sub> to Gî± <sub>q</sub> and Cooperation between ERK1/2 and Rho Kinase Signaling Pathways. Molecular Biology of the Cell, 2008, 19, 2520-2533.	2.1	51
556	Increased c-Jun-NH2-Kinase Signaling in Neurofibromatosis-1 Heterozygous Microglia Drives Microglia Activation and Promotes Optic Glioma Proliferation. Cancer Research, 2008, 68, 10358-10366.	0.9	105
557	Acrolein Induces Heme Oxygenase-1 through PKC-δ and PI3K in Human Bronchial Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2008, 38, 483-490.	2.9	79
558	Phosphorylation of Steroidogenic Factor 1 Is Mediated by Cyclin-Dependent Kinase 7. Molecular Endocrinology, 2008, 22, 91-104.	3.7	39
559	Expression of the Transcriptional Repressor ATF3 in Gonadotrophs Is Regulated by Egr-1, CREB, and ATF2 after Gonadotropin-Releasing Hormone Receptor Stimulation. Endocrinology, 2008, 149, 6311-6325.	2.8	52
560	Migration of Airway Smooth Muscle Cells. Proceedings of the American Thoracic Society, 2008, 5, 97-105.	3.5	67
561	Seliciclib, a cell-cycle modulator that acts through the inhibition of cyclin-dependent kinases. Expert Opinion on Drug Discovery, 2008, 3, 131-143.	5.0	17
562	Characterization of compound 584, an Abl kinase inhibitor with lasting effects. Haematologica, 2008, 93, 653-661.	3.5	14
563	Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia. Blood, 2008, 112, 4665-4674.	1.4	53
564	GSK-3 Inhibitors: Recent Developments and Therapeutic Potential. Current Signal Transduction Therapy, 2008, 3, 195-205.	0.5	3
565	Organ- and Cell-Type Specific Delivery of Kinase Inhibitors: A Novel Approach in the Development of Targeted Drugs. Current Molecular Pharmacology, 2008, 1, 1-12.	1.5	15

#	Article	IF	CITATIONS
566	The diverse functions of Src family kinases in macrophages. Frontiers in Bioscience - Landmark, 2008, Volume, 4426.	3.0	55
567	Post-transcriptional gene regulation by MAP kinases via AU-rich elements. Frontiers in Bioscience - Landmark, 2009, Volume, 847.	3.0	54
568	Src-family tyrosine kinases as therapeutic targets in advanced cancer. Frontiers in Bioscience - Elite, 2009, E3, 801.	1.8	0
569	Nonprimed and DYRK1A-primed GSK3β-phosphorylation sites on MAP1B regulate microtubule dynamics in growing axons. Journal of Cell Science, 2009, 122, 2424-2435.	2.0	92
570	The Tumor Suppressor p53 Transcriptionally Regulates cGKI Expression during Neuronal Maturation and Is Required for cGMP-Dependent Growth Cone Collapse. Journal of Neuroscience, 2009, 29, 15155-15160.	3.6	29
571	Akt Inhibitor Akt-IV Blocks Virus Replication through an Akt-Independent Mechanism. Journal of Virology, 2009, 83, 11665-11672.	3.4	26
572	Phosphorylation of Histone H3 by Protein Kinase C Signaling Plays a Critical Role in the Regulation of the Developmentally Important TBX2 Gene. Journal of Biological Chemistry, 2009, 284, 26368-26376.	3.4	13
573	The Commonly Used cGMP-dependent Protein Kinase Type I (cGKI) Inhibitor Rp-8-Br-PET-cGMPS Can Activate cGKI in Vitro and in Intact Cells. Journal of Biological Chemistry, 2009, 284, 556-562.	3.4	37
574	Characterization of a Selective Inhibitor of Inositol Hexakisphosphate Kinases. Journal of Biological Chemistry, 2009, 284, 10571-10582.	3.4	102
575	Differential activation of JNK1 isoforms by TRAIL receptors modulate apoptosis of colon cancer cell lines. British Journal of Cancer, 2009, 100, 1415-1424.	6.4	35
576	Vg1RBP phosphorylation by Erk2 MAP kinase correlates with the cortical release of Vg1 mRNA during meiotic maturation of <i>Xenopus</i> oocytes. Rna, 2009, 15, 1121-1133.	3.5	21
577	Dynamin Reduces Pyk2 Y402 Phosphorylation and Src Binding in Osteoclasts. Molecular and Cellular Biology, 2009, 29, 3644-3656.	2.3	43
578	Protein kinase C activation stabilizes LDL receptor mRNA via the JNK pathway in HepG2 cells. Journal of Lipid Research, 2009, 50, 386-397.	4.2	18
579	Kinase Inhibitors as Potential Therapeutics for Acute and Chronic Neurodegenerative Conditions. Current Pharmaceutical Design, 2009, 15, 3919-3939.	1.9	56
580	Global Effects of Kinase Inhibitors on Signaling Networks Revealed by Quantitative Phosphoproteomics. Molecular and Cellular Proteomics, 2009, 8, 2796-2808.	3.8	194
581	Epigallocatechin-3-Gallate, a Histone Acetyltransferase Inhibitor, Inhibits EBV-Induced B Lymphocyte Transformation via Suppression of RelA Acetylation. Cancer Research, 2009, 69, 583-592.	0.9	331
582	Development of Extracellular Signal-Regulated Kinase Inhibitors. Current Topics in Medicinal Chemistry, 2009, 9, 678-689.	2.1	30
583	Peptides as Signaling Inhibitors for Mammalian MAP Kinase Cascades. Current Pharmaceutical Design, 2009, 15, 2471-2480.	1.9	21

#	Article	IF	CITATIONS
584	Inhibition of myosin light chain phosphorylation decreases rat mesenteric lymphatic contractile activity. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 297, H726-H734.	3.2	61
585	The Ste20-like kinase SLK promotes p53 transactivation and apoptosis. American Journal of Physiology - Renal Physiology, 2009, 297, F971-F980.	2.7	21
586	N-Acetyl Cysteine Mediates Protection from 2-Hydroxyethyl Methacrylate Induced Apoptosis via Nuclear Factor Kappa B–Dependent and Independent Pathways: Potential Involvement of JNK. Toxicological Sciences, 2009, 108, 356-366.	3.1	34
587	Src Family Kinases Accelerate Prolactin Receptor Internalization, Modulating Trafficking and Signaling in Breast Cancer Cells. Molecular Endocrinology, 2009, 23, 202-212.	3.7	43
588	The Fibroblast Growth Factor Receptor Inhibitor PD173074 Blocks Small Cell Lung Cancer Growth <i>In vitro</i> and <i>In vivo</i> . Cancer Research, 2009, 69, 8645-8651.	0.9	155
589	Inhibition of basal p38 or JNK activity enhances epithelial barrier function through differential modulation of claudin expression. American Journal of Physiology - Cell Physiology, 2009, 297, C775-C787.	4.6	64
590	Blockage by SP600125 of Fc Receptor-Induced Degranulation and Cytokine Gene Expression in Mast Cells is Mediated Through Inhibition of Phosphatidylinositol 3-Kinase Signalling Pathway. Journal of Biochemistry, 2009, 145, 345-354.	1.7	31
591	A novel inhibitor of Chlamydophila pneumoniae protein kinase D (PknD) inhibits phosphorylation of CdsD and suppresses bacterial replication. BMC Microbiology, 2009, 9, 218.	3.3	16
592	Grp94 is Tyr-phosphorylated by Fyn in the lumen of the endoplasmic reticulum and translocates to Golgi in differentiating myoblasts. Biochimica Et Biophysica Acta - Molecular Cell Research, 2009, 1793, 239-252.	4.1	31
593	SP600125 negatively regulates the mammalian target of rapamycin via ATF4â€induced Redd1 expression. FEBS Letters, 2009, 583, 123-127.	2.8	27
594	Distinct Nrf1/2-independent mechanisms mediate As3+-induced glutamate-cysteine ligase subunit gene expression in murine hepatocytes. Free Radical Biology and Medicine, 2009, 46, 1614-1625.	2.9	33
595	Suppression of the lipopolysaccharide-induced expression of MARCKS-related protein (MRP) affects transmigration in activated RAW264.7 cells. Cellular Immunology, 2009, 256, 92-98.	3.0	14
596	Amphiregulin is a factor for resistance of glioma cells to cannabinoidâ€induced apoptosis. Glia, 2009, 57, 1374-1385.	4.9	37
597	Targeting transforming growth factor (TGF)-βRI inhibits activation of β1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology, 2009, 49, 839-850.	7.3	127
598	CREB and APâ€1 activation regulates MKPâ€1 induction by LPS or Mâ€CSF and their kinetics correlate with macrophage activation <i>versus</i> proliferation. European Journal of Immunology, 2009, 39, 1902-1913.	2.9	38
599	The Cdk5 inhibitor roscovitine strongly inhibits glucose uptake in 3T3‣1 adipocytes without altering GLUT4 translocation from internal pools to the cell surface. Journal of Cellular Physiology, 2009, 220, 238-244.	4.1	5
600	Mutual effects of caveolin and nerve growth factor signaling in pig oligodendrocytes. Journal of Neuroscience Research, 2010, 88, 572-588.	2.9	12
601	Staurosporine tethered peptide ligands that target cAMP-dependent protein kinase (PKA): Optimization and selectivity profiling. Bioorganic and Medicinal Chemistry, 2009, 17, 6196-6202.	3.0	25

#	Article	IF	CITATIONS
602	Measuring and interpreting the selectivity of protein kinase inhibitors. Journal of Chemical Biology, 2009, 2, 131-151.	2.2	151
603	Cell Cycle Activation and CNS Injury. Neurotoxicity Research, 2009, 16, 221-237.	2.7	55
604	Design of a bioactive cellâ€penetrating peptide: when a transduction domain does more than transduce. Journal of Peptide Science, 2009, 15, 668-674.	1.4	39
605	Inhibition of cyclinâ€dependent kinases by olomoucine and roscovitine reduces lipopolysaccharideâ€induced inflammatory responses via downâ€regulation of nuclear factor κB. Cell Proliferation, 2009, 42, 141-149.	5.3	28
606	Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation. FEBS Journal, 2009, 276, 6324-6337.	4.7	224
607	Blocking UVâ€Induced eIF2α Phosphorylation with Small Molecule Inhibitors of GCN2. Chemical Biology and Drug Design, 2009, 74, 57-67.	3.2	32
608	Targeting inhibition of GluR1 Ser845 phosphorylation with an RNA aptamer that blocks AMPA receptor trafficking. Journal of Neurochemistry, 2009, 108, 147-157.	3.9	20
609	Chemical Inhibition of a Subset of Arabidopsis thaliana GSK3-like Kinases Activates Brassinosteroid Signaling. Chemistry and Biology, 2009, 16, 594-604.	6.0	240
610	QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2324-2328.	2.2	44
611	Structure–activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: Development of potential substrate-specific ERK1/2 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6042-6046.	2.2	39
612	Roles of protein kinase C isotypes during seawaterâ€versus cAMPâ€induced oocyte maturation in a marine worm. Molecular Reproduction and Development, 2009, 76, 693-707.	2.0	11
613	Interactions between mitogenâ€activated protein kinase and protein kinase C signaling during oocyte maturation and fertilization in a marine worm. Molecular Reproduction and Development, 2009, 76, 708-721.	2.0	12
614	Regulation of JNK and p38 MAPK in the immune system: Signal integration, propagation and termination. Cytokine, 2009, 48, 161-169.	3.2	255
615	Multiple Wnts are involved in Hydra organizer formation and regeneration. Developmental Biology, 2009, 330, 186-199.	2.0	277
616	Identification of c‧rc tyrosine kinase substrates in plateletâ€derived growth factor receptor signaling. Molecular Oncology, 2009, 3, 439-450.	4.6	65
617	3,5-Diphenylpent-2-enoic Acids as Allosteric Activators of the Protein Kinase PDK1: Structureâ^'Activity Relationships and Thermodynamic Characterization of Binding as Paradigms for PIF-Binding Pocket-Targeting Compoundsâ€PDB code of <b>2Z</b> with PDK1: 3HRF Journal of Medicinal Chemistry, 2009. 52. 4683-4693.	6.4	72
618	A systematic investigation of the protein kinases involved in NMDA receptor-dependent LTD: evidence for a role of GSK-3 but not other serine/threonine kinases. Molecular Brain, 2009, 2, 22.	2.6	82
620	Class 2 Transferases. , 2009, , .		О

#	Article	IF	CITATIONS
621	cGMP: Generators, Effectors and Therapeutic Implications. Handbook of Experimental Pharmacology, 2009, , .	1.8	21
622	Affinity Classification of Kinase Inhibitors by Mass Spectrometric Methods and Validation Using Standard IC50 Measurements. Analytical Chemistry, 2009, 81, 408-419.	6.5	27
623	Fulfilling the Krebs and Beavo criteria for studying protein phosphorylation in the era of mass spectrometry-driven kinome research. Archives of Physiology and Biochemistry, 2009, 115, 298-310.	2.1	3
624	Comparison of the Luminescent ADP-Glo Assay to a Standard Radiometric Assay for Measurement of Protein Kinase Activity. Assay and Drug Development Technologies, 2009, 7, 615-622.	1.2	12
625	Physiology of Cell Volume Regulation in Vertebrates. Physiological Reviews, 2009, 89, 193-277.	28.8	1,229
626	Effects of chemical manipulation of mitotic arrest and slippage on cancer cell survival and proliferation. Cell Cycle, 2009, 8, 3029-3042.	2.6	35
627	INHIBITION OF C-JUN N-TERMINAL KINASE AFTER HEMORRHAGE BUT BEFORE RESUSCITATION MITIGATES HEPATIC DAMAGE AND INFLAMMATORY RESPONSE IN MALE RATS. Shock, 2009, 32, 509-516.	2.1	28
628	Utility and Limitations of SP600125, an Inhibitor of Stress-Responsive c-Jun N-Terminal Kinase. Current Enzyme Inhibition, 2010, 6, 26-33.	0.4	7
629	Src tyrosine kinase preactivation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera. Blood, 2010, 115, 667-676.	1.4	14
630	Spatiotemporal organization, regulation, and functions of tractions during neutrophil chemotaxis. Blood, 2010, 116, 3297-3310.	1.4	33
631	Lyn-mediated mitochondrial tyrosine phosphorylation is required to preserve mitochondrial integrity in early liver regeneration. Biochemical Journal, 2010, 425, 401-412.	3.7	23
632	Palmitate Attenuates Insulin Signaling and Induces Endoplasmic Reticulum Stress and Apoptosis in Hypothalamic Neurons: Rescue of Resistance and Apoptosis through Adenosine 5′ Monophosphate-Activated Protein Kinase Activation. Endocrinology, 2010, 151, 576-585.	2.8	189
633	Anti-angiogenic potential of small molecular inhibitors of cyclin dependent kinases in vitro. Angiogenesis, 2010, 13, 239-249.	7.2	20
634	Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of central nervous system diseases. Neurobiology of Disease, 2010, 37, 549-557.	4.4	23
635	Increased responsiveness to JNK1/2 mediates the enhanced H2O2-induced stimulation of Clâ^'/HCO3â^' exchanger activity in immortalized renal proximal tubular epithelial cells from the SHR. Biochemical Pharmacology, 2010, 80, 913-919.	4.4	7
636	Activation of the p38 pathway by a novel monoketone curcumin analog, EF24, suggests a potential combination strategy. Biochemical Pharmacology, 2010, 80, 1309-1316.	4.4	48
637	Effect of quercetin on platelet spreading on collagen and fibrinogen and on multiple platelet kinases. Fìtoterapìâ, 2010, 81, 75-80.	2.2	28
638	Induction of ANGPTL4 expression in human airway smooth muscle cells by PMA through activation of PKC and MAPK pathways. Experimental Cell Research, 2010, 316, 507-516.	2.6	22

#	Article	IF	CITATIONS
639	Understanding Kinase Selectivity Through Energetic Analysis of Binding Site Waters. ChemMedChem, 2010, 5, 618-627.	3.2	112
640	Human remyelination promoting antibody inhibits apoptotic signaling and differentiation through Lyn kinase in primary rat oligodendrocytes. Glia, 2010, 58, 1782-1793.	4.9	52
641	Wntâ€3a and Wntâ€3 differently stimulate proliferation and neurogenesis of spinal neural precursors and promote neurite outgrowth by canonical signaling. Journal of Neuroscience Research, 2010, 88, 3011-3023.	2.9	47
642	Dishevelled-1 and dishevelled-3 affect cell invasion mainly through canonical and noncanonical Wnt pathway, respectively, and associate with poor prognosis in nonsmall cell lung cancer. Molecular Carcinogenesis, 2010, 49, n/a-n/a.	2.7	53
643	Matrixâ€independent stimulation of human tubular epithelial cell migration by Rho kinase inhibitors. Journal of Cellular Physiology, 2010, 223, 703-712.	4.1	17
644	Crossâ€ŧalk between MAP kinase pathways is involved in IGFâ€independent, IGFBPâ€6â€induced Rh30 rhabdomyosarcoma cell migration. Journal of Cellular Physiology, 2010, 224, 636-643.	4.1	23
645	Malaria: Targeting parasite and host cell kinomes. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2010, 1804, 604-612.	2.3	76
646	Vitamin D3-driven signals for myeloid cell differentiation—Implications for differentiation therapy. Leukemia Research, 2010, 34, 553-565.	0.8	66
647	Regulation of cell proliferation and survival: Convergence of protein kinases and caspases. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2010, 1804, 505-510.	2.3	75
648	Adenosine analogue–oligo-arginine conjugates (ARCs) serve as high-affinity inhibitors and fluorescence probes of type I cGMP-dependent protein kinase (PKGII±). Biochimica Et Biophysica Acta - Proteins and Proteomics, 2010, 1804, 1857-1868.	2.3	8
649	Probing the Probes: Fitness Factors For Small Molecule Tools. Chemistry and Biology, 2010, 17, 561-577.	6.0	253
650	Discovery of potent and bioavailable GSK-3β inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1693-1696.	2.2	27
651	Rational design of potent GSK3β inhibitors with selectivity for Cdk1 and Cdk2. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1985-1989.	2.2	23
652	High-Efficiency Induction of Neural Conversion in Human ESCs and Human Induced Pluripotent Stem Cells with a Single Chemical Inhibitor of Transforming Growth Factor Beta Superfamily Receptors Â. Stem Cells, 2010, 28, 1741-1750.	3.2	151
653	Role of the câ€ <i>Jun</i> Nâ€ŧerminal kinase pathway in retinal excitotoxicity, and neuroprotection by its inhibition. Journal of Neurochemistry, 2010, 113, 1307-1318.	3.9	35
654	Myristoylation of the dualâ€specificity phosphatase câ€JUN Nâ€terminal kinase (JNK) stimulatory phosphatase 1 is necessary for its activation of JNK signaling and apoptosis. FEBS Journal, 2010, 277, 2463-2473.	4.7	23
655	Contribution of BCR–ABLâ€independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells. Cancer Science, 2010, 101, 137-142.	3.9	27
656	SP600125 suppresses Cdk1 and induces endoreplication directly from G2 phase, independent of JNK inhibition. Oncogene, 2010, 29, 1702-1716.	5.9	51

#	Article	IF	CITATIONS
657	Phosphorylation of Mcl-1 by CDK1–cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO Journal, 2010, 29, 2407-2420.	7.8	297
658	Different responses in transformation of MDCK cells in 2D and 3D culture by v-Src as revealed by microarray techniques, RT-PCR and functional assays. Laboratory Investigation, 2010, 90, 915-928.	3.7	13
659	Role of Clycogen Synthase Kinase-3Î <sup>2</sup> in APP Hyperphosphorylation Induced by NMDA Stimulation in Cortical Neurons. Pharmaceuticals, 2010, 3, 42-58.	3.8	6
661	Cyclic Nucleotide Specificity and Cross-Activation of Cyclic Nucleotide Receptors. , 2010, , 1549-1554.		2
662	Prolactin Enhances Insulin-like Growth Factor I Receptor Phosphorylation by Decreasing Its Association with the Tyrosine Phosphatase SHP-2 in MCF-7 Breast Cancer Cells. Journal of Biological Chemistry, 2010, 285, 8003-8012.	3.4	22
663	Guidelines for the effective use of chemical inhibitors of protein function to understand their roles in cell regulation. Biochemical Journal, 2010, 425, 53-54.	3.7	62
664	Phosphorylation of STIM1 at ERK1/2 target sites modulates store-operated calcium entry. Journal of Cell Science, 2010, 123, 3084-3093.	2.0	108
665	Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic. Cancer Research, 2010, 70, 2146-2157.	0.9	254
666	Feedback Control Through cGMP-Dependent Protein Kinase Contributes to Differential Regulation and Compartmentation of cGMP in Rat Cardiac Myocytes. Circulation Research, 2010, 107, 1232-1240.	4.5	86
667	GSK3Î <sup>2</sup> Regulates Myelin-Dependent Axon Outgrowth Inhibition through CRMP4. Journal of Neuroscience, 2010, 30, 5635-5643.	3.6	99
668	Cross-talk between the p38α and JNK MAPK Pathways Mediated by MAP Kinase Phosphatase-1 Determines Cellular Sensitivity to UV Radiation. Journal of Biological Chemistry, 2010, 285, 25928-25940.	3.4	63
669	Glycogen Synthase Kinase-3β Regulates Post–Myocardial Infarction Remodeling and Stress-Induced Cardiomyocyte Proliferation In Vivo. Circulation Research, 2010, 106, 1635-1645.	4.5	108
670	The Keap1-Nrf2 Cellular Defense Pathway: Mechanisms of Regulation and Role in Protection Against Drug-Induced Toxicity. Handbook of Experimental Pharmacology, 2010, , 233-266.	1.8	82
671	Induction of long interspersed nucleotide element-1 (L1) retrotransposition by 6-formylindolo[3,2- <i>b</i> ]carbazole (FICZ), a tryptophan photoproduct. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18487-18492.	7.1	43
672	Pairwise network mechanisms in the host signaling response to coxsackievirus B3 infection. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 17053-17058.	7.1	42
673	Inhibition of the mitochondrial permeability transition by protein kinase A in rat liver mitochondria and hepatocytes. Biochemical Journal, 2010, 431, 411-421.	3.7	28
674	Activation of Adenosine A2A Receptors Induces TrkB Translocation and Increases BDNF-Mediated Phospho-TrkB Localization in Lipid Rafts: Implications for Neuromodulation. Journal of Neuroscience, 2010, 30, 8468-8480.	3.6	50
675	Dissecting the Factors Involved in the Locomotion Mode of Neuronal Migration in the Developing Cerebral Cortex. Journal of Biological Chemistry, 2010, 285, 5878-5887.	3.4	48

#	Article	IF	Citations
676	JNK1 controls mast cell degranulation and IL-1Î <sup>2</sup> production in inflammatory arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 22122-22127.	7.1	61
677	Mitogen-Activated Protein Kinase Signaling in the Heart: Angels Versus Demons in a Heart-Breaking Tale. Physiological Reviews, 2010, 90, 1507-1546.	28.8	610
678	Measuring the Constitutive Activation of c-Jun N-terminal Kinase Isoforms. Methods in Enzymology, 2010, 484, 531-548.	1.0	3
679	Natural Polyphenols that Display Anticancer Properties through Inhibition of Kinase Activity. Current Medicinal Chemistry, 2010, 17, 812-825.	2.4	116
680	A Multitude of Kinases—Which are the Best Targets in Treating Rheumatoid Arthritis?. Rheumatic Disease Clinics of North America, 2010, 36, 367-383.	1.9	37
681	Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A. Nature Communications, 2010, 1, 86.	12.8	226
682	5,5′-Substituted Indirubin-3′-oxime Derivatives as Potent Cyclin-Dependent Kinase Inhibitors with Anticancer Activity. Journal of Medicinal Chemistry, 2010, 53, 3696-3706.	6.4	79
683	Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion. Molecular Cancer, 2010, 9, 117.	19.2	47
684	Biophysical and X-ray Crystallographic Analysis of Mps1 Kinase Inhibitor Complexes <sup>,</sup> . Biochemistry, 2010, 49, 1689-1701.	2.5	35
685	cGMP-dependent protein kinases as potential targets for colon cancer prevention and treatment. Future Medicinal Chemistry, 2010, 2, 65-80.	2.3	55
686	Anti-inflammatory actions of Syk inhibitors in macrophages involve non-specific inhibition of toll-like receptors-mediated JNK signaling pathway. Molecular Immunology, 2010, 47, 1569-1578.	2.2	66
687	Neuronal differentiation by analogs of staurosporine. Neurochemistry International, 2010, 56, 554-560.	3.8	18
688	The Antimicrobial Peptide LL37 Induces the Migration of Human Pulp Cells: A Possible Adjunct for Regenerative Endodontics. Journal of Endodontics, 2010, 36, 1009-1013.	3.1	33
689	Nonmuscle Myosin-Dependent Synthesis of Type I Collagen. Journal of Molecular Biology, 2010, 401, 564-578.	4.2	41
690	MDR1 function is sensitive to the phosphorylation state of myosin regulatory light chain. Biochemical and Biophysical Research Communications, 2010, 398, 7-12.	2.1	4
691	Characterization of neuronal Src kinase purified from a bacterial expression system. Protein Expression and Purification, 2010, 74, 289-297.	1.3	8
692	Molecular basis of pharmacotherapies for cognition in Down syndrome. Trends in Pharmacological Sciences, 2010, 31, 66-73.	8.7	70
693	Activation of MTK1/MEKK4 induces cardiomyocyte death and heart failure. Journal of Molecular and Cellular Cardiology, 2010, 48, 302-309.	1.9	14

#	Article	IF	CITATIONS
694	Feeling the stress: MAPKKK-MAPKK-MAPK signaling cascades in heart failure. Journal of Molecular and Cellular Cardiology, 2010, 48, 283-285.	1.9	3
695	Epigallocatechin gallate-induced modulation of FoxO signaling in mammalian cells and C. elegans: FoxO stimulation is masked via PI3K/Akt activation by hydrogen peroxide formed in cell culture. Archives of Biochemistry and Biophysics, 2010, 501, 58-64.	3.0	85
696	Phosphoproteomics in cancer. Molecular Oncology, 2010, 4, 482-495.	4.6	159
697	Protein kinase inhibition of clinically important staurosporine analogues. Natural Product Reports, 2010, 27, 489.	10.3	122
698	Cytoskeletal Regulation of Epithelial Barrier Function During Inflammation. American Journal of Pathology, 2010, 177, 512-524.	3.8	304
699	Protein Kinases: Docking and Homology Modeling Reliability. Journal of Chemical Information and Modeling, 2010, 50, 1432-1441.	5.4	58
700	Molecular Imaging for Integrated Medical Therapy and Drug Development. , 2010, , .		6
702	A Coiled-Coil Enabled Split-Luciferase Three-Hybrid System: Applied Toward Profiling Inhibitors of Protein Kinases. Journal of the American Chemical Society, 2010, 132, 11727-11735.	13.7	67
703	Chemical approaches towards unravelling kinase-mediated signalling pathways. Chemical Society Reviews, 2011, 40, 1211-1223.	38.1	17
704	The Effects of Mitogen-Activated Protein Kinase Inhibitors or Small Interfering RNAs on Gallic Acid-Induced HeLa Cell Death in Relation to Reactive Oxygen Species and Clutathione. Journal of Agricultural and Food Chemistry, 2011, 59, 763-771.	5.2	25
705	Structurally Sophisticated Octahedral Metal Complexes as Highly Selective Protein Kinase Inhibitors. Journal of the American Chemical Society, 2011, 133, 5976-5986.	13.7	218
706	Axis Formation in Hydra. Annual Review of Genetics, 2011, 45, 105-117.	7.6	34
707	Lyn-mediated SHP-1 recruitment to CD5 contributes to resistance to apoptosis of B-cell chronic lymphocytic leukemia cells. Leukemia, 2011, 25, 1768-1781.	7.2	55
708	Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A). Archives of Biochemistry and Biophysics, 2011, 507, 212-218.	3.0	99
709	Nanosecond pulsed electric fields activate MAPK pathways in human cells. Archives of Biochemistry and Biophysics, 2011, 515, 99-106.	3.0	50
710	Rapid preparation of triazolyl substituted NH-heterocyclic kinase inhibitors via one-pot Sonogashira coupling–TMS-deprotection–CuAAC sequence. Organic and Biomolecular Chemistry, 2011, 9, 5129.	2.8	35
711	Small molecule GSK-3 inhibitors increase neurogenesis of human neural progenitor cells. Neuroscience Letters, 2011, 488, 36-40.	2.1	95
712	A key role for KCl cotransport in cell volume regulation in human erythroleukemia cells. Life Sciences, 2011, 88, 1001-1008.	4.3	1

#	Article	IF	Citations
713	Design and Characterization of a Potent and Selective Dual ATP- and Substrate-Competitive Subnanomolar Bidentate c-Jun N-Terminal Kinase (JNK) Inhibitor. Journal of Medicinal Chemistry, 2011, 54, 6206-6214.	6.4	33
714	Comparison of the specificity of Trk inhibitors in recombinant and neuronal assays. Neuropharmacology, 2011, 61, 148-155.	4.1	17
715	Comprehensive analysis of kinase inhibitor selectivity. Nature Biotechnology, 2011, 29, 1046-1051.	17.5	1,715
716	SP600125 Inhibits Cap-dependent Translation Independently of the c-Jun N-terminal Kinase Pathway. Cell Structure and Function, 2011, 36, 27-33.	1.1	5
717	New perspectives on molecular and genic therapies in Down syndrome. , 0, , 52-70.		0
719	Src-family tyrosine kinases as therapeutic targets in advanced cancer. Frontiers in Bioscience - Elite, 2011, E3, 801-807.	1.8	38
720	G12 Signaling through c-Jun NH2-Terminal Kinase Promotes Breast Cancer Cell Invasion. PLoS ONE, 2011, 6, e26085.	2.5	21
721	Efficient Generation of Fully Reprogrammed Human iPS Cells via Polycistronic Retroviral Vector and a New Cocktail of Chemical Compounds. PLoS ONE, 2011, 6, e26592.	2.5	41
722	Regulation of thrombin-induced plasminogen activator inhibitor-1 in 4T1 murine breast cancer cells. Blood Coagulation and Fibrinolysis, 2011, 22, 576-582.	1.0	9
723	The Src Family Kinase Inhibitors PP2 and PP1 Block TGF-Beta1-Mediated Cellular Responses by Direct and Differential Inhibition of Type I and Type II TGF-Beta Receptors. Current Cancer Drug Targets, 2011, 11, 524-535.	1.6	36
724	Characterization of a novel JNK (c-Jun N-terminal kinase) inhibitory peptide. Biochemical Journal, 2011, 434, 399-413.	3.7	27
725	Novel role of c-jun N-terminal kinase in regulating the initiation of cap-dependent translation. International Journal of Oncology, 2012, 40, 577-82.	3.3	7
726	The role of DYRK1A in neurodegenerative diseases. FEBS Journal, 2011, 278, 236-245.	4.7	209
727	Activation, regulation, and inhibition of DYRK1A. FEBS Journal, 2011, 278, 246-256.	4.7	175
728	Differential effects of myosin light chain kinase inhibition on contractility, force development and myosin light chain 20 phosphorylation of rat cervical and thoracic duct lymphatics. Journal of Physiology, 2011, 589, 5415-5429.	2.9	34
729	Inhibition of glycogen synthase kinase-3 enhances the differentiation and reduces the proliferation of adult human olfactory epithelium neural precursors. Experimental Cell Research, 2011, 317, 2086-2098.	2.6	21
730	Activation of p38 MAPK by damnacanthal mediates apoptosis in SKHep 1 cells through the DR5/TRAIL and TNFR1/TNF-α and p53 pathways. European Journal of Pharmacology, 2011, 650, 120-129.	3.5	40
731	Electrochemical investigations of sarcoma-related protein kinase inhibition. Electrochimica Acta, 2011, 56, 10676-10682.	5.2	22

#	Article	IF	CITATIONS
732	Atypical (RIO) protein kinases from Haemonchus contortus — Promise as new targets for nematocidal drugs. Biotechnology Advances, 2011, 29, 338-350.	11.7	28
733	Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nature Biotechnology, 2011, 29, 1039-1045.	17.5	760
734	Protein tyrosine kinase signaling during oocyte maturation and fertilization. Molecular Reproduction and Development, 2011, 78, 831-845.	2.0	49
735	Heck reaction and Stille coupling as the key steps in the synthesis of carbon-14-labeled gsk-3 inhibitor alsterpaullone. Journal of Labelled Compounds and Radiopharmaceuticals, 2011, 54, 272-277.	1.0	4
736	A force-activated kinase in a catch smooth muscle. Journal of Muscle Research and Cell Motility, 2011, 31, 349-358.	2.0	13
737	Enteral arginine modulates inhibition of AP-1/c-Jun by SP600125 in the postischemic gut. Molecular and Cellular Biochemistry, 2011, 347, 191-199.	3.1	10
738	The NMDA Receptor NR1 Subunit is Critically Involved in the Regulation of NMDA Receptor Activity by C-terminal Src kinase (Csk). Neurochemical Research, 2011, 36, 319-326.	3.3	3
739	The diterpenoid alkaloid noroxoaconitine is a Mapkap kinase 5 (MK5/PRAK) inhibitor. Cellular and Molecular Life Sciences, 2011, 68, 289-301.	5.4	8
740	Functional impact of PTP1B-mediated Src regulation on oxidative phosphorylation in rat brain mitochondria. Cellular and Molecular Life Sciences, 2011, 68, 2603-2613.	5.4	31
741	Design and evaluation of 3-aminopyrazolopyridinone kinase inhibitors inspired by the natural product indirubin. Bioorganic and Medicinal Chemistry, 2011, 19, 3569-3578.	3.0	14
742	Staphylococcus aureus Biofilm and Planktonic cultures differentially impact gene expression, mapk phosphorylation, and cytokine production in human keratinocytes. BMC Microbiology, 2011, 11, 143.	3.3	101
743	Inhibition of myosin II triggers morphological transition and increased nuclear motility. Cytoskeleton, 2011, 68, 325-339.	2.0	10
744	JNK-1 deficiency limits macrophage-mediated antigen-induced arthritis. Arthritis and Rheumatism, 2011, 63, 1603-1612.	6.7	39
745	Increased level of exogenous zinc induces cytotoxicity and up-regulates the expression of the ZnT-1 zinc transporter gene in pancreatic cancer cells. Journal of Nutritional Biochemistry, 2011, 22, 79-88.	4.2	52
746	Steroid-Insensitive ERK1/2 Activity Drives CXCL8 Synthesis and Neutrophilia by Airway Smooth Muscle. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 984-990.	2.9	22
747	Paullones as Inhibitors of Protein Kinases. Current Topics in Medicinal Chemistry, 2011, 11, 1320-1332.	2.1	47
748	Progress Towards Discovery of Antifibrotic Drugs Targeting Synthesis of Type I Collagen. Current Medicinal Chemistry, 2011, 18, 3410-3416.	2.4	11
749	Caspase-3–Dependent Mitotic Checkpoint Inactivation by the Small-Molecule Inducers of Mitotic Slippage SU6656 and Geraldol. Molecular Cancer Therapeutics, 2011, 10, 839-849.	4.1	13

#	Article	IF	CITATIONS
750	Chemical Genetics of Zipper-interacting Protein Kinase Reveal Myosin Light Chain as a Bona Fide Substrate in Permeabilized Arterial Smooth Muscle. Journal of Biological Chemistry, 2011, 286, 36978-36991.	3.4	38
751	Epidermal growth factor induces adult human islet cell dedifferentiation. Journal of Endocrinology, 2011, 211, 231-239.	2.6	20
752	High-Content Screening for Chemical Modulators of Embryonal Carcinoma Cell Differentiation and Survival. Journal of Biomolecular Screening, 2011, 16, 603-617.	2.6	17
753	Chemical modulation of memory formation in larval zebrafish. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 15468-15473.	7.1	170
754	Is it possible to improve neurodevelopmental abnormalities in Down syndrome?. Reviews in the Neurosciences, 2011, 22, 419-455.	2.9	66
755	Regulation of Serotonin Transport in Human Platelets by Tyrosine Kinase Syk. Cellular Physiology and Biochemistry, 2011, 27, 139-148.	1.6	18
756	Scapinin-induced Inhibition of Axon Elongation Is Attenuated by Phosphorylation and Translocation to the Cytoplasm. Journal of Biological Chemistry, 2011, 286, 19724-19734.	3.4	22
757	Transient expression of <i>Mnb/Dyrk1a</i> couples cell cycle exit and differentiation of neuronal precursors by inducing <i>p27KIP1</i> expression and suppressing NOTCH signaling. Development (Cambridge), 2011, 138, 2543-2554.	2.5	107
758	Differential roles of Src in transforming growth factor-ß regulation of growth arrest, epithelial-to-mesenchymal transition and cell migration in pancreatic ductal adenocarcinoma cells. International Journal of Oncology, 2011, 38, 797-805.	3.3	34
759	c-Jun N-terminal Kinase (JNK-1) Confers Protection against Brief but Not Extended Ischemia during Acute Myocardial Infarction. Journal of Biological Chemistry, 2011, 286, 13995-14006.	3.4	33
760	Rho kinase inhibitors for treatment of glaucoma. Expert Review of Ophthalmology, 2011, 6, 611-622.	0.6	18
761	Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases. Future Medicinal Chemistry, 2011, 3, 29-43.	2.3	50
766	Encountering unpredicted off-target effects of pharmacological inhibitors. Journal of Biochemistry, 2011, 150, 1-3.	1.7	14
767	A role for zinc in regulating hypoxia-induced contractile events in pulmonary endothelium. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2011, 300, L874-L886.	2.9	25
768	GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS. Frontiers in Molecular Neuroscience, 2011, 4, 32.	2.9	274
769	Pyk2 regulates H <sup>+</sup> -ATPase-mediated proton secretion in the outer medullary collecting duct via an ERK1/2 signaling pathway. American Journal of Physiology - Renal Physiology, 2012, 303, F1353-F1362.	2.7	13
770	A Framework for the Establishment of a Cnidarian Gene Regulatory Network for "Endomesoderm― Specification: The Inputs of ß-Catenin/TCF Signaling. PLoS Genetics, 2012, 8, e1003164.	3.5	116
771	Insulin inhibits hepatocyte iNOS expression induced by cytokines by an Akt-dependent mechanism. American Journal of Physiology - Renal Physiology, 2012, 302, G116-G122.	3.4	14

#	Article	IF	CITATIONS
772	Morphine Desensitization and Cellular Tolerance Are Distinguished in Rat Locus Ceruleus Neurons. Molecular Pharmacology, 2012, 82, 983-992.	2.3	44
773	Signal Transduction Pathways of the Epidermal Growth Factor Receptor in Colorectal Cancer and their Inhibition by Small Molecules. Current Medicinal Chemistry, 2012, 19, 5735-5744.	2.4	49
774	Not just inductive: a crucial mechanical role for the endoderm during heart tube assembly. Development (Cambridge), 2012, 139, 1680-1690.	2.5	79
775	Quantitative Imaging of Epithelial Cell Scattering Identifies Specific Inhibitors of Cell Motility and Cell-Cell Dissociation. Science Signaling, 2012, 5, rs5.	3.6	29
776	Regulation of a Myb Transcription Factor by Cyclin-dependent Kinase 2 in Giardia lamblia. Journal of Biological Chemistry, 2012, 287, 3733-3750.	3.4	15
777	Role of JNK in Mammary Gland Development and Breast Cancer. Cancer Research, 2012, 72, 472-481.	0.9	95
778	Extracellular Signal-Regulated Kinase Mitogen-Activated Protein Kinase-Dependent <i>SOCS-3</i> Gene Induction Requires c-Jun, Signal Transducer and Activator of Transcription 3, and Specificity Protein 3 Transcription Factors. Molecular Pharmacology, 2012, 81, 657-668.	2.3	24
779	Mouse Models of Down Syndrome as a Tool to Unravel the Causes of Mental Disabilities. Neural Plasticity, 2012, 2012, 1-26.	2.2	151
780	Use of Kinase Inhibitors to Correct ΔF508-CFTR Function. Molecular and Cellular Proteomics, 2012, 11, 745-757.	3.8	31
781	Identification and Characterization of a Novel Class of c-Jun N-terminal Kinase Inhibitors. Molecular Pharmacology, 2012, 81, 832-845.	2.3	72
782	JNK regulates the photic response of the mammalian circadian clock. EMBO Reports, 2012, 13, 455-461.	4.5	50
783	DYRK1A Kinase Inhibitors with Emphasis on Cancer. Mini-Reviews in Medicinal Chemistry, 2012, 12, 1315-1329.	2.4	4
784	Exploiting Substrate Recognition for Selective Inhibition of Protein Kinases. Current Pharmaceutical Design, 2012, 18, 2914-2920.	1.9	10
785	Conformationally Constrained Peptides as Protein Tyrosine Kinase Inhibitors. Current Pharmaceutical Design, 2012, 18, 2852-2866.	1.9	6
787	The oligopeptide DTâ€2 is a specific PKG I inhibitor only <i>in vitro</i> , not in living cells. British Journal of Pharmacology, 2012, 167, 826-838.	5.4	17
788	Equal sensitivity of Cav1.2 and Cav1.3 channels to the opposing modulations of PKA and PKG in mouse chromaffin cells. Journal of Physiology, 2012, 590, 5053-5073.	2.9	33
789	Pharmacological evaluation of benzimidazole derivatives with potential antiviral and antitumor activity. Research on Chemical Intermediates, 2012, 38, 2523-2545.	2.7	22
790	Effect of the myosin light chain kinase inhibitor ML-7 on the proteome of hearts subjected to ischemia–reperfusion injury. Journal of Proteomics, 2012, 75, 5386-5395.	2.4	27

#	Article	IF	CITATIONS
791	Proteins kinase CÉ> is required for non-small cell lung carcinoma growth and regulates the expression of apoptotic genes. Oncogene, 2012, 31, 2593-2600.	5.9	38
792	Discovery and structural insight of a highly selective protein kinase inhibitor hit through click chemistry. Chemical Communications, 2012, 48, 2788.	4.1	7
793	Cell-Based Proteome Profiling of Potential Dasatinib Targets by Use of Affinity-Based Probes. Journal of the American Chemical Society, 2012, 134, 3001-3014.	13.7	204
794	The JAK/STAT Pathway Is Involved in Synaptic Plasticity. Neuron, 2012, 73, 374-390.	8.1	185
795	Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease. Trends in Pharmacological Sciences, 2012, 33, 365-373.	8.7	69
796	Inhibition of adrenergic human prostate smooth muscle contraction by the inhibitors of câ€Jun Nâ€terminal kinase, SP600125 and Blâ€78D3. British Journal of Pharmacology, 2012, 166, 1926-1935.	5.4	19
797	Spatially Coordinated Kinase Signaling Regulates Local Axon Degeneration. Journal of Neuroscience, 2012, 32, 13439-13453.	3.6	33
798	System-based drug discovery within the human kinome. Expert Opinion on Drug Discovery, 2012, 7, 1053-1070.	5.0	32
799	NR2A and NR2B subunits differentially mediate MAP kinase signaling and mitochondrial morphology following excitotoxic insult. Neurochemistry International, 2012, 60, 506-516.	3.8	52
800	Identification of a Wnt-induced protein complex by affinity proteomics using an antibody that recognizes a sub-population of β-catenin. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2012, 1824, 925-937.	2.3	5
801	Distinct functions of JNK and câ€jun in oxidantâ€induced hepatocyte death. Journal of Cellular Biochemistry, 2012, 113, 3254-3265.	2.6	21
802	Therapeutic approaches in the improvement of cognitive performance in Down syndrome. Progress in Brain Research, 2012, 197, 1-14.	1.4	53
803	Trk Activation of the ERK1/2 Kinase Pathway Stimulates Intermediate Chain Phosphorylation and Recruits Cytoplasmic Dynein to Signaling Endosomes for Retrograde Axonal Transport. Journal of Neuroscience, 2012, 32, 15495-15510.	3.6	79
804	Role of the JNK Pathway in Human Diseases. Progress in Molecular Biology and Translational Science, 2012, 106, 145-169.	1.7	119
805	Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimer's?. ACS Chemical Neuroscience, 2012, 3, 857-872.	3.5	126
806	Stabilizers of Neuronal and Mitochondrial Calcium Cycling as a Strategy for Developing a Medicine for Alzheimer's Disease. ACS Chemical Neuroscience, 2012, 3, 873-883.	3.5	33
807	Chemoproteomic Characterization of Protein Kinase Inhibitors Using Immobilized ATP. Methods in Molecular Biology, 2012, 795, 119-134.	0.9	10
808	Effects of commonly used protein kinase inhibitors on vascular contraction and L-type Ca2+ current. Biochemical Pharmacology, 2012, 84, 1055-1061.	4.4	9

#	Article	IF	CITATIONS
809	Actin Filament Elasticity and Retrograde Flow Shape the Force-Velocity Relation of Motile Cells. Biophysical Journal, 2012, 102, 287-295.	0.5	69
810	The Substrate-Activity-Screening methodology applied to receptor tyrosine kinases: A proof-of-concept study. European Journal of Medicinal Chemistry, 2012, 57, 1-9.	5.5	16
811	Selective kinase inhibitors as tools for neuroscience research. Neuropharmacology, 2012, 63, 1227-1237.	4.1	14
812	Identification of Allosteric Inhibitors of p21-Activated Kinase. , 2012, 928, 67-79.		1
813	Small molecule inhibitors of the c-Jun N-terminal kinase (JNK) possess antiviral activity against highly pathogenic avian and human pandemic influenza A viruses. Biological Chemistry, 2012, 393, 525-534.	2.5	41
814	Testing the Promiscuity of Commercial Kinase Inhibitors Against the AGC Kinase Group Using a Split-luciferase Screen. Journal of Medicinal Chemistry, 2012, 55, 1526-1537.	6.4	35
815	c-Jun N-Terminal Kinase Mediated VEGFR2 Sustained Phosphorylation is Critical for VEGFA-Induced Angiogenesis In Vitro and In Vivo. Cell Biochemistry and Biophysics, 2012, 64, 17-27.	1.8	18
816	Protein Kinase Technologies. Neuromethods, 2012, , .	0.3	Ο
817	Prothoracicotropic Hormone. , 2012, , 1-62.		30
818	Rational Drug Design. Methods in Molecular Biology, 2012, , .	0.9	2
819	Kinase Inhibitors. Methods in Molecular Biology, 2012, , .	0.9	2
819 820	Kinase Inhibitors. Methods in Molecular Biology, 2012, , . Novel Protein Kinase Signaling Systems Regulating Lifespan Identified by Small Molecule Library Screening Using Drosophila. PLoS ONE, 2012, 7, e29782.	0.9 2.5	2 26
	Novel Protein Kinase Signaling Systems Regulating Lifespan Identified by Small Molecule Library		
820	Novel Protein Kinase Signaling Systems Regulating Lifespan Identified by Small Molecule Library Screening Using Drosophila. PLoS ONE, 2012, 7, e29782. A Chemical Screen Probing the Relationship between Mitochondrial Content and Cell Size. PLoS ONE,	2.5	26
820 821	Novel Protein Kinase Signaling Systems Regulating Lifespan Identified by Small Molecule Library Screening Using Drosophila. PLoS ONE, 2012, 7, e29782. A Chemical Screen Probing the Relationship between Mitochondrial Content and Cell Size. PLoS ONE, 2012, 7, e33755. Rottlerin-Mediated Inhibition of Chlamydia trachomatis Growth and Uptake of Sphingolipids Is	2.5 2.5	26 51
820 821 822	Novel Protein Kinase Signaling Systems Regulating Lifespan Identified by Small Molecule Library   Screening Using Drosophila. PLoS ONE, 2012, 7, e29782.   A Chemical Screen Probing the Relationship between Mitochondrial Content and Cell Size. PLoS ONE, 2012, 7, e33755.   Rottlerin-Mediated Inhibition of Chlamydia trachomatis Growth and Uptake of Sphingolipids Is   Independent of p38-Regulated/Activated Protein Kinase (PRAK). PLoS ONE, 2012, 7, e44733.   PI3K–AKT–mTOR inhibitors for the systemic treatment of endometrial cancer. Expert Review of	2.5 2.5 2.5	26 51 5
820 821 822 823	Novel Protein Kinase Signaling Systems Regulating Lifespan Identified by Small Molecule Library   Screening Using Drosophila. PLoS ONE, 2012, 7, e29782.   A Chemical Screen Probing the Relationship between Mitochondrial Content and Cell Size. PLoS ONE, 2012, 7, e33755.   Rottlerin-Mediated Inhibition of Chlamydia trachomatis Growth and Uptake of Sphingolipids Is   Independent of p38-Regulated/Activated Protein Kinase (PRAK). PLoS ONE, 2012, 7, e44733.   PI3K–AKT–mTOR inhibitors for the systemic treatment of endometrial cancer. Expert Review of Obstetrics and Gynecology, 2012, 7, 421-430.	2.5 2.5 2.5 0.4	26 51 5 1

	CHAHON R	EPORT	
#	Article	IF	CITATIONS
827	Affinityâ€based proteomic profiling: Problems and achievements. Proteomics, 2012, 12, 621-637.	2.2	38
828	Mammalian MAPK Signal Transduction Pathways Activated by Stress and Inflammation: A 10-Year Update. Physiological Reviews, 2012, 92, 689-737.	28.8	1,122
829	Epidermal Growth Factor Induces Human Oviductal Epithelial Cell Invasion by Down-Regulating E-Cadherin Expression. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1380-E1389.	3.6	15
830	Characterization of the cellular action of the MSK inhibitor SB-747651A. Biochemical Journal, 2012, 441, 347-357.	3.7	59
831	Harpagoside attenuates MPTP/MPP <sup>+</sup> induced dopaminergic neurodegeneration and movement disorder via elevating glial cell lineâ€derived neurotrophic factor. Journal of Neurochemistry, 2012, 120, 1072-1083.	3.9	22
832	MEK/Erk-based negative feedback mechanism involved in control of Steel Factor-triggered production of Krüppel-like factor 2 in mast cells. Cellular Signalling, 2012, 24, 879-888.	3.6	12
833	Cigarette smoke extract stimulates epithelial–mesenchymal transition through Src activation. Free Radical Biology and Medicine, 2012, 52, 1437-1442.	2.9	61
834	SP600125 inhibits Orthopoxviruses replication in a JNK1/2 -independent manner: Implication as a potential antipoxviral. Antiviral Research, 2012, 93, 69-77.	4.1	15
835	Cyclic stretch induces reorientation of cells in a Src family kinase- and p130Cas-dependent manner. European Journal of Cell Biology, 2012, 91, 118-128.	3.6	25
836	Preservation of NADH ubiquinone-oxidoreductase activity by Src kinase-mediated phosphorylation of NDUFB10. Biochimica Et Biophysica Acta - Bioenergetics, 2012, 1817, 718-725.	1.0	50
837	Discovery of potent small molecule inhibitors of DYRK1A by structure-based virtual screening and bioassay. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 168-171.	2.2	22
838	Ischemia/reperfusionâ€induced myosin light chain 1 phosphorylation increases its degradation by matrix metalloproteinase 2. FEBS Journal, 2012, 279, 2444-2454.	4.7	36
839	Myosin light chain kinase: pulling the strings of epithelial tight junction function. Annals of the New York Academy of Sciences, 2012, 1258, 34-42.	3.8	269
840	Plasmodium induced by SU6656, an Src family kinase inhibitor, is accompanied by a contractile ring defect. Cell Biochemistry and Function, 2012, 30, 33-40.	2.9	1
841	Regulation of voltage-gated sodium current by endogenous Src family kinases in cochlear spiral ganglion neurons in culture. Pflugers Archiv European Journal of Physiology, 2012, 463, 571-584.	2.8	6
842	Recent advances in the multitargetâ€directed ligands approach for the treatment of Alzheimer's disease. Medicinal Research Reviews, 2013, 33, 139-189.	10.5	394
843	Validation of microarray data in human lymphoblasts shows a role of the ubiquitin-proteasome system and NF-kB in the pathogenesis of Down syndrome. BMC Medical Genomics, 2013, 6, 24.	1.5	22
844	Epigallocatechin-3-gallate prevents oxidative phosphorylation deficit and promotes mitochondrial biogenesis in human cells from subjects with Down's syndrome. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 542-552.	3.8	124

#	Article	IF	CITATIONS
845	Cellular signalling of the receptor for advanced glycation end products (RAGE). Cellular Signalling, 2013, 25, 2185-2197.	3.6	410
846	Comparative amino acid decomposition analysis of potent type I p38α inhibitors. DARU, Journal of Pharmaceutical Sciences, 2013, 21, 41.	2.0	4
847	Tyrosine phosphorylation of the orphan receptor ESDN/DCBLD2 serves as a scaffold for the signaling adaptor CrkL. FEBS Letters, 2013, 587, 2313-2318.	2.8	15
848	Profiling the kinome: Current capabilities and future challenges. Journal of Proteomics, 2013, 81, 43-55.	2.4	27
849	Transcriptional regulation of the growth-regulated oncogene α gene by early growth response protein-1 in response to tumor necrosis factor α stimulation. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2013, 1829, 1066-1074.	1.9	25
850	Formaldehyde induces hyperphosphorylation and polymerization of Tau protein both in vitro and in vivo. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 4102-4116.	2.4	96
851	A Casein kinase 1/Checkpoint kinase 1 pyrazolo-pyridine protein kinase inhibitor as novel activator of the p53 pathway. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5578-5585.	2.2	13
852	Off-target effect of the Epac agonist 8-pCPT-2â€2-O-Me-cAMP on P2Y12 receptors in blood platelets. Biochemical and Biophysical Research Communications, 2013, 437, 603-608.	2.1	15
853	Development of DANDYs, New 3,5-Diaryl-7-azaindoles Demonstrating Potent DYRK1A Kinase Inhibitory Activity. Journal of Medicinal Chemistry, 2013, 56, 9569-9585.	6.4	55
854	The Coming of Age of Phosphoproteomics—from Large Data Sets to Inference of Protein Functions. Molecular and Cellular Proteomics, 2013, 12, 3453-3464.	3.8	90
855	Comparing Immobilized Kinase Inhibitors and Covalent ATP Probes for Proteomic Profiling of Kinase Expression and Drug Selectivity. Journal of Proteome Research, 2013, 12, 1723-1731.	3.7	48
856	Beyond Secretases. Annual Reports in Medicinal Chemistry, 2013, 48, 57-71.	0.9	3
857	Molecular mechanisms involved in cochlear implantation trauma and the protection of hearing and auditory sensory cells by inhibition of câ€junâ€Nâ€ŧerminal kinase signaling. Laryngoscope, 2013, 123, S1-14.	2.0	64
858	Diversity oriented approach to triazole based peptidomimetics as mammalian sterile 20 kinase inhibitors. RSC Advances, 2013, 3, 24447.	3.6	12
859	Large-scale cytological profiling for functional analysis of bioactive compounds. Molecular BioSystems, 2013, 9, 2604.	2.9	45
860	Chemical proteomics and functional proteomics strategies for protein kinase inhibitor validation and protein kinase substrate identification: Applications to protein kinase CK2. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 1352-1358.	2.3	13
861	<scp>BDNF</scp> â€mediated regulation of ethanol consumption requires the activation of the <scp>MAP</scp> kinase pathway and protein synthesis. European Journal of Neuroscience, 2013, 37, 607-612.	2.6	61
862	Different Head Environments in Tarantula Thick Filaments Support aÂCooperative Activation Process. Biophysical Journal, 2013, 105, 2114-2122.	0.5	22

#	Article	IF	CITATIONS
864	Anti-obesity effects of 3-hydroxychromone derivative, a novel small-molecule inhibitor of glycogen synthase kinase-3. Biochemical Pharmacology, 2013, 85, 965-976.	4.4	22
865	CDK inhibitors suppress Th17 and promote iTreg differentiation, and ameliorate experimental autoimmune encephalomyelitis in mice. Biochemical and Biophysical Research Communications, 2013, 435, 378-384.	2.1	21
866	Human protein kinase inhibitor screening by capillary electrophoresis using transverse diffusion of laminar flow profiles for reactant mixing. Journal of Chromatography A, 2013, 1314, 298-305.	3.7	33
867	Affinity Profiling of the Cellular Kinome for the Nucleotide Cofactors ATP, ADP, and GTP. ACS Chemical Biology, 2013, 8, 599-607.	3.4	73
868	Activityâ€based kinase profiling of approved tyrosine kinase inhibitors. Genes To Cells, 2013, 18, 110-122.	1.2	171
869	Using Phosphoâ€Motif Antibodies to Determine Kinase Substrates. Current Protocols in Molecular Biology, 2013, 101, Unit 18.20	2.9	6
870	Interleukin-6 in the pathogenesis of posterior capsule opacification and the potential role for interleukin-6 inhibition in the future of cataract surgery. Medical Hypotheses, 2013, 80, 466-474.	1.5	21
871	A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochemical Journal, 2013, 451, 313-328.	3.7	115
872	JNK inhibitors as anti-inflammatory and neuroprotective agents. Future Medicinal Chemistry, 2013, 5, 539-551.	2.3	35
873	Prospects for Improving Brain Function in Individuals with Down Syndrome. CNS Drugs, 2013, 27, 679-702.	5.9	69
874	TNFR2 Activates MLCK-Dependent Tight Junction Dysregulation to Cause Apoptosis-Mediated Barrier Loss and Experimental Colitis. Gastroenterology, 2013, 145, 407-415.	1.3	300
875	5′-OH-5-nitro-Indirubin oxime (AGM130), an Indirubin derivative, induces apoptosis of Imatinib-resistant chronic myeloid leukemia cells. Leukemia Research, 2013, 37, 427-433.	0.8	25
876	MAPK inhibitors augment gallic acid-induced A549 lung cancer cell death through the enhancement of glutathione depletion. Oncology Reports, 2013, 30, 513-519.	2.6	16
877	Insights into dietary flavonoids as molecular templates for the design of anti-platelet drugs. Cardiovascular Research, 2013, 97, 13-22.	3.8	46
878	Mitogen-Activated Protein Kinases and Their Role in Radiation Response. Genes and Cancer, 2013, 4, 401-408.	1.9	256
879	Inhibitors of the ROCK Serine/Threonine Kinases. The Enzymes, 2013, 33 Pt A, 193-212.	1.7	6
880	Role of a Hippocampal Src-Family Kinase-Mediated Glutamatergic Mechanism in Drug Context-Induced Cocaine Seeking. Neuropsychopharmacology, 2013, 38, 2657-2665.	5.4	36
881	A BCR/ABL-hIL-2 DNA Vaccine Enhances the Immune Responses in BALB/c Mice. BioMed Research International, 2013, 2013, 1-9.	1.9	6

#	Article	IF	CITATIONS
882	Pyrvinium pamoate does not activate protein kinase CK1, but promotes Akt/PKB down-regulation and CSK3 activation. Biochemical Journal, 2013, 452, 131-137.	3.7	47
883	Flavanoids induce expression of the suppressor of cytokine signalling 3 ( <i>SOCS3</i> ) gene and suppress IL-6-activated signal transducer and activator of transcription 3 (STAT3) activation in vascular endothelial cells. Biochemical Journal, 2013, 454, 283-293.	3.7	48
884	Chemical tools to probe cellular <i>O</i> -GlcNAc signalling. Biochemical Journal, 2013, 456, 1-12.	3.7	27
885	Requirement for active glycogen synthase kinase-3β in TGF-β <sub>1</sub> upregulation of connective tissue growth factor (CCN2/CTGF) levels in human gingival fibroblasts. American Journal of Physiology - Cell Physiology, 2013, 305, C581-C590.	4.6	11
886	Structure and function of MK5/PRAK: the loner among the mitogen-activated protein kinase-activated protein kinase. Biological Chemistry, 2013, 394, 1115-1132.	2.5	28
887	Myosin VI small insert isoform maintains exocytosis by tethering secretory granules to the cortical actin. Journal of Cell Biology, 2013, 200, 301-320.	5.2	68
888	Design of Glycogen Synthase Kinase-3 Inhibitors: An Overview on Recent Advancements. Current Pharmaceutical Design, 2013, 19, 4755-4775.	1.9	33
889	Nonredundant Roles of Src-Family Kinases and Syk in the Initiation of B-Cell Antigen Receptor Signaling. Journal of Immunology, 2013, 190, 1807-1818.	0.8	23
890	Investigating Flavonoids as Molecular Templates for the Design of Smallâ€Molecule Inhibitors of Cell Signaling. Journal of Food Science, 2013, 78, N1921-8.	3.1	6
891	mTOR complex 2 phosphorylates IMP1 cotranslationally to promote IGF2 production and the proliferation of mouse embryonic fibroblasts. Genes and Development, 2013, 27, 301-312.	5.9	80
892	Diverse Roles for MAPK Signaling in Circadian Clocks. Advances in Genetics, 2013, 84, 1-39.	1.8	76
893	Egr-1 mediates epidermal growth factor-induced downregulation of E-cadherin expression via Slug in human ovarian cancer cells. Oncogene, 2013, 32, 1041-1049.	5.9	57
894	Contrasting Roles of Mitogen-Activated Protein Kinases in Cellular Entry and Replication of Hepatitis C Virus: MKNK1 Facilitates Cell Entry. Journal of Virology, 2013, 87, 4214-4224.	3.4	28
895	Olomoucine II, but Not Purvalanol A, Is Transported by Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1). PLoS ONE, 2013, 8, e75520.	2.5	6
896	A Phenotypic Screen in Zebrafish Identifies a Novel Small-Molecule Inducer of Ectopic Tail Formation Suggestive of Alterations in Non-Canonical Wnt/PCP Signaling. PLoS ONE, 2013, 8, e83293.	2.5	19
897	Genetics of melanoma. Frontiers in Genetics, 2012, 3, 330.	2.3	27
898	DYRK1A: A Potential Drug Target for Multiple Down Syndrome Neuropathologies. CNS and Neurological Disorders - Drug Targets, 2014, 13, 26-33.	1.4	88
899	Wnt Signaling Activates Shh Signaling in Early Postnatal Intervertebral Discs, and Re-Activates Shh Signaling in Old Discs in the Mouse. PLoS ONE, 2014, 9, e98444.	2.5	54

#	Article	IF	CITATIONS
900	Role of LARP6 and Nonmuscle Myosin in Partitioning of Collagen mRNAs to the ER Membrane. PLoS ONE, 2014, 9, e108870.	2.5	19
901	Casein Kinase II Inhibitor Enhances Production of Infectious Genotype 1a Hepatitis C Virus (H77S). PLoS ONE, 2014, 9, e113938.	2.5	7
902	Stimulation of Insulin Signaling and Inhibition of JNK-AP1 Activation Protect Cells from Amyloid-β-Induced Signaling Dysregulation and Inflammatory Response. Journal of Alzheimer's Disease, 2014, 40, 105-122.	2.6	23
903	Green tea compounds in breast cancer prevention and treatment. World Journal of Clinical Oncology, 2014, 5, 520.	2.3	74
904	c-Src and Pyk2 Protein Tyrosine Kinases Play Protective Roles in Early HIV-1 Infection of CD4+ T-Cell Lines. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 118-126.	2.1	6
905	Glycogen Synthase Kinase-3l² Inhibition Ameliorates Cardiac Parasympathetic Dysfunction in Type 1 Diabetic Akita Mice. Diabetes, 2014, 63, 2097-2113.	0.6	16
906	<i>Challenges of assigning protein kinases to in vivo phosphorylation events</i> . Focus on "Use of LC-MS/MS and Bayes' theorem to identify protein kinases that phosphorylate aquaporin-2 at Ser <sup>256</sup> ― American Journal of Physiology - Cell Physiology, 2014, 307, C121-C122.	4.6	4
907	Targets and Small Molecules Against Tauopathies. Part 1: From Genes to Soluble, Aggregation-Prone Tau Proteins. , 2014, , 643-715.		0
908	Src-Family Tyrosine Kinases in Oogenesis, Oocyte Maturation and Fertilization: An Evolutionary Perspective. Advances in Experimental Medicine and Biology, 2014, 759, 33-56.	1.6	11
909	The Haemophilus ducreyi LspA1 Protein Inhibits Phagocytosis By Using a New Mechanism Involving Activation of C-Terminal Src Kinase. MBio, 2014, 5, e01178-14.	4.1	12
910	<scp>JNK</scp> signalling in cancer: in need of new, smarter therapeutic targets. British Journal of Pharmacology, 2014, 171, 24-37.	5.4	292
911	The Resistance Tetrad. Methods in Enzymology, 2014, 548, 117-146.	1.0	16
912	Quantitative Structureâ€Activity Relationship Analysis and a Combined Ligandâ€Based/Structureâ€Based Virtual Screening Study for Glycogen Synthase Kinaseâ€3. Molecular Informatics, 2014, 33, 627-640.	2.5	7
913	Selective inhibition of RET mediated cell proliferation in vitro by the kinase inhibitor SPP86. BMC Cancer, 2014, 14, 853.	2.6	14
914	Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations. Drug Design, Development and Therapy, 2015, 9, 103.	4.3	87
915	Glycogen synthase kinase 3, circadian rhythms, and bipolar disorder: a molecular link in the therapeutic action of lithium. Journal of Circadian Rhythms, 2014, 5, 3.	1.3	110
916	Epigallocatechinâ€3â€gallate, a DYRK1A inhibitor, rescues cognitive deficits in <scp>D</scp> own syndrome mouse models and in humans. Molecular Nutrition and Food Research, 2014, 58, 278-288.	3.3	234
917	Regulation of TrkB receptor translocation to lipid rafts by adenosine A2A receptors and its functional implications for BDNF-induced regulation of synaptic plasticity. Purinergic Signalling, 2014, 10, 251-267.	2.2	36

#	Article	IF	CITATIONS
918	Dyrk1a haploinsufficiency induces diabetes in mice through decreased pancreatic beta cell mass. Diabetologia, 2014, 57, 960-969.	6.3	33
919	Reciprocal Encoding of Signal Intensity and Duration in a Glucose-Sensing Circuit. Cell, 2014, 156, 1084-1095.	28.9	78
920	Synthesis of Dynole 34-2, Dynole 2-24 and Dyngo 4a for investigating dynamin GTPase. Nature Protocols, 2014, 9, 851-870.	12.0	49
921	Nuclear and cytosolic JNK signalling in neurons. Nature Reviews Neuroscience, 2014, 15, 285-299.	10.2	268
922	EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy. Cellular and Molecular Life Sciences, 2014, 71, 3465-3488.	5.4	55
923	Anti-inflammatory and antiviral effects of indirubin derivatives in influenza A (H5N1) virus infected primary human peripheral blood-derived macrophages and alveolar epithelial cells. Antiviral Research, 2014, 106, 95-104.	4.1	34
924	A high-performance liquid chromatography assay for Dyrk1a, a Down syndrome-associated kinase. Analytical Biochemistry, 2014, 449, 172-178.	2.4	15
925	CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells. Oncogene, 2014, 33, 5675-5687.	5.9	59
926	A critical role for the regulation of Syk from agglutination to aggregation in human platelets. Biochemical and Biophysical Research Communications, 2014, 443, 580-585.	2.1	3
927	Advances in Therapeutics for Neurodegenerative Tauopathies: Moving toward the Specific Targeting of the Most Toxic Tau Species. ACS Chemical Neuroscience, 2014, 5, 752-769.	3.5	63
928	Adaptive Cellular Stress Pathways as Therapeutic Targets of Dietary Phytochemicals: Focus on the Nervous System. Pharmacological Reviews, 2014, 66, 815-868.	16.0	122
929	Phosphorylation of Hepatitis C Virus RNA Polymerases Ser29 and Ser42 by Protein Kinase C-Related Kinase 2 Regulates Viral RNA Replication. Journal of Virology, 2014, 88, 11240-11252.	3.4	20
930	Inhibition of JNK2 and JNK3 by JNK inhibitor IX induces prometaphase arrest-dependent apoptotic cell death in human Jurkat T cells. Biochemical and Biophysical Research Communications, 2014, 452, 845-851.	2.1	11
931	An Inhibitor's-Eye View of the ATP-Binding Site of CDKs in Different Regulatory States. ACS Chemical Biology, 2014, 9, 1251-1256.	3.4	27
932	Tsc2 Is a Molecular Checkpoint Controlling Osteoblast Development and Glucose Homeostasis. Molecular and Cellular Biology, 2014, 34, 1850-1862.	2.3	52
933	Stress-Induced Enzyme Activation Primes Murine Embryonic Stem Cells to Differentiate Toward the First Extraembryonic Lineage. Stem Cells and Development, 2014, 23, 3049-3064.	2.1	22
934	Dominant Role of Peroxiredoxin/JNK Axis in Stemness Regulation During Neurogenesis from Embryonic Stem Cells. Stem Cells, 2014, 32, 998-1011.	3.2	37
936	Cdk5 and its substrates, Dcx and p27kip1, regulate cytoplasmic dilation formation and nuclear elongation in migrating neurons. Development (Cambridge), 2014, 141, 3540-3550.	2.5	43

#	Article	IF	CITATIONS
937	Pharmacophore Modeling, Ensemble Docking, Virtual Screening, and Biological Evaluation on Glycogen Synthase Kinaseâ $\in$ 3Î <sup>2</sup> . Molecular Informatics, 2014, 33, 610-626.	2.5	15
938	Dual inhibition of Src family kinases and Aurora kinases by SU6656 modulates CTGF (connective tissue) Tj ETQq1	1 0.7843 2.8	14 rgBT /O
	Cell Biology, 2014, 46, 39-48.		
939	Time-dependent inhibitory effects of cGMP-analogues on thrombin-induced platelet-derived microparticles formation, platelet aggregation, and P-selectin expression. Biochemical and Biophysical Research Communications, 2014, 449, 357-363.	2.1	5
940	FoxO3a Nuclear Localization and Its Association with β-Catenin and Smads in IFN-α-Treated Hepatocellular Carcinoma Cell Lines. Journal of Interferon and Cytokine Research, 2014, 34, 858-869.	1.2	8
941	Pyridinyl imidazole compounds interfere with melanosomes sorting through the inhibition of Cyclin G-associated Kinase, a regulator of cathepsins maturation. Cellular Signalling, 2014, 26, 716-723.	3.6	12
943	Inhibition of JNK Aggravates the Recovery of Rat Hearts after Global Ischemia: The Role of Mitochondrial JNK. PLoS ONE, 2014, 9, e113526.	2.5	29
944	<scp>GPCR</scp> â€mediated <scp>EGF</scp> receptor transactivation regulates <scp>TRPV</scp> 4 action in the vasculature. British Journal of Pharmacology, 2015, 172, 2493-2506.	5.4	49
945	Response to Wnt Signaling Pathways. Journal of Bone and Mineral Research, 2015, 30, 2135-2136.	2.8	1
946	The Rhoâ€GTPase effector ROCK regulates meiotic maturation of the bovine oocyte via myosin light chain phosphorylation and cofilin phosphorylation. Molecular Reproduction and Development, 2015, 82, 849-858.	2.0	21
947	Pharmacological correction of excitation/inhibition imbalance in Down syndrome mouse models. Frontiers in Behavioral Neuroscience, 2015, 9, 267.	2.0	57
948	Principal Component Analysis of the Effects of Environmental Enrichment and (-)-epigallocatechin-3-gallate on Age-Associated Learning Deficits in a Mouse Model of Down Syndrome. Frontiers in Behavioral Neuroscience, 2015, 9, 330.	2.0	44
949	Identifying a Kinase Network Regulating FGF14:Nav1.6 Complex Assembly Using Split-Luciferase Complementation. PLoS ONE, 2015, 10, e0117246.	2.5	41
950	SnapShot: Kinase Inhibitors I. Molecular Cell, 2015, 58, 708-708.e1.	9.7	14
951	SnapShot: Kinase Inhibitors II. Molecular Cell, 2015, 58, 710-710.e1.	9.7	10
952	Anti-Inflammatory Effects and Joint Protection in Collagen-Induced Arthritis after Treatment with IQ-1S, a Selective c-Jun N-Terminal Kinase Inhibitor. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 505-516.	2.5	44
953	Pancreatic Stellate Cells. , 2015, , 271-306.		4
954	Anthrapyrazolone analogues intercept inflammatory JNK signals to moderate endotoxin induced septic shock. Scientific Reports, 2014, 4, 7214.	3.3	6
955	Meridianin derivatives as potent Dyrk1A inhibitors and neuroprotective agents. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2948-2952.	2.2	33

#	Article	IF	CITATIONS
956	Mechanical Tension Promotes the Osteogenic Differentiation of Rat Tendon-derived Stem Cells Through the Wnt5a/Wnt5b/JNK Signaling Pathway. Cellular Physiology and Biochemistry, 2015, 36, 517-530.	1.6	34
957	Modulation of Alternative Splicing with Chemical Compounds in New Therapeutics for Human Diseases. ACS Chemical Biology, 2015, 10, 914-924.	3.4	39
958	Screening of cell cycle fusion proteins to identify kinase signaling networks. Cell Cycle, 2015, 14, 1274-1281.	2.6	1
959	Discovery of novel inhibitors for the treatment of glaucoma. Expert Opinion on Drug Discovery, 2015, 10, 293-313.	5.0	35
960	Yeast as a model system to screen purine derivatives against human CDK1 and CDK2 kinases. Journal of Biotechnology, 2015, 195, 30-36.	3.8	4
961	Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors. European Journal of Medicinal Chemistry, 2015, 94, 140-148.	5.5	21
962	Selectivity of pharmacological tools: implications for use in cell physiology. A Review in the Theme: Cell Signaling: Proteins, Pathways and Mechanisms. American Journal of Physiology - Cell Physiology, 2015, 308, C505-C520.	4.6	20
963	Stress-induced ceramide generation and apoptosis via the phosphorylation and activation of nSMase1 by JNK signaling. Cell Death and Differentiation, 2015, 22, 258-273.	11.2	89
964	Rational Polypharmacology: Systematically Identifying and Engaging Multiple Drug Targets To Promote Axon Growth. ACS Chemical Biology, 2015, 10, 1939-1951.	3.4	58
965	Hologram QSAR Models of a Series of 6-Arylquinazolin-4-Amine Inhibitors of a New Alzheimer's Disease Target: Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase-1A Enzyme. International Journal of Molecular Sciences, 2015, 16, 5235-5253.	4.1	12
966	Palytoxin Induces Dissociation of HSP 27 Oligomers through a p38 Protein Kinase Pathway. Chemical Research in Toxicology, 2015, 28, 752-764.	3.3	4
967	Myosin II Activity Softens Cells in Suspension. Biophysical Journal, 2015, 108, 1856-1869.	0.5	96
968	Dynasore enhances the formation of mitochondrial antiviral signalling aggregates and endocytosisâ€independent <scp>NF</scp> â€iº <scp>B</scp> activation. British Journal of Pharmacology, 2015, 172, 3748-3763.	5.4	9
969	DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications. , 2015, 151, 87-98.		122
970	10-lodo-11 <i>H</i> -indolo[3,2- <i>c</i> ]quinoline-6-carboxylic Acids Are Selective Inhibitors of DYRK1A. Journal of Medicinal Chemistry, 2015, 58, 3131-3143.	6.4	87
971	Mechanical induction of the tumorigenic β-catenin pathway by tumour growth pressure. Nature, 2015, 523, 92-95.	27.8	288
972	PP2 Prevents Isoproterenol Stimulation of Cardiac Pacemaker Activity. Journal of Cardiovascular Pharmacology, 2015, 65, 193-202.	1.9	9
973	Critical role of c-jun N-terminal protein kinase in promoting mitochondrial dysfunction and acute liver injury. Redox Biology, 2015, 6, 552-564.	9.0	41

#	Article	IF	CITATIONS
974	miR-200c Targets CDK2 and Suppresses Tumorigenesis in Renal Cell Carcinoma. Molecular Cancer Research, 2015, 13, 1567-1577.	3.4	36
975	<scp>p</scp> 38 <scp>MAPK</scp> in cardioprotection – are we there yet?. British Journal of Pharmacology, 2015, 172, 2101-2113.	5.4	60
976	Coincidence detection in a neural correlate of classical conditioning is initiated by bidirectional 3â€phosphoinositideâ€dependent kinaseâ€1 signalling and modulated by adenosine receptors. Journal of Physiology, 2015, 593, 1581-1595.	2.9	7
977	Studies on Experimental Toxicology and Pharmacology. Oxidative Stress in Applied Basic Research and Clinical Practice, 2015, , .	0.4	7
978	Redox regulation of FoxO transcription factors. Redox Biology, 2015, 6, 51-72.	9.0	566
979	New Perspectives for the Rescue of Cognitive Disability in Down Syndrome. Journal of Neuroscience, 2015, 35, 13843-13852.	3.6	28
980	Rescue of the abnormal skeletal phenotype in Ts65Dn Down syndrome mice using genetic and therapeutic modulation of trisomic <i>Dyrk1a</i> . Human Molecular Genetics, 2015, 24, 5687-5696.	2.9	42
981	Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance. Journal of Biotechnology, 2015, 202, 40-49.	3.8	50
982	DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis. Molecular and Cellular Oncology, 2015, 2, e970048.	0.7	75
983	The Discovery of Polo-Like Kinase 4 Inhibitors: Identification of (1 <i>R</i> ,2 <i>S</i> )-2-(3-(( <i>E</i> )-4-((( <i>cis</i> )-2,6-Dimethylmorpholino)methyl)styryl)-1 <i>H</i> -indazol-6- (CFI-400945) as a Potent, Orally Active Antitumor Agent. Journal of Medicinal Chemistry, 2015, 58, 147-169.	-yl)-5′-n 6.4	nethoxyspirc 118
984	Where Environment Meets Cognition: A Focus on Two Developmental Intellectual Disability Disorders. Neural Plasticity, 2016, 2016, 1-20.	2.2	18
985	DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome. Frontiers in Behavioral Neuroscience, 2016, 10, 104.	2.0	142
986	AMPA Receptors Are Involved in Store-Operated Calcium Entry and Interact with STIM Proteins in Rat Primary Cortical Neurons. Frontiers in Cellular Neuroscience, 2016, 10, 251.	3.7	32
987	c-Jun N-terminal Kinase (JNK) Signaling as a Therapeutic Target for Alzheimer's Disease. Frontiers in Pharmacology, 2015, 6, 321.	3.5	284
988	Synthesis and preliminary characterization of radioiodinated benzofuranâ€3â€ylâ€(indolâ€3â€yl)maleimide derivatives as potential SPECT imaging probes for the detection of glycogen synthase kinaseâ€3l² (GSKâ€3l²) in the brain. Journal of Labelled Compounds and Radiopharmaceuticals, 2016, 59, 317-321.	1.0	1
989	Differential effects of Epigallocatechinâ€3â€gallate containing supplements on correcting skeletal defects in a Down syndrome mouse model. Molecular Nutrition and Food Research, 2016, 60, 717-726.	3.3	33
990	CaMKII and at least two unidentified kinases phosphorylate regulatory light chain in non-contracting cardiomyocytes. Biochemical and Biophysical Research Communications, 2016, 477, 14-19.	2.1	0
991	The Dynamics and Regulatory Mechanism of Pronuclear H3k9me2 Asymmetry in Mouse Zygotes. Scientific Reports, 2016, 5, 17924.	3.3	16

#	Article	IF	CITATIONS
992	Image-based compound profiling reveals a dual inhibitor of tyrosine kinase and microtubule polymerization. Scientific Reports, 2016, 6, 25095.	3.3	7
993	Inflammation, Aging, and Oxidative Stress. Oxidative Stress in Applied Basic Research and Clinical Practice, 2016, , .	0.4	9
994	L1000CDS2: LINCS L1000 characteristic direction signatures search engine. Npj Systems Biology and Applications, 2016, 2, .	3.0	250
996	Prostaglandins from Cytosolic Phospholipase A2α/Cyclooxygenase-1 Pathway and Mitogen-activated Protein Kinases Regulate Gene Expression in Candida albicans-infected Macrophages. Journal of Biological Chemistry, 2016, 291, 7070-7086.	3.4	20
997	DYRK1A inhibition as potential treatment for Alzheimer's disease. Future Medicinal Chemistry, 2016, 8, 681-696.	2.3	58
998	Influence of prenatal EGCG treatment and <i>Dyrk1a</i> dosage reduction on craniofacial features associated with Down syndrome. Human Molecular Genetics, 2016, 25, ddw309.	2.9	42
999	Phospholipid Ozonation Products Activate the 5-Lipoxygenase Pathway in Macrophages. Chemical Research in Toxicology, 2016, 29, 1355-1364.	3.3	8
1000	MRCK-1 Drives Apical Constriction in C.Âelegans by Linking Developmental Patterning to Force Generation. Current Biology, 2016, 26, 2079-2089.	3.9	96
1001	Smooth muscle contraction and growth of stromal cells in the human prostate are both inhibited by the Src family kinase inhibitors, AZM475271 and PP2. British Journal of Pharmacology, 2016, 173, 3342-3358.	5.4	19
1002	Nonmuscle Myosin Light Chain Kinase Activity Modulates Radiationâ€Induced Lung Injury. Pulmonary Circulation, 2016, 6, 234-239.	1.7	9
1003	The relationship between basal and regulated Gnrhr expression in rodent pituitary gonadotrophs. Molecular and Cellular Endocrinology, 2016, 437, 302-311.	3.2	11
1004	A unique type of GSK-3 inhibitor brings new opportunities to the clinic. Science Signaling, 2016, 9, ra110.	3.6	53
1005	The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain. Journal of Medicinal Chemistry, 2016, 59, 10084-10099.	6.4	78
1006	A novel inhibitory effect of oxazol-5-one compounds on ROCKII signaling in human coronary artery vascular smooth muscle cells. Scientific Reports, 2016, 6, 32118.	3.3	17
1007	Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2016, 15, 801-810.	10.2	227
1008	Phorbol-12-myristate-13-acetate induces nociceptin in human Mono Mac 6 cells via multiple transduction signalling pathways. British Journal of Anaesthesia, 2016, 117, 250-257.	3.4	5
1009	Down-modulation of antigen-induced activation of murine cultured mast cells sensitized with a highly cytokinergic IgE clone. Immunology Letters, 2016, 174, 1-8.	2.5	3
1010	Current pharmacotherapy and putative disease-modifying therapy for Alzheimer's disease. Neurological Sciences, 2016, 37, 1403-1435.	1.9	60

#	Article	IF	CITATIONS
1011	The inhibitors of cyclin-dependent kinases and GSK-3β enhance osteoclastogenesis. Biochemistry and Biophysics Reports, 2016, 5, 253-258.	1.3	9
1012	Src kinases play a novel dual role in acute pancreatitis affecting severity but no role in stimulated enzyme secretion. American Journal of Physiology - Renal Physiology, 2016, 310, G1015-G1027.	3.4	16
1013	Synthesis and pharmacological evaluation of dehydroabietic acid thiourea derivatives containing bisphosphonate moiety as an inducer of apoptosis. European Journal of Medicinal Chemistry, 2016, 108, 381-391.	5.5	39
1014	Prevention of adenosine A2A receptor activation diminishes beat-to-beat alternation in human atrial myocytes. Basic Research in Cardiology, 2016, 111, 5.	5.9	28
1015	A cardiac myocyte-restricted Lin28/let-7 regulatory axis promotes hypoxia-mediated apoptosis by inducing the AKT signaling suppressor PIK3IP1. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 240-251.	3.8	39
1016	Modulation of FAK and Src adhesion signaling occurs independently of adhesion complex composition. Journal of Cell Biology, 2016, 212, 349-364.	5.2	85
1017	A novel dual NO-donating oxime and c-Jun N-terminal kinase inhibitor protects against cerebral ischemia–reperfusion injury in mice. Neuroscience Letters, 2016, 618, 45-49.	2.1	43
1018	Weak-binding molecules are not drugs?—toward a systematic strategy for finding effective weak-binding drugs. Briefings in Bioinformatics, 2017, 18, bbw018.	6.5	22
1019	Protein Arginine Methyltransferase 6 (Prmt6) Is Essential for Early Zebrafish Development through the Direct Suppression of gadd45αa Stress Sensor Gene. Journal of Biological Chemistry, 2016, 291, 402-412.	3.4	30
1020	Evaluation of the Role of JNK1 in the Hippocampus in an Experimental Model of Familial Alzheimer's Disease. Molecular Neurobiology, 2016, 53, 6183-6193.	4.0	19
1021	Contribution of an SFK-Mediated Signaling Pathway in the Dorsal Hippocampus to Cocaine-Memory Reconsolidation in Rats. Neuropsychopharmacology, 2016, 41, 675-685.	5.4	38
1022	Extracellular Signal-Regulated Protein Kinase, c-Jun N-Terminal Protein Kinase, and Calcineurin Regulate Transient Receptor Potential M3 (TRPM3) Induced Activation of AP-1. Journal of Cellular Biochemistry, 2017, 118, 2409-2419.	2.6	21
1023	JNK activation is essential for activation of MEK/ERK signaling in IL-1β-induced COX-2 expression in synovial fibroblasts. Scientific Reports, 2017, 7, 39914.	3.3	40
1024	A review of connectivity map and computational approaches in pharmacogenomics. Briefings in Bioinformatics, 2018, 19, bbw112.	6.5	182
1025	Profiling Subcellular Protein Phosphatase Responses to Coxsackievirus B3 Infection of Cardiomyocytes. Molecular and Cellular Proteomics, 2017, 16, S244-S262.	3.8	13
1026	Kinase targets in CNS drug discovery. Future Medicinal Chemistry, 2017, 9, 303-314.	2.3	24
1027	An HTRF® Assay for the Protein Kinase ATM. Methods in Molecular Biology, 2017, 1599, 43-56.	0.9	1
1028	Novel tumor-suppressor function of KLF4 in pediatric T-cell acute lymphoblastic leukemia. Experimental Hematology, 2017, 53, 16-25.	0.4	22

#	Article	IF	CITATIONS
1029	Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes. Physiology and Behavior, 2017, 177, 230-241.	2.1	62
1030	The associated pyrazolopyrimidines PP1 and PP2 inhibit protein tyrosine kinase 6 activity and suppress breast cancer cell proliferation. Oncology Letters, 2017, 13, 1463-1469.	1.8	12
1031	A Chemical-Genetic Approach to Generate Selective Covalent Inhibitors of Protein Kinases. ACS Chemical Biology, 2017, 12, 1499-1503.	3.4	18
1032	A Flexible Workflow for Automated Bioluminescent Kinase Selectivity Profiling. SLAS Technology, 2017, 22, 153-162.	1.9	6
1033	Development of Selective Clk1 and -4 Inhibitors for Cellular Depletion of Cancer-Relevant Proteins. Journal of Medicinal Chemistry, 2017, 60, 5377-5391.	6.4	41
1034	Age exacerbates abnormal protein expression in a mouse model of Down syndrome. Neurobiology of Aging, 2017, 57, 120-132.	3.1	16
1035	Cyclic GMP-dependent protein kinase-I localized in nociceptors modulates nociceptive cortical neuronal activity and pain hypersensitivity. Molecular Pain, 2017, 13, 174480691770174.	2.1	11
1036	Pharmacology of Modulators of Alternative Splicing. Pharmacological Reviews, 2017, 69, 63-79.	16.0	72
1037	Characteristics and trends in global tea research: a Science Citation Index Expandedâ€based analysis. International Journal of Food Science and Technology, 2017, 52, 644-651.	2.7	20
1038	Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance. Journal of Molecular Biology, 2017, 429, 574-586.	4.2	34
1039	Synthesis, Binding Mode, and Antihyperglycemic Activity of Potent and Selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine Inhibitors of Glycogen Synthase Kinase 3. Journal of Medicinal Chemistry, 2017, 60, 8482-8514.	6.4	30
1040	Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits. Molecular Genetics & Genomic Medicine, 2017, 5, 451-465.	1.2	38
1041	Function and structure-based screening of compounds, peptides and proteins to identify drug candidates. Methods, 2017, 131, 10-21.	3.8	10
1042	Pharmacological interventions to improve cognition and adaptive functioning in Down syndrome: Strides to date. American Journal of Medical Genetics, Part A, 2017, 173, 3029-3041.	1.2	37
1043	A Split-Abl Kinase for Direct Activation in Cells. Cell Chemical Biology, 2017, 24, 1250-1258.e4.	5.2	12
1044	Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice. Scientific Reports, 2017, 7, 619.	3.3	66
1045	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature. Expert Opinion on Therapeutic Patents, 2017, 27, 1183-1199.	5.0	50
1046	Selective HIF-1 Regulation under Nonhypoxic Conditions by the p42/p44 MAP Kinase Inhibitor PD184161. Molecular Pharmacology, 2017, 92, 510-518.	2.3	5

#	Article	IF	CITATIONS
1047	JNK Promotes Epithelial Cell Anoikis by Transcriptional and Post-translational Regulation of BH3-Only Proteins. Cell Reports, 2017, 21, 1910-1921.	6.4	29
1048	Inhibition of Vascular c″un Nâ€Terminal Kinase 2 Improves Obesityâ€Induced Endothelial Dysfunction After Rouxâ€en‥ Gastric Bypass. Journal of the American Heart Association, 2017, 6, .	3.7	4
1049	A novel inhibitor of active protein kinase G attenuates chronic inflammatory and osteoarthritic pain. Pain, 2017, 158, 822-832.	4.2	18
1050	Screening for small molecule inhibitors of HIV-1 Gag expression. Methods, 2017, 126, 201-208.	3.8	3
1051	IL-1β-Induced Downregulation of the Multifunctional PDZ Adaptor PDZK1 Is Attenuated by ERK Inhibition, RXRα, or PPARα Stimulation in Enterocytes. Frontiers in Physiology, 2017, 8, 61.	2.8	13
1052	An Update on the Health Benefits of Green Tea. Beverages, 2017, 3, 6.	2.8	55
1053	Wnt5a Signaling in Normal and Cancer Stem Cells. Stem Cells International, 2017, 2017, 1-6.	2.5	41
1054	Microtubule Depolymerization by Kinase Inhibitors: Unexpected Findings of Dual Inhibitors. International Journal of Molecular Sciences, 2017, 18, 2508.	4.1	27
1056	GSK3 Inhibitors in the Therapeutic Development of Diabetes, Cancer and Neurodegeneration: Past, Present and Future. Current Pharmaceutical Design, 2017, 23, 4332-4350.	1.9	54
1057	Conflicting evidence for the role of <scp>JNK</scp> as a target in breast cancer cell proliferation: Comparisons between pharmacological inhibition and selective shRNA knockdown approaches. Pharmacology Research and Perspectives, 2018, 6, e00376.	2.4	6
1058	Selective inhibition of intestinal guanosine 3′,5′-cyclic monophosphate signaling by small-molecule protein kinase inhibitors. Journal of Biological Chemistry, 2018, 293, 8173-8181.	3.4	8
1059	Gender differences in the regulation of MLC20 phosphorylation and smooth muscle contraction in rat stomach. Biomedical Reports, 2018, 8, 283-288.	2.0	5
1060	DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives. Scientific Reports, 2018, 8, 2859.	3.3	49
1061	Emerging role of the Jun Nâ€ŧerminal kinase interactome in human health. Cell Biology International, 2018, 42, 756-768.	3.0	17
1062	Cardiac glycoside/aglycones inhibit HIV-1 gene expression by a mechanism requiring MEK1/2-ERK1/2 signaling. Scientific Reports, 2018, 8, 850.	3.3	38
1063	Sarcoma family kinase activity is required for cortical spreading depression. Cephalalgia, 2018, 38, 1748-1758.	3.9	9
1064	Developmental effects of the protein kinase inhibitor kenpaullone on the sea urchin embryo. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2018, 204, 36-44.	2.6	3
1065	Cell Biology of Tight Junction Barrier Regulation and Mucosal Disease. Cold Spring Harbor Perspectives in Biology, 2018, 10, a029314.	5.5	434

#	Article	IF	CITATIONS
1066	Direct and tunable modulation of protein levels in rice and wheat with a synthetic small molecule. Plant Biotechnology Journal, 2018, 16, 472-481.	8.3	3
1067	High-content screening assay-based discovery of paullones as novel podocyte-protective agents. American Journal of Physiology - Renal Physiology, 2018, 314, F280-F292.	2.7	12
1068	Melatonin promotes sheep Leydig cell testosterone secretion in a co-culture with Sertoli cells. Theriogenology, 2018, 106, 170-177.	2.1	49
1069	Can Green Tea Polyphenols Improve Phenotypes Associated With Down Syndrome?. , 2018, , 439-454.		2
1070	Physiological Stimuli Induce PAD4-Dependent, ROS-Independent NETosis, With Early and Late Events Controlled by Discrete Signaling Pathways. Frontiers in Immunology, 2018, 9, 2036.	4.8	117
1071	Development of novel amide–derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification. European Journal of Medicinal Chemistry, 2018, 158, 270-285.	5.5	16
1072	Expression of the Alternative Oxidase Influences Jun N-Terminal Kinase Signaling and Cell Migration. Molecular and Cellular Biology, 2018, 38, .	2.3	11
1073	DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective. European Journal of Medicinal Chemistry, 2018, 158, 559-592.	5.5	37
1074	FAF1 mediates necrosis through JNK1-mediated mitochondrial dysfunction leading to retinal degeneration in the ganglion cell layer upon ischemic insult. Cell Communication and Signaling, 2018, 16, 56.	6.5	4
1075	Sulbactam Protects Hippocampal Neurons Against Oxygen-Glucose Deprivation by Up-Regulating Astrocytic GLT-1 via p38 MAPK Signal Pathway. Frontiers in Molecular Neuroscience, 2018, 11, 281.	2.9	9
1076	Design and synthesis of conformationally constraint Dyrk1A inhibitors by creating an intramolecular H-bond involving a benzothiazole core. MedChemComm, 2018, 9, 1045-1053.	3.4	10
1077	Cyclin-dependent kinase 1 (CDK1) and CDK2 have opposing roles in regulating interactions of splicing factor 3B1 with chromatin. Journal of Biological Chemistry, 2018, 293, 10220-10234.	3.4	15
1078	Structural basis for selective inhibition of human PKG lα by the balanol-like compound N46. Journal of Biological Chemistry, 2018, 293, 10985-10992.	3.4	9
1079	β-Catenin–dependent mechanotransduction dates back to the common ancestor of Cnidaria and Bilateria. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 6231-6236.	7.1	62
1080	Structural and biological evaluation of halogen derivatives of 1,9-pyrazoloanthrones towards the design of a specific potent inhibitor of c-Jun-N-terminal kinase (JNK). New Journal of Chemistry, 2018, 42, 10651-10660.	2.8	3
1081	Role of the MAPK/cJun NH <sub>2</sub> -terminal kinase signaling pathway in starvation-induced autophagy. Autophagy, 2018, 14, 1586-1595.	9.1	27
1082	Brimapitide Reduced Neuronal Stress Markers and Cognitive Deficits in 5XFAD Transgenic Mice. Journal of Alzheimer's Disease, 2018, 63, 665-674.	2.6	10
1083	aPKC-mediated displacement and actomyosin-mediated retention polarize Miranda in Drosophila neuroblasts. ELife, 2018, 7, .	6.0	31

#	Article	IF	CITATIONS
1084	Murine leukemia virus p12 tethers the capsid-containing pre-integration complex to chromatin by binding directly to host nucleosomes in mitosis. PLoS Pathogens, 2018, 14, e1007117.	4.7	25
1085	Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation. Journal of Medicinal Chemistry, 2018, 61, 7687-7699.	6.4	58
1086	Usage of Mitogen-Activated Protein Kinase Small Molecule Inhibitors: More Than Just Inhibition!. Frontiers in Pharmacology, 2018, 9, 98.	3.5	11
1087	c-Jun N-Terminal Kinases and Their Pharmacological Modulation in Ischemic and Reperfusion Brain Injury. Neuroscience and Behavioral Physiology, 2018, 48, 721-728.	0.4	3
1088	Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics. Journal of Medicinal Chemistry, 2018, 61, 9791-9810.	6.4	79
1089	Targeting Pim Kinases and DAPK3 to Control Hypertension. Cell Chemical Biology, 2018, 25, 1195-1207.e32.	5.2	21
1090	Development of novel 2,4-bispyridyl thiophene–based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivatives. European Journal of Medicinal Chemistry, 2018, 157, 1031-1050.	5.5	18
1091	c-Jun N-Terminal Kinases (JNKs) in Myocardial and Cerebral Ischemia/Reperfusion Injury. Frontiers in Pharmacology, 2018, 9, 715.	3.5	87
1092	Importance of Validating Antibodies and Small Compound Inhibitors Using Genetic Knockout Studies—T Cell Receptor-Induced CYLD Phosphorylation by IKKε/TBK1 as a Case Study. Frontiers in Cell and Developmental Biology, 2018, 6, 40.	3.7	16
1093	Inhibition of neddylation facilitates cell migration through enhanced phosphorylation of caveolin-1 in PC3 and U373MG cells. BMC Cancer, 2018, 18, 30.	2.6	18
1094	Experimental Planning and Execution. , 2018, , 67-106.		1
1095	Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic Î <sup>2</sup> -cell proliferation activity. European Journal of Medicinal Chemistry, 2018, 157, 1005-1016.	5.5	36
1096	Inhibition of FGF Receptor-1 Suppresses Alcohol Consumption: Role of PI3 Kinase Signaling in Dorsomedial Striatum. Journal of Neuroscience, 2019, 39, 7947-7957.	3.6	23
1097	Identification of GSK3β inhibitor kenpaullone as a temozolomide enhancer against glioblastoma. Scientific Reports, 2019, 9, 10049.	3.3	30
1098	Usage of and attitudes about green tea extract and Epigallocathechin-3-gallate (EGCG) as a therapy in individuals with Down syndrome. Complementary Therapies in Medicine, 2019, 45, 234-241.	2.7	9
1099	Phosphomimetic substitution at Ser-33 of the chloroquine resistance transporter PfCRT reconstitutes drug responses in Plasmodium falciparum. Journal of Biological Chemistry, 2019, 294, 12766-12778.	3.4	11
1100	The Discovery of the Nav1.7 Inhibitor GDC-0276 and Development of an Efficient Large-Scale Synthesis. ACS Symposium Series, 2019, , 107-123.	0.5	1
1101	Discovery and Development of AMG 333: A TRPM8 Antagonist for Migraine. ACS Symposium Series, 2019, , 125-154.	0.5	1

#	Article	IF	CITATIONS
1102	The Discovery and Chemical Development of PF-06273340: A Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor for Pain. ACS Symposium Series, 2019, , 155-183.	0.5	0
1103	Discovery and Development of Non-Covalent, Reversible Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853). ACS Symposium Series, 2019, , 239-266.	0.5	2
1104	Discovery and Early Development of Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors. ACS Symposium Series, 2019, , 267-296.	0.5	0
1105	Rational Design to Large-Scale Synthesis: Development of GSK8175 for the Treatment of Hepatitis C Virus Infection. ACS Symposium Series, 2019, , 297-322.	0.5	2
1111	Anti-Inflammatory Effects of <i>Licania macrocarpa</i> Cuatrec Methanol Extract Target Src- and TAK1-Mediated Pathways. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-13.	1.2	11
1112	The Link of the Prion Protein with Ca2+ Metabolism and ROS Production, and the Possible Implication in Al <sup>2</sup> Toxicity. International Journal of Molecular Sciences, 2019, 20, 4640.	4.1	12
1113	Synthetic Routes for Venetoclax at Different Stages of Development. ACS Symposium Series, 2019, , 1-25.	0.5	0
1114	Discovery and Development of Lorlatinib: A Macrocyclic Inhibitor of EML4-ALK for the Treatment of NSCLC. ACS Symposium Series, 2019, , 27-59.	0.5	3
1115	From Discovery to Market Readiness: The Research and Development of the β-Sparing Phosphatidylinositol 3-Kinase Inhibitor Taselisib. ACS Symposium Series, 2019, , 61-83.	0.5	2
1116	Optimization of an Azaindazole Series of CCR1 Antagonists and Development of a Semicontinuous-Flow Synthesis. ACS Symposium Series, 2019, , 185-238.	0.5	0
1117	Discovery and Development of the First Antibody–Antibiotic Conjugate Linker-Drug. ACS Symposium Series, 2019, , 85-105.	0.5	2
1118	A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia. Molecular Cancer Therapeutics, 2019, 18, 567-578.	4.1	13
1119	ERK and p38 contribute to the regulation of nociceptin and the nociceptin receptor in human peripheral blood leukocytes. Molecular Pain, 2019, 15, 174480691982892.	2.1	6
1120	Regulation of proline-directed kinases and the trans-histone code H3K9me3/H4K20me3 during human myogenesis. Journal of Biological Chemistry, 2019, 294, 8296-8308.	3.4	11
1121	Prenatal treatment with EGCG enriched green tea extract rescues GAD67 related developmental and cognitive defects in Down syndrome mouse models. Scientific Reports, 2019, 9, 3914.	3.3	35
1122	Src activation in the hypothalamic arcuate nucleus may play an important role in pain hypersensitivity. Scientific Reports, 2019, 9, 3827.	3.3	7
1123	CDK7 is a component of the integrated stress response regulating SNAT2 (SLC38A2)/System A adaptation in response to cellular amino acid deprivation. Biochimica Et Biophysica Acta - Molecular Cell Research, 2019, 1866, 978-991.	4.1	6
1124	RNA Splicing: A New Paradigm in Host–Pathogen Interactions. Journal of Molecular Biology, 2019, 431,	4.2	59

ARTICLE IF CITATIONS New strategies for inhibition of nonâ€adrenergic prostate smooth muscle contraction by 1125 2.3 16 pharmacologic intervention. Prostate, 2019, 79, 746-756. TNF-alpha inhibits pregnancy-adapted Ca2+ signaling in uterine artery endothelial cells. Molecular and 3.2 Cellular Endocrinology, 2019, 488, 14-24. The Hyaluronidase, TMEM2, Promotes ER Homeostasis and Longevity Independent of the UPRER. Cell, 1127 28.9 87 2019, 179, 1306-1318.e18. Rho-associated kinase and zipper-interacting protein kinase, but not myosin light chain kinase, are involved in the regulation of myosin phosphorylation in serum-stimulated human arterial smooth muscle cells. PLoS ONE, 2019, 14, e0226406. Integrative Multi-Kinase Approach for the Identification of Potent Antiplasmodial Hits. Frontiers in 1129 19 3.6 Chemistry, 2019, 7, 773. Portraying the selectivity of GSK-3 inhibitors towards CDK-2 by 3D similarity and molecular docking. Structural Chemistry, 2019, 30, 911-923. A chemical-genetics approach to study the role of atypical protein kinase C in  $\langle i \rangle$  Drosophila $\langle i \rangle$ . 1131 2.5 22 Development (Cambridge), 2019, 146, . Synthesis, biological evaluation, and molecular modeling of 11H-indeno[1,2-b]quinoxalin-11-one derivatives and tryptanthrin-6-oxime as c-Jun N-terminal kinase inhibitors. European Journal of 5.5 Medicinal Chemistry, 2019, 161, 179-191. 1133 Nuclear trapping of inactive FOXO1 by the Nrf2 activator diethyl maleate. Redox Biology, 2019, 20, 19-27. 9.0 12 1134 DYRK1A and cognition: A lifelong relationship., 2019, 194, 199-221. Tau-based therapies for Alzheimer's disease: Promising novel neuroprotective approaches. , 2020, , 1135 3 245-272. Reaction of Vinyl Aziridines with Arynes: Synthesis of Benzazepines and Branched Allyl Fluorides. 3.3 Chemistry - A European Journal, 2020, 26, 1501-1505. Skeletal dynamics of Down syndrome: A developing perspective. Bone, 2020, 133, 115215. 1137 2.9 18 Promiscuity analysis of a kinase panel screen with designated p38 alpha inhibitors. European Journal 5.5 of Medicinal Chemistry, 2020, 187, 112004. The role of JNK in prostate cancer progression and therapeutic strategies. Biomedicine and 1139 5.6 62 Pharmacotherapy, 2020, 121, 109679. Calreticulin regulates Src kinase in osteogenic differentiation from embryonic stem cells. Stem Cell 1140 Research, 2020, 48, 101972. Reply. Arthritis and Rheumatology, 2020, 72, 2162-2163. 1141 5.6 0 Perturbation biology links temporal protein changes to drug responses in a melanoma cell line. PLoS 1142 3.2 Computational Biology, 2020, 16, e1007909.

#	Article	IF	CITATIONS
1143	JNK Pathway as a Target for Osteoarthritis: Comment on the Article by Loeser et al. Arthritis and Rheumatology, 2020, 72, 2162-2162.	5.6	1
1144	Vascular endothelial growth factor contributes to lung vascular hyperpermeability in sepsis-associated acute lung injury. Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393, 2365-2374.	3.0	18
1145	Proposed Allosteric Inhibitors Bind to the ATP Site of CK2α. Journal of Medicinal Chemistry, 2020, 63, 12786-12798.	6.4	12
1146	Antibacterial activity of Barbatimão ( <i>Stryphnodendron adstringens</i> ) against <i>Staphylococcus aureus</i> : <i>in vitro</i> and <i>in silico</i> studies. Letters in Applied Microbiology, 2020, 71, 259-271.	2.2	12
1147	Plasticity as a therapeutic target for improving cognition and behavior in Down syndrome. Progress in Brain Research, 2020, 251, 269-302.	1.4	13
1148	Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult Down syndrome mice. Scientific Reports, 2020, 10, 10426.	3.3	26
1149	A Src family kinase maintains latent sensitization in rats, a model of inflammatory and neuropathic pain. Brain Research, 2020, 1746, 146999.	2.2	8
1150	Platelet MAPKs—a 20+Âyear history: What do we really know?. Journal of Thrombosis and Haemostasis, 2020, 18, 2087-2102.	3.8	32
1151	A Dual Inhibitor of DYRK1A and GSK3β for β ell Proliferation: Aminopyrazine Derivative GNF4877. ChemMedChem, 2020, 15, 1562-1570.	3.2	9
1152	Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133. Journal of Medicinal Chemistry, 2020, 63, 2958-2973.	6.4	49
1153	Cell Cycle Deficits in Neurodegenerative Disorders: Uncovering Molecular Mechanisms to Drive Innovative Therapeutic Development. , 2020, 11, 946.		51
1154	Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor. Journal of Medicinal Chemistry, 2020, 63, 2986-3003.	6.4	36
1155	Structure–Activity Relationships and Biological Evaluation of 7-Substituted Harmine Analogs for Human β-Cell Proliferation. Molecules, 2020, 25, 1983.	3.8	13
1156	Src-family kinase inhibitors block early steps of caveolin-1-enhanced lung metastasis by melanoma cells. Biochemical Pharmacology, 2020, 177, 113941.	4.4	7
1157	The JNK Signaling Pathway in Inflammatory Skin Disorders and Cancer. Cells, 2020, 9, 857.	4.1	141
1158	Interactive role of Wnt signaling and Zn in regulating testicular function of the common carp, Cyprinus carpio. Theriogenology, 2021, 161, 161-175.	2.1	5
1159	Loss of Aurora Kinase Signaling Allows Lung Cancer Cells to Adopt Endoreplication and Form Polyploid Giant Cancer Cells That Resist Antimitotic Drugs. Cancer Research, 2021, 81, 400-413.	0.9	29
1160	Chemogenomics and bioinformatics approaches for prioritizing kinases as drug targets for neglected tropical diseases. Advances in Protein Chemistry and Structural Biology, 2021, 124, 187-223.	2.3	2

#	Article	IF	CITATIONS
1161	Alphaherpesvirus Latency and Reactivation with a Focus on Herpes Simplex Virus. Current Issues in Molecular Biology, 2021, 41, 267-356.	2.4	12
1162	Activation of Interferon Signaling in Chronic Lymphocytic Leukemia Cells Contributes to Apoptosis Resistance via a JAK-Src/STAT3/Mcl-1 Signaling Pathway. Biomedicines, 2021, 9, 188.	3.2	8
1163	Green tea extracts containing epigallocatechin-3-gallate modulate facial development in Down syndrome. Scientific Reports, 2021, 11, 4715.	3.3	15
1164	5-Methoxybenzothiophene-2-Carboxamides as Inhibitors of Clk1/4: Optimization of Selectivity and Cellular Potency. Molecules, 2021, 26, 1001.	3.8	4
1166	Epigallocatechin-3-Gallate Plus Omega-3 Restores the Mitochondrial Complex I and FOF1-ATP Synthase Activities in PBMCs of Young Children with Down Syndrome: A Pilot Study of Safety and Efficacy. Antioxidants, 2021, 10, 469.	5.1	15
1167	Phosphorylation of MYL12 by Myosin Light Chain Kinase Regulates Cellular Shape Changes in Cochlear Hair Cells. JARO - Journal of the Association for Research in Otolaryngology, 2021, 22, 425-441.	1.8	6
1168	JNK Pathway in CNS Pathologies. International Journal of Molecular Sciences, 2021, 22, 3883.	4.1	27
1169	Multiscale analysis of single and double maternal-zygotic Myh9 and Myh10 mutants during mouse preimplantation development. ELife, 2021, 10, .	6.0	15
1170	Oximes: Novel Therapeutics with Anticancer and Anti-Inflammatory Potential. Biomolecules, 2021, 11, 777.	4.0	35
1171	JUN Amino-Terminal Kinase 1 Signaling in the Proximal Tubule Causes Cell Death and Acute Renal Failure in Rat and Mouse Models of Renal Ischemia/Reperfusion Injury. American Journal of Pathology, 2021, 191, 817-828.	3.8	12
1172	Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview. International Journal of Molecular Sciences, 2021, 22, 6047.	4.1	54
1173	Irreversible JNK blockade overcomes PD-L1-mediated resistance to chemotherapy in colorectal cancer. Oncogene, 2021, 40, 5105-5115.	5.9	7
1174	Regulation of mRNA Translation by Hormone Receptors in Breast and Prostate Cancer. Cancers, 2021, 13, 3254.	3.7	10
1175	A natural compound harmine decreases melanin synthesis through regulation of the DYRK1A/NFATC3 pathway. Journal of Dermatological Science, 2021, 103, 16-24.	1.9	2
1176	Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer. Science Translational Medicine, 2021, 13, .	12.4	19
1177	CSK-3β, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways. International Journal of Molecular Sciences, 2021, 22, 9098.	4.1	42
1178	Novel Mechanism for an Old Drug: Phenazopyridine is a Kinase Inhibitor Affecting Autophagy and Cellular Differentiation. Frontiers in Pharmacology, 2021, 12, 664608.	3.5	5
1179	Tumor Necrosis Factor Alpha Effects on the Porcine Intestinal Epithelial Barrier Include Enhanced Expression of TNF Receptor 1. International Journal of Molecular Sciences, 2021, 22, 8746.	4.1	7

#	Article	IF	CITATIONS
1180	RSK1 vs. RSK2 Inhibitory Activity of the Marine β-Carboline Alkaloid Manzamine A: A Biochemical, Cervical Cancer Protein Expression, and Computational Study. Marine Drugs, 2021, 19, 506.	4.6	8
1181	3â€phosphoinositideâ€dependent protein kinase 1 (PDK1) mediates crosstalk between Src and Akt pathways in MET receptor signaling. FEBS Letters, 2021, 595, 2655-2664.	2.8	1
1182	Anticancer potential of indirubins in medicinal chemistry: Biological activity, structural modification, and structure-activity relationship. European Journal of Medicinal Chemistry, 2021, 223, 113652.	5.5	29
1183	Hydrogen Peroxide: The Good, The Bad, and The Ugly. , 2008, , 1-17.		12
1184	Approaches to Kinesin-1 Phosphorylation. Methods in Molecular Biology, 2007, 392, 51-69.	0.9	9
1185	Use of Inhibitors in the Study of MAP Kinases. Methods in Molecular Biology, 2010, 661, 107-122.	0.9	22
1186	On the Biochemistry of Antioxidants: Current Aspects. Oxidative Stress in Applied Basic Research and Clinical Practice, 2015, , 383-396.	0.4	4
1187	Tyrosine Kinase Inhibitors and Neurodegenerative Disorders. Oxidative Stress in Applied Basic Research and Clinical Practice, 2016, , 81-91.	0.4	1
1188	cGMP-Dependent Protein Kinase Modulators. Handbook of Experimental Pharmacology, 2009, , 409-421.	1.8	12
1189	Prothoracicotropic Hormone. , 2005, , 61-123.		43
1191	Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy. JCI Insight, 2020, 5, .	5.0	25
1192	Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. Journal of Clinical Investigation, 2005, 115, 369-378.	8.2	192
1193	Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo. Journal of Clinical Investigation, 2005, 115, 2702-2715.	8.2	346
1194	Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. Journal of Clinical Investigation, 2008, 118, 3943-3953.	8.2	273
1195	Development, Selectivity, and Application of Paullones, a Family of CDK Inhibitors. Enzyme Inhibitors Series, 2006, , 227-249.	0.1	2
1197	Calmodulin-dependent protein kinase II, and not protein kinase C, is sufficient for triggering cell-cycle resumption in mammalian eggs. Journal of Cell Science, 2005, 118, 3849-3859.	2.0	90
1198	The Src kinases Hck, Fgr, and Lyn activate Abl2/Arg to facilitate IgG-mediated phagocytosis and <i>Leishmania</i> infection. Journal of Cell Science, 2016, 129, 3130-43.	2.0	18
1199	An ELISA DYRK1A non-radioactive kinase assay suitable for the characterization of inhibitors. F1000Research, 2017, 6, 42.	1.6	7

#	Article	IF	CITATIONS
1200	Green Tea Polyphenols Rescue of Brain Defects Induced by Overexpression of DYRK1A. PLoS ONE, 2009, 4, e4606.	2.5	185
1201	Quantitative Analysis of Lipid Droplet Fusion: Inefficient Steady State Fusion but Rapid Stimulation by Chemical Fusogens. PLoS ONE, 2010, 5, e15030.	2.5	77
1202	Differential Inhibitor Sensitivity between Human Kinases VRK1 and VRK2. PLoS ONE, 2011, 6, e23235.	2.5	39
1203	BMP-9 Induced Endothelial Cell Tubule Formation and Inhibition of Migration Involves Smad1 Driven Endothelin-1 Production. PLoS ONE, 2012, 7, e30075.	2.5	43
1204	Role of c-Jun N-Terminal Protein Kinase 1/2 (JNK1/2) in Macrophage-Mediated MMP-9 Production in Response to Moraxella catarrhalis Lipooligosaccharide (LOS). PLoS ONE, 2012, 7, e37912.	2.5	10
1205	Combination of a Proteomics Approach and Reengineering of Meso Scale Network Models for Prediction of Mode-of-Action for Tyrosine Kinase Inhibitors. PLoS ONE, 2013, 8, e53668.	2.5	7
1206	An Indirubin Derivative, Indirubin-3′-Monoxime Suppresses Oral Cancer Tumorigenesis through the Downregulation of Survivin. PLoS ONE, 2013, 8, e70198.	2.5	23
1207	MEK Inhibitor U0126 Reverses Protection of Axons from Wallerian Degeneration Independently of MEK–ERK Signaling. PLoS ONE, 2013, 8, e76505.	2.5	8
1208	Tumor Stiffness Is Unrelated to Myosin Light Chain Phosphorylation in Cancer Cells. PLoS ONE, 2013, 8, e79776.	2.5	7
1209	Design and Synthesis of a Library of Lead-Like 2,4-Bisheterocyclic Substituted Thiophenes as Selective Dyrk/Clk Inhibitors. PLoS ONE, 2014, 9, e87851.	2.5	43
1210	Synthesis and Properties of a Selective Inhibitor of Homeodomain–Interacting Protein Kinase 2 (HIPK2). PLoS ONE, 2014, 9, e89176.	2.5	23
1211	Biophysical Induction of Vascular Smooth Muscle Cell Podosomes. PLoS ONE, 2015, 10, e0119008.	2.5	13
1212	Differential Relevance of NF-ήB and JNK in the Pathophysiology of Hemorrhage/Resususcitation-Induced Liver Injury after Chronic Ethanol Feeding. PLoS ONE, 2015, 10, e0137875.	2.5	10
1213	Regulation of N-Formyl Peptide Receptor Signaling and Trafficking by Arrestin-Src Kinase Interaction. PLoS ONE, 2016, 11, e0147442.	2.5	11
1214	Dissection of the Influenza A Virus Endocytic Routes Reveals Macropinocytosis as an Alternative Entry Pathway. PLoS Pathogens, 2011, 7, e1001329.	4.7	267
1215	Roles of Src family kinase signaling during fertilization and the first cell cycle in the marine protostome worm Cerebratulus. International Journal of Developmental Biology, 2010, 54, 787-793.	0.6	22
1216	Combined Treatment With Environmental Enrichment and (-)-Epigallocatechin-3-Gallate Ameliorates Learning Deficits and Hippocampal Alterations in a Mouse Model of Down Syndrome. ENeuro, 2016, 3, ENEURO.0103-16.2016.	1.9	42
1217	A c-Jun N-terminal kinase inhibitor, JNK-IN-8, sensitizes triple negative breast cancer cells to lapatinib. Oncotarget, 2017, 8, 104894-104912.	1.8	28

$\sim$			<u> </u>	
	ΙΤΑΤ	ION	Rep	ORT
$\sim$	/			

#	Article	IF	CITATIONS
1218	SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways. Oncotarget, 2015, 6, 36383-36399.	1.8	32
1219	DNA damaging agent-induced apoptosis is regulated by MCL-1 phosphorylation and degradation mediated by the Noxa/MCL-1/CDK2 complex. Oncotarget, 2016, 7, 36353-36365.	1.8	23
1220	DYRK1A Kinase Inhibitors with Emphasis on Cancer. Mini-Reviews in Medicinal Chemistry, 2012, 12, 1315-1329.	2.4	46
1221	Prediction of Specificity and Cross-Reactivity of Kinase Inhibitors. Letters in Drug Design and Discovery, 2011, 8, 223-228.	0.7	26
1222	Wrapping technology and the enhancement of specificity in cancer drug treatment. Frontiers in Bioscience - Landmark, 2007, 12, 3617.	3.0	4
1223	PI3K expression and PIK3CA mutations are related to colorectal cancer metastases. World Journal of Gastroenterology, 2012, 18, 3745.	3.3	49
1224	Roscovitine in cancer and other diseases. Annals of Translational Medicine, 2015, 3, 135.	1.7	99
1225	The Level of TWIST1 expression determines the response of colon cancer cells to mitogen-activated protein kinases inhibitors. Saudi Journal of Gastroenterology, 2018, 24, 37.	1.1	2
1226	Development of Novel C1 Domain Ligands of Protein Kinase C to Clarify the Precise Structure and Activation Mechanism. Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry, 2006, 64, 515-528.	0.1	2
1227	Two key genes closely implicated with the neuropathological characteristics in Down syndrome: DYRK1A and RCAN1. BMB Reports, 2009, 42, 6-15.	2.4	68
1228	c-Jun N-Terminal Kinase Signaling Inhibitors Under Development. Toxicological Research, 2008, 24, 93-100.	2.1	3
1229	Application of mitogen-activated protein kinase inhibitor SP 600125 for wound healing control. Journal of Regenerative Medicine & Tissue Engineering, 2013, 2, 9.	1.5	3
1230	Cinnamomum Iners as Mitogen-Activated Protein Kinase Kinase (MKK1) Inhibitor. International Journal of Engineering and Technology, 2009, 1, 310-313.	0.2	4
1231	Recent research and development of DYRK1A inhibitors. Chinese Chemical Letters, 2022, 33, 1841-1849.	9.0	7
1232	Protein kinase A Mediated Effects of Protein kinase C Partial Agonist HMI-1a3 in Colorectal Cancer Cells. Journal of Pharmacology and Experimental Therapeutics, 2021, , JPET-AR-2021-000848.	2.5	2
1233	Polyphenols and neuroprotection: Therapeutic implications for cognitive decline. , 2022, 232, 108013.		71
1234	Introduction to molecular exercise physiology. , 2006, , 121-163.		1
1235	Development, Selectivity, and Application of Paullones, a Family of CDK Inhibitors. , 2006, , 245-268.		0

#	Article	IF	CITATIONS
1237	Regulation of Smad Activity by Phosphorylation. , 2008, , 105-123.		0
1239	Cyclin-dependent kinase. , 2009, , 156-219.		0
1240	Mitogen-activated protein kinase. , 2009, , 233-277.		0
1241	cAMP-dependent protein kinase. , 2009, , 241-287.		0
1242	Protein kinase C. , 2009, , 325-369.		0
1243	Non-specific serine/threonine protein kinase. , 2009, , 1-123.		0
1244	Non-specific protein-tyrosine kinase. , 2009, , 441-565.		0
1245	Anti-Cancer Effect of Indirubin-3'-Monoxime for Human Laryngeal Carcinoma. International Journal of Cancer Research, 2009, 6, 27-34.	0.2	0
1246	Mps1. The AFCS-nature Molecule Pages, 0, , .	0.2	0
1247	Mitogen-Activated Protein Kinase-Activated Protein Kinases and Metastasis. Cancer Metastasis - Biology and Treatment, 2010, , 41-76.	0.1	2
1248	Ultra-High Throughput Screening (uHTS) Chemical Genetics to Identify Novel Chronotherapeutics. , 2010, , 167-175.		0
1249	Wrapping Patterns as Universal Markers for Specificity in the Therapeutic Interference with Signaling Pathways. , 2010, , 141-161.		0
1251	Glycogen Synthase Kinase-3 in Neurological Diseases. Neuromethods, 2012, , 153-188.	0.3	2
1252	Something from Nothing: The First Phosphorylation. Postdoc Journal, 0, , .	0.4	1
1253	Regulation of Cancerous inhibitor of PP2A (CIP2A) by small molecule inhibitor for c-Jun NH2-Terminal Kinases (JNKs), SP600125, in Human Fibrosarcoma (HT1080) cellsÂ. F1000Research, 0, 2, 174.	1.6	0
1254	Regulation of Cancerous inhibitor of PP2A (CIP2A) by small molecule inhibitor for c-Jun NH2-Terminal Kinases (JNKs), SP600125, in Human Fibrosarcoma (HT1080) cells. F1000Research, 0, 2, 174.	1.6	1
1255	Oxidative Stress, Antioxidants, and Chemoprevention: On the Role of Oxidant-Induced Signaling in Cellular Adaptation. , 2014, , 119-146.		2
1256	Protein Kinase Inhibitors in Rheumatology. Journal of Autoimmune Diseases and Rheumatology, 2014, 2, 13-27.	0.2	0

#	Article	IF	CITATIONS
1257	Partial Purification and Characterization of the Rat Parotid Gland Protein Kinase Catalyzing Phosphorylation of Matured Destrin at Ser-2. Advances in Enzyme Research, 2014, 02, 100-112.	1.6	0
1258	Biomolecular Interfaces Provide Universal Markers for Drug Specificity and Personalized Medicine. , 2015, , 217-241.		0
1259	Epistructural Informatics for the Drug Designer. Soft and Biological Matter, 2016, , 267-304.	0.3	0
1260	An ELISA DYRK1A non-radioactive assay suitable for the characterization of inhibitors. F1000Research, 2017, 6, 42.	1.6	7
1267	Developing Kinase Inhibitors Using Computer-Aided Drug Design Approaches. , 2020, , 81-108.		0
1268	The endocytic pathway taken by cationic substances requires Rab14 but not Rab5 and Rab7. Cell Reports, 2021, 37, 109945.	6.4	18
1269	Discovery of Hydroxybenzothiazole Urea Compounds as Multitargeted Agents Suppressing Major Cytotoxic Mechanisms in Neurodegenerative Diseases. ACS Chemical Neuroscience, 2021, 12, 4302-4318.	3.5	4
1271	Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. Journal of Clinical Investigation, 2005, 115, 369-378.	8.2	117
1275	c-Src kinase inhibits osteogenic differentiation via enhancing STAT1 stability. PLoS ONE, 2020, 15, e0241646.	2.5	8
1278	Effects of a myosin light chain kinase inhibitor on the optics and accommodation of the avian crystalline lens. Molecular Vision, 2011, 17, 2759-64.	1.1	3
1280	Effect of roscovitine on developmental competence of small follicle-derived buffalo oocytes. Indian Journal of Medical Research, 2018, 148, S140-S150.	1.0	0
1281	MAP kinases in regulation of NOX activity stimulated through two types of formyl peptide receptors in murine bone marrow granulocytes. Cellular Signalling, 2022, 90, 110205.	3.6	9
1282	Dyrk1a from Gene Function in Development and Physiology to Dosage Correction across Life Span in Down Syndrome. Genes, 2021, 12, 1833.	2.4	28
1283	Potential and limitations of PKA/ PKG inhibitors for platelet studies. Platelets, 2021, , 1-10.	2.3	0
1284	Antiplatelet Effect of Nobiletin is Mediated by Activation of A2A Adenosine Receptor. Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology, 2021, 15, 387-394.	0.6	1
1285	The Src-Kinase Fyn is Required for Cocaine-Associated Memory Through Regulation of Tau. Frontiers in Pharmacology, 2022, 13, 769827.	3.5	0
1286	Transcription Factor 21 Promotes Chicken Adipocyte Differentiation at Least in Part via Activating MAPK/JNK Signaling. Genes, 2021, 12, 1971.	2.4	3
1287	Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models. PLoS ONE, 2022, 17, e0264254.	2.5	10

#	Article	IF	CITATIONS
1288	Design, synthesis, and biological evaluation of polyphenol derivatives as DYRK1A inhibitors. The discovery of a potentially promising treatment for Multiple Sclerosis. Bioorganic and Medicinal Chemistry Letters, 2022, 64, 128675.	2.2	3
1289	A MEKK1 – JNK mitogen activated kinase (MAPK) cascade module is active in Echinococcus multilocularis stem cells. PLoS Neglected Tropical Diseases, 2021, 15, e0010027.	3.0	4
1290	Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Molecular Cancer Therapeutics, 2004, 3, 1427-1438.	4.1	1,040
1300	Catechins as a Potential Dietary Supplementation in Prevention of Comorbidities Linked with Down Syndrome. Nutrients, 2022, 14, 2039.	4.1	5
1301	Organ- and Cell-Type Specific Delivery of Kinase Inhibitors: A Novel Approach in the Development of Targeted Drugs. Current Molecular Pharmacology, 2008, 1, 1-12.	1.5	3
1302	A critical update on the strategies towards small molecule inhibitors targeting Serine/arginine-rich (SR) proteins and Serine/arginine-rich proteins related kinases in alternative splicing. Bioorganic and Medicinal Chemistry, 2022, 70, 116921.	3.0	7
1303	Epigallocatechin gallate is a potent inhibitor of cystathionine beta-synthase: Structure-activity relationship and mechanism of action. Nitric Oxide - Biology and Chemistry, 2022, 128, 12-24.	2.7	5
1304	Multi-Level High-Throughput Screening for Discovery of Ligands That Inhibit Insulin Aggregation. Molecular Pharmaceutics, 2022, 19, 3770-3783.	4.6	0
1305	The microtubule network enables Src kinase interaction with the Na,K-ATPase to generate Ca2+ flashes in smooth muscle cells. Frontiers in Physiology, 0, 13, .	2.8	4
1306	Influenza A virus activates cellular Tropomyosin receptor kinase A (TrkA) signaling to promote viral replication and lung inflammation. PLoS Pathogens, 2022, 18, e1010874.	4.7	2
1307	Crystal structure of the Rho-associated coiled-coil kinase 2 inhibitor belumosudil bound to CK2α. Acta Crystallographica Section F, Structural Biology Communications, 2022, 78, 348-353.	0.8	1
1308	Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics. Molecular Aspects of Medicine, 2023, 91, 101151.	6.4	16
1309	Fyn nanoclustering requires switching to an open conformation and is enhanced by FTLD-Tau biomolecular condensates. Molecular Psychiatry, 2023, 28, 946-962.	7.9	6
1310	Src family kinase targeting in head and neck tumor cells using <scp>SU6656</scp> , <scp>PP2</scp> and dasatinib. Head and Neck, 0, , .	2.0	1
1311	An overview of cdc2â€like kinase 1 (Clk1) inhibitors and their therapeutic indications. Medicinal Research Reviews, 2023, 43, 343-398.	10.5	8
1312	In silico identification of chemical compounds in Spondias mombin targeting aldose reductase and glycogen synthase kinase 3β to abate diabetes mellitus. Informatics in Medicine Unlocked, 2023, 36, 101126.	3.4	5
1313	The Role of NO/sGC/cGMP/PKG Signaling Pathway in Regulation of Platelet Function. Cells, 2022, 11, 3704.	4.1	11
1314	Enriching Chemical Space of Bioactive Scaffolds by New Ring Systems: Benzazocines and Their Metal Complexes as Potential Anticancer Drugs, Inorganic Chemistry, 2022, 61, 20445-20460	4.0	6

ARTICLE IF CITATIONS CDK5/p35-Dependent Microtubule Reorganization Contributes to Homeostatic Shortening of the Axon 1315 3.6 10 Initial Segment. Journal of Neuroscience, 2023, 43, 359-372. Straightforward Access to a New Class of Dual DYRK1A/CLK1 Inhibitors Possessing a Simple 3.8 Dihydroquinoline Core. Molecules, 2023, 28, 36. Latonduine-1-Amino-Hydantoin Hybrid, Triazole-Fused Latonduine Schiff Bases and Their Metal 1318 Complexes: Synthesis, X-ray and Électron Diffraction, Molecular Docking Studies and 2.7 3 Antiproliferative Activity. Inorganics, 2023, 11, 30. high potency and unprecedented Clk1 isoenzyme selectivity. European Journal of Medicinal Chemistry, 2023, 247, 115019. Discovery of novel 5-methoxybenzothiophene hydrazides as metabolically stable Clk1 inhibitors with 5.5 Regeneration of Pancreatic Î<sup>2</sup>-Cells for Diabetes Therapeutics by Natural DYRK1A Inhibitors. Metabolites, 1320 2.9 2 2023, 13, 51. Non-kinase targeting of oncogenic c-Jun N-terminal kinase (JNK) signaling: the future of clinically viable cancer treatments. Biochemical Society Transactions, 2022, 50, 1823-1836. 1321 3.4 HER2-driven breast cancer suppression by the JNK signaling pathway. Proceedings of the National 1322 7.1 4 Academy of Sciences of the United States of America, 2023, 120, . Ubiquitin-Specific Proteases (USPs) and Metabolic Disorders. International Journal of Molecular 4.1 16 Sciences, 2023, 24, 3219. Identifying bioactive phytoconstituents as C-terminal Src kinase inhibitors: a virtual screening and 1324 0 3.5 molecular simulation approach. Journal of Biomolecular Structure and Dynamics, 2023, 41, 13415-13424. In-silico study for African plants with possible beta-cell regeneration effect through inhibition of DYRK1A., 2022, 1, 13-28. Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases. 1326 6.4 11 Journal of Medicinal Chemistry, 2023, 66, 4106-4130. Development of Novel Fluorinated Polyphenols as Selective Inhibitors of DYRK1A/B Kinase for Treatment of Neuroinflammatory Diseases including Parkinson's Disease. Pharmaceuticals, 2023, 16, 3.8 443. Function and inhibition of DYRK1A: Emerging roles of treating multiple human diseases. Biochemical 1328 4.4 2 Pharmacology, 2023, 212, 115521. Biosynthesis of Indolocarbazole Alkaloids and Generation of Novel Derivatives by Combinatorial 1329 Biosynthesis., 2012,, 99-115. 1330 Unbiased evaluation of rapamycin's specificity as an <scp>mTOR</scp> inhibitor. Aging Cell, 2023, 22, . 2 6.7 Effects of Inhibition of IKK Kinase Phosphorylation On the Cellular Defence System and HSP90 Activity. Inflammation, 0, , . Promising therapeutic approaches in Down Syndrome: addressing parents' doubts. Pediatric Oncall, 1332 0.0 0 2024, 21, . Tyrosine hydroxylase phosphorylation is under the control of serine 40. Journal of Neurochemistry, 2023, 167, 376-393.

#	Article	IF	CITATIONS
1334	Novel Secondary Metabolites in Tea and Their Biological Role in Communicable and Noncommunicable Human Diseases. Food Bioactive Ingredients, 2023, , 287-329.	0.4	0
1336	An Improved Protocol for the Matrigel Duplex Assay: A Method to Measure Retinal Angiogenesis. Bio-protocol, 2023, 13, .	0.4	0
1337	Pharmacological approaches to understanding protein kinase signaling networks. Frontiers in Pharmacology, 0, 14, .	3.5	0
1338	EGCC-like non-competitive inhibitor of DYRK1A rescues cognitive defect in a down syndrome model. European Journal of Medicinal Chemistry, 2024, 265, 116098.	5.5	1
1339	A dualâ€omics approach on the effects of fibroblast growth factorâ€2 (FGFâ€2) on ventral tegmental area dopaminergic neurons in response to alcohol consumption in mice. European Journal of Neuroscience, 2024, 59, 1519-1535.	2.6	0